<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, viewport-fit=cover">
    <meta name="description" content="STSFT Clinical Guidelines - Mobile-first clinical reference">
    <meta name="theme-color" content="#003087">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
    <meta name="apple-mobile-web-app-title" content="STSFT Guidelines">
    <link rel="manifest" href="manifest.json">
    <link rel="icon" type="image/png" href="favicon.png">
    <link rel="apple-touch-icon" href="icon-192x192.png">
    <title>STSFT Clinical Guidelines</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        html, body {
            width: 100%;
            height: 100%;
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            background-color: #f9fafb;
            color: #1f2937;
        }

        :root {
            --nhs-blue: #003087;
            --nhs-blue-light: #0066cc;
            --nhs-blue-dark: #002060;
            --text-primary: #1f2937;
            --text-secondary: #6b7280;
            --bg-light: #f9fafb;
            --bg-white: #ffffff;
            --border-color: #e5e7eb;
            --shadow: 0 1px 3px rgba(0, 0, 0, 0.1), 0 1px 2px rgba(0, 0, 0, 0.06);
            --shadow-md: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .screen {
            display: none;
            height: 100vh;
            width: 100%;
            overflow: hidden;
            flex-direction: column;
        }

        .screen.active {
            display: flex;
        }

        @keyframes slideIn {
            from { transform: translateX(100%); opacity: 0; }
            to { transform: translateX(0); opacity: 1; }
        }

        @keyframes slideOut {
            from { transform: translateX(0); opacity: 1; }
            to { transform: translateX(-100%); opacity: 0; }
        }

        .screen.slide-in { animation: slideIn 0.3s ease-out; }
        .screen.slide-out { animation: slideOut 0.3s ease-out; }

        .header {
            background: var(--nhs-blue);
            color: white;
            padding: 1rem;
            display: flex;
            align-items: center;
            justify-content: space-between;
            border-bottom: 1px solid rgba(255, 255, 255, 0.1);
            flex-shrink: 0;
        }

        .header-home {
            flex-direction: row;
            align-items: center;
            justify-content: space-between;
            gap: 0.5rem;
        }

        .home-button {
            background: none;
            border: 2px solid rgba(255, 255, 255, 0.5);
            color: white;
            cursor: pointer;
            padding: 0.4rem 0.75rem;
            display: flex;
            align-items: center;
            justify-content: center;
            min-width: 44px;
            min-height: 44px;
            border-radius: 6px;
            font-size: 0.8rem;
            font-weight: 600;
            gap: 0.4rem;
            transition: background 0.2s;
            white-space: nowrap;
            flex-shrink: 0;
        }

        .home-button:active {
            background: rgba(255, 255, 255, 0.15);
        }

        .nhs-logo {
            display: flex;
            align-items: center;
            gap: 0.75rem;
            margin-bottom: 0.5rem;
        }

        .nhs-lozenge {
            background: white;
            color: var(--nhs-blue);
            padding: 0.25rem 0.5rem;
            border-radius: 2px;
            font-weight: bold;
            font-size: 0.875rem;
            line-height: 1;
        }

        .trust-name {
            font-size: 0.875rem;
            font-weight: 500;
            opacity: 0.95;
        }

        .header-nav {
            display: flex;
            align-items: center;
            gap: 1rem;
            flex: 1;
        }

        .back-button, .header-info {
            background: none;
            border: none;
            color: white;
            cursor: pointer;
            padding: 0.5rem;
            display: flex;
            align-items: center;
            justify-content: center;
            min-width: 44px;
            min-height: 44px;
            border-radius: 6px;
            transition: background 0.2s;
        }

        .back-button { font-size: 1.5rem; }
        .header-info { font-size: 1.25rem; }

        .back-button:active, .header-info:active {
            background: rgba(255, 255, 255, 0.1);
        }

        .header-title {
            flex: 1;
            font-size: 1.125rem;
            font-weight: 600;
            white-space: nowrap;
            overflow: hidden;
            text-overflow: ellipsis;
        }

        .search-container {
            padding: 1rem;
            background: var(--bg-white);
            border-bottom: 1px solid var(--border-color);
            flex-shrink: 0;
            position: relative;
        }

        .search-input {
            width: 100%;
            padding: 0.75rem 1rem;
            border: 1px solid var(--border-color);
            border-radius: 8px;
            font-size: 1rem;
            background: var(--bg-light);
            color: var(--text-primary);
            transition: border-color 0.2s, background 0.2s;
        }

        .search-input:focus {
            outline: none;
            border-color: var(--nhs-blue);
            background: var(--bg-white);
        }

        .search-input::placeholder { color: var(--text-secondary); }

        .content {
            flex: 1;
            overflow-y: auto;
            overflow-x: hidden;
            -webkit-overflow-scrolling: touch;
        }

        .home-content {
            padding: 1rem;
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
            gap: 1rem;
        }

        @media (max-width: 600px) {
            .home-content {
                grid-template-columns: repeat(2, 1fr);
                gap: 0.75rem;
                padding: 0.75rem;
            }
        }

        .category-card {
            background: var(--nhs-blue);
            color: white;
            padding: 1.5rem 1rem;
            border-radius: 12px;
            cursor: pointer;
            transition: all 0.2s;
            text-align: center;
            display: flex;
            flex-direction: column;
            justify-content: center;
            align-items: center;
            gap: 0.75rem;
            min-height: 140px;
            box-shadow: var(--shadow);
            user-select: none;
            -webkit-user-select: none;
            touch-action: manipulation;
        }

        .category-card:active {
            background: var(--nhs-blue-dark);
            transform: scale(0.98);
        }

        .category-emoji { font-size: 2.5rem; line-height: 1; }
        .category-name { font-weight: 600; font-size: 1rem; line-height: 1.3; }
        .category-count { font-size: 0.75rem; opacity: 0.9; font-weight: 500; }

        .guideline-list {
            padding: 1rem;
            display: flex;
            flex-direction: column;
            gap: 0.75rem;
        }

        .guideline-card {
            background: white;
            border: 1px solid var(--border-color);
            padding: 1rem;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s;
            text-align: left;
            color: var(--nhs-blue);
            font-weight: 500;
            display: flex;
            align-items: center;
            justify-content: space-between;
            min-height: 44px;
            box-shadow: var(--shadow);
        }

        .guideline-card:active { background: #f3f4f6; }
        .guideline-card-arrow { font-size: 1.25rem; margin-left: 0.5rem; opacity: 0.5; }

        .guideline-content { padding: 1rem; }

        .accordion-section {
            background: white;
            border: 1px solid var(--border-color);
            border-radius: 8px;
            margin-bottom: 1rem;
            overflow: hidden;
            box-shadow: var(--shadow);
        }

        .accordion-header {
            padding: 1rem;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
            font-weight: 600;
            user-select: none;
            -webkit-user-select: none;
            touch-action: manipulation;
            transition: all 0.2s;
            min-height: 44px;
        }

        .accordion-header:active { opacity: 0.8; }

        .accordion-header-text {
            display: flex;
            align-items: center;
            gap: 0.75rem;
            flex: 1;
        }

        .accordion-toggle {
            font-size: 1.5rem;
            transition: transform 0.3s;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .accordion-section.expanded .accordion-toggle { transform: rotate(180deg); }

        .accordion-body {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease;
            border-top: 1px solid var(--border-color);
        }

        .accordion-section.expanded .accordion-body { max-height: none; }

        .accordion-body-content {
            padding: 1rem;
            font-size: 0.95rem;
            line-height: 1.7;
            color: var(--text-primary);
        }

        .accordion-body-content p { margin-bottom: 1rem; }
        .accordion-body-content p:last-child { margin-bottom: 0; }
        .accordion-body-content h3 { font-size: 1.1rem; font-weight: 700; margin-top: 1.75rem; margin-bottom: 0.75rem; color: var(--nhs-blue); border-bottom: 2px solid #e5e7eb; padding-bottom: 0.4rem; }
        .accordion-body-content h3:first-child { margin-top: 0.5rem; }
        .accordion-body-content h4 { font-size: 1rem; font-weight: 600; margin-top: 1.25rem; margin-bottom: 0.5rem; color: #374151; padding-left: 0.5rem; border-left: 3px solid var(--nhs-blue); }
        .accordion-body-content ul { margin: 0.75rem 0; padding-left: 1.5rem; }
        .accordion-body-content li { margin-bottom: 0.4rem; line-height: 1.6; }
        .accordion-body-content li::marker { color: var(--nhs-blue); }
        .accordion-body-content strong { font-weight: 600; color: #1e293b; }
        .accordion-body-content a, .accordion-body-content .cross-link { color: var(--nhs-blue); text-decoration: underline; cursor: pointer; font-weight: 500; }
        .accordion-body-content a:active, .accordion-body-content .cross-link:active { opacity: 0.7; background-color: #dbeafe; border-radius: 2px; }
        .accordion-body-content .cross-link::after { content: ' â†’'; font-size: 0.85em; }

        .modal {
            display: none;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: rgba(0, 0, 0, 0.5);
            z-index: 1000;
            justify-content: center;
            align-items: flex-end;
            animation: slideUp 0.3s ease-out;
        }

        @keyframes slideUp {
            from { opacity: 0; transform: translateY(100%); }
            to { opacity: 1; transform: translateY(0); }
        }

        .modal.active { display: flex; }

        .modal-content {
            background: white;
            width: 100%;
            max-width: 100%;
            border-radius: 12px 12px 0 0;
            padding: 2rem 1rem 1rem;
            max-height: 80vh;
            overflow-y: auto;
        }

        .modal-close {
            position: absolute;
            top: 1rem;
            right: 1rem;
            background: none;
            border: none;
            font-size: 1.5rem;
            cursor: pointer;
            color: var(--text-secondary);
            padding: 0.5rem;
            min-width: 44px;
            min-height: 44px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .metadata-item { margin-bottom: 1rem; }
        .metadata-label { font-weight: 600; color: var(--text-secondary); font-size: 0.875rem; text-transform: uppercase; letter-spacing: 0.5px; }
        .metadata-value { color: var(--text-primary); margin-top: 0.25rem; }

        .search-results {
            position: absolute;
            top: calc(100% - 1rem);
            left: 1rem;
            right: 1rem;
            background: white;
            border: 1px solid var(--border-color);
            border-top: none;
            border-radius: 0 0 8px 8px;
            max-height: 400px;
            overflow-y: auto;
            z-index: 100;
            display: none;
        }

        .search-results.active { display: block; }

        .search-result-item {
            padding: 1rem;
            border-bottom: 1px solid var(--border-color);
            cursor: pointer;
            transition: background 0.2s;
        }

        .search-result-item:last-child { border-bottom: none; }
        .search-result-item:active { background: var(--bg-light); }
        .search-result-guideline { font-weight: 600; color: var(--nhs-blue); margin-bottom: 0.25rem; }
        .search-result-section { font-size: 0.875rem; color: var(--text-secondary); }

        @media print {
            .header, .search-container, .back-button, .header-info { display: none; }
            .screen { height: auto; }
            .screen.active { display: block; }
            .accordion-section.expanded { page-break-inside: avoid; }
            .accordion-body { max-height: none; }
        }

        @media (min-width: 600px) {
            .home-content {
                grid-template-columns: repeat(3, 1fr);
                gap: 1.5rem;
                padding: 1.5rem;
            }
            .category-card { min-height: 180px; }
            .category-emoji { font-size: 3rem; }
            .guideline-list { padding: 1.5rem; gap: 1rem; }
            .guideline-content { padding: 1.5rem; }
            .modal-content { max-width: 600px; border-radius: 12px; }
        }
    </style>
</head>
<body>
    <div id="homeScreen" class="screen active">
        <header class="header header-home">
            <div class="nhs-logo">
                <div class="nhs-lozenge">NHS</div>
                <div class="trust-name">South Tyneside and Sunderland NHS Foundation Trust</div>
            </div>
        </header>
        <div class="search-container">
            <input type="text" id="searchInputHome" class="search-input" placeholder="Search all guidelines...">
            <div class="search-results" id="searchResultsHome"></div>
        </div>
        <div class="content">
            <div class="home-content" id="homeContent"></div>
        </div>
    </div>

    <div id="categoryScreen" class="screen">
        <header class="header">
            <div class="header-nav">
                <button class="back-button" onclick="app.goHome()">â†</button>
                <div class="header-title" id="categoryTitle"></div>
                <button class="home-button" onclick="app.goHome()">ğŸ  Menu</button>
            </div>
        </header>
        <div class="search-container">
            <input type="text" id="searchInputCategory" class="search-input" placeholder="Search guidelines...">
            <div class="search-results" id="searchResultsCategory"></div>
        </div>
        <div class="content">
            <div class="guideline-list" id="guidelineList"></div>
        </div>
    </div>

    <div id="guidelineScreen" class="screen">
        <header class="header">
            <div class="header-nav">
                <button class="back-button" onclick="app.goBack()">â†</button>
                <div class="header-title" id="guidelineTitle"></div>
                <button class="home-button" onclick="app.goHome()">ğŸ  Menu</button>
            </div>
        </header>
        <div class="search-container">
            <input type="text" id="searchInputGuideline" class="search-input" placeholder="Search in guideline...">
            <div class="search-results" id="searchResultsGuideline"></div>
        </div>
        <div class="content">
            <div class="guideline-content" id="guidelineContent"></div>
        </div>
    </div>

    <div class="modal" id="metadataModal">
        <div class="modal-content">
            <button class="modal-close" onclick="app.hideMetadata()">âœ•</button>
            <div id="metadataContent"></div>
        </div>
    </div>

    <script>
const guidelinesData = [{"title":"Abdominal Pain in Adults","filename":"Abdominal Pain in Adults Draft V.1.docx","category":"General Surgery","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<ul>\n<li>Old age</li>\n<li>Immunosuppression, e.g. steroids</li>\n<li>Peritonitis</li>\n<li>Signs of shock</li>\n</ul>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Abdominal Pain</h3>\n<p>Abdominal pain is a frequent presenting symptom in both primary and secondary care. While often benign, there are multiple serious or life-threatening diagnoses that need to be considered, as urgent treatment may be needed.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<h3>Immediate assessment</h3>\n<strong>Use theÂ ABCDE approachÂ to rapidly assess your patient. If they present with anyÂ red flagsÂ or haemodynamic instability:</strong>\n<h4>Red flags</h4>\n<ul>\n<li>Age extremity</li>\n<li>Immunosuppression, e.g. steroids</li>\n<li>Peritonitis</li>\n<li>Signs of shock</li>\n<li>contact a senior clinician or activate aÂ clinical emergencyÂ as appropriate.</li>\n<li>do not delay immediate management steps (below), commence in parallel with assessment.</li>\n</ul>\n<p><strong>2. Investigation:</strong></p>\n<ul>\n<li>Insert anÂ intravenous cannulaÂ if clinically indicatedÂ and take anÂ emergency department abdominal set.</li>\n</ul>\n<h4>Emergency department abdominal set</h4>\n<p>Full blood count</p>\n<p>Liver function tests</p>\n<p>CRP</p>\n<ul>\n<li>Urea and electrolytes</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n<li>Venous blood gas</li>\n<li>Urinalysis</li>\n<li>Pregnancy test, if relevant</li>\n<li>Calculate the patient'sÂ NEWS2 score.</li>\n<li>Take the patient's observations.</li>\n</ul>\n<strong>Perform a focused initial assessment to exclude immediately life-threatening conditions â€“ if the patient is not excluded, proceed to immediate management and manage as the condition:</strong>\n<h4>Ruptured abdominal aortic aneurysm</h4>\n<h3>Exclude if:</h3>\n<p>an ultrasound or CT taken within the last 3 years shows an aorta of less than 3Â cm</p>\n<p>a point-of-care ultrasound shows no abdominal aortic aneurysm</p>\n<p>the patient is younger than 50Â years and has no back, loin, or groin pain, has not collapsed, and is normotensive</p>\n<p>an emergency department senior has assessed the patient and found a clear alternative cause.</p>\n<strong>If not excluded, arrange CT.</strong>\n<h4>Ectopic pregnancy</h4>\n<ul>\n<li>Exclude if:</li>\n<li>the patient is male, or</li>\n<li>there is a negative pregnancy test result or intrauterine pregnancy is confirmed.</li>\n</ul>\n<h4>Ureteric colic</h4>\n<strong>If suspected, arrange urgent CT-KUB and seekÂ urology adviceÂ to review images for ureteric stone after scan, with the patient to be managed based on the result.</strong>\n<strong>If the patient isÂ very ill, arrange acute abdominal pain CT and proceed to immediate management. Otherwise, they must be further reviewed by a senior clinician in the emergency department to determine whether the scan is necessary.</strong>\n<h4>Very ill</h4>\n<ul>\n<li>Abdominal pain andÂ any of:</li>\n<li>CRP of more thanÂ 200</li>\n<li>Lactate of more thanÂ 4</li>\n<li>NEWS2Â score of more thanÂ 5</li>\n<li>Septic.</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Ongoing Assessment","content":"<strong>Consider:</strong>\n<strong>differential diagnoses by specialty:</strong>\n<h4>General surgery</h4>\n<ul>\n<li>Adhesions</li>\n<li>Appendicitis</li>\n<li>Biliary colic</li>\n<li>Cholecystitis</li>\n<li>Diverticulitis</li>\n<li>Strangulated or incarcerated hernia</li>\n<li>Ileus</li>\n</ul>\n<p>Inflammatory bowel diseaseÂ (e.g. Chrohn's disease or ulcerative colitis) â€“ if the patient's first presentation or they are under the care of the surgical team already</p>\n<ul>\n<li>Ischaemic colitis</li>\n<li>Pancreatitis</li>\n<li>Bowel or peptic ulcer perforation</li>\n<li>Small bowel obstruction</li>\n<li>Splenic infarction</li>\n<li>Volvulus</li>\n</ul>\n<h4>Gynaecology</h4>\n<p>Adenomyosis</p>\n<p>Dysmenorrhoea</p>\n<h4>Ectopic pregnancy</h4>\n<ul>\n<li>Endometriosis</li>\n<li>Endometritis</li>\n<li>Degeneration of fibroids</li>\n<li>Miscarriage</li>\n<li>Mittelschmerz</li>\n<li>Pelvic inflammatory disease (PID)</li>\n<li>Ruptured ovarian cyst</li>\n<li>Rupture of corpus luteum cyst</li>\n<li>Salpingitis</li>\n<li>Torsion of the ovary</li>\n<li>Tubo ovarian in abscess</li>\n</ul>\n<h4>Obstetrics</h4>\n<ul>\n<li>Braxton-Hicks contractions (rarely painful)</li>\n<li>Labour</li>\n<li>Placenta praevia</li>\n<li>Placental abruption</li>\n<li>Rupture of the uterus</li>\n</ul>\n<h4>Urology</h4>\n<p>PyelonephritisÂ with ureteric obstruction â€“ consider possibility of impacted stone causing pyelonephritis if pain is significant</p>\n<ul>\n<li>Renal abscess</li>\n<li>Renal colic</li>\n<li>Torsion of the testes</li>\n<li>Torsion of testicular appendage</li>\n<li>Urinary retention</li>\n</ul>\n<h4>Medical causes</h4>\n<ul>\n<li>Aortic dissection</li>\n<li>Cholangitis</li>\n<li>Diabetic ketoacidosis</li>\n<li>Gastritis</li>\n<li>Gastroenteritis</li>\n<li>Hepatitis</li>\n<li>Herpes Zoster (Shingles)</li>\n<li>Irritable bowel syndrome</li>\n<li>Lower lobe pneumonia</li>\n<li>Myocardial infarction</li>\n<li>Oesophagitis</li>\n<li>Peptic ulcer</li>\n<li>Pulmonary embolism</li>\n<li>Urinary tract infectionÂ inÂ menÂ orÂ women, including non-obstructive pyelonephritis</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<h3>Immediate management</h3>\n<ul>\n<li>If unable to exclude:</li>\n<li>ruptured aortic abdominal aneurysm:</li>\n<li>involve a senior emergency department doctor (ST3 or above)</li>\n<li>resuscitate with 2 wide-bore cannulas</li>\n</ul>\n<p>seekÂ vascular surgery adviceÂ at the same time as arranging further scans, for decision on further management after scan has taken place.</p>\n<ul>\n<li>ectopic pregnancy:</li>\n<li>involve a senior emergency department doctor (ST3 or above)</li>\n<li>resuscitate with 2 wide-bore cannulas</li>\n<li>requestÂ acute gynaecology assessment.</li>\n<li>If the patient is very ill:</li>\n<li>resuscitate with antibiotics and analgesia</li>\n<li>ensure there is adequateÂ intravenous therapy</li>\n<li>requestÂ acute general surgery assessmentÂ at the same time as requesting further scans.</li>\n<li>If ureteric colic is suspected:</li>\n<li>start the patient on analgesia</li>\n<li>after CT-KUB has been reviewed, if there is:</li>\n<li>ureteric stone,Â follow theÂ Renal Colic and Urinary Tract StonesÂ pathway.</li>\n</ul>\n<p>no stone, re-evaluate diagnosis and/or consider further imaging and referral to appropriate specialty.</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Ongoing Management","content":"<p>If a specific surgical or gynaecological diagnosis is suspected or confirmed, manage according to the relevant pathway where available. If there is no pathway available for specific management and the patient requires admission, request assessment based on the relevant specialty, e.g.Â general surgery,Â gynaecology,Â urology.</p>\n<strong>If there is a working diagnosis for the cause with a medical pathology, or the patient is currently under the care of the medical specialty team in the emergency department for the pathology, requestÂ acute general medicine assessmentÂ for admission if considered appropriate and:</strong>\n<ul>\n<li>lactate of 2 or more,</li>\n<li>CRP is less than 100, and</li>\n<li>the patient has a soft abdomen with no peritonism.</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<strong>Ensure theÂ standard discharge informationÂ and GP letter is completed.</strong>\n<h3>Standard discharge information</h3>\n<ul>\n<li>Complete the discharge ensuring clear concise information about the:</li>\n<li>Diagnosis</li>\n<li>significant procedures performed in hospital</li>\n<li>key results</li>\n<li>changes to medication</li>\n<li>ongoing monitoring requirements</li>\n</ul>\n<p>significant conversations with the patient or family (e.g. cancer diagnosis or do not attempt cardiopulmonary resuscitation (DNACPR) decision).</p>\n<ul>\n<li>Ensure the patient is informed of:</li>\n<li>their diagnosis and prognosis</li>\n<li>lifestyle changes that will support the management of their condition</li>\n<li>how and when to access support if symptoms are ongoing or worsen.</li>\n</ul>\n<p>Review any take-home medications and provide any relevant information about new medicines using theÂ MaPPs tool.</p>\n<strong>If the patient had surgery, provide wound care instructions.</strong>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<h3>If unable to exclude:</h3>\n<p>ruptured abdominal aortic aneurysm, seekÂ vascular surgery adviceÂ at the same time as arranging further scans</p>\n<p>ectopic pregnancy, requestÂ acute gynaecology assessment.</p>\n<strong>If the patient is very ill, requestÂ acute general surgery assessment.</strong>\n<p>If there is no pathway available for specific management and the patient requires admission, request assessment based on the relevant specialty, e.g.Â general surgery,Â gynaecology,Â urology.</p>\n<strong>If there is a working diagnosis for the cause with a medical pathology, or the patient is currently under the care of the medical specialty team in the emergency department for the pathology, requestÂ acute general medicine assessmentÂ for admission if considered appropriate and:</strong>\n<ul>\n<li>lactate of 2 or more,</li>\n<li>CRP is less than 100, and</li>\n<li>the patient has a soft abdomen with no peritonism.</li>\n</ul>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>Information</h4>\n<h4>For health professionals</h4>\n<p>Patient â€“Â Acute Abdomen</p>\n<h4>For patients</h4>\n<p>Patient â€“Â Abdominal Pain</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nAcute Abdominal Pain in Adults","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Acute Hypertension","filename":"Acute Hypertension Draft V.1.docx","category":"Acute Medicine","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<p>Severe hypertension with acute end-organ damage</p>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Acute Hypertension</h3>\n<p>Systemic arterial hypertension is one of the most important risk factors associated with mortality and morbidity worldwide and increases the risk of stroke and cardiovascular events.</p>\n<p>It isÂ defined as aÂ blood pressure (BP)Â higherÂ thanÂ 140/90Â mmHg, orÂ 135/85Â mmHg with ambulatory BP monitoring. Some high-risk patients may benefit from treatment if their BP is higherÂ thanÂ 130/80Â mmHg.</p>\n<p>End-organ damage and other clinical outcomes are more closely associated with elevated home and ambulatory BP than isolated elevated BP measurements taken in a medical setting.</p>\n<p>Hypertension is progressive and often requires more than one medication to reach optimal levels. Treatment is typically lifelong.</p>\n<p>Therapeutic inertia is common when medication regimens are not intensified to meet BP goals.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<ul>\n<li>Take aÂ history</li>\n<li>Ask about:</li>\n<li>Focused history of any symptom onset and severity</li>\n<li>Past medical history</li>\n<li>Family historyÂ â€“Â in particularÂ cardiovascularÂ diseaseÂ orÂ hypertension at young age, renal disease</li>\n</ul>\n<p>Medications includingÂ over the counter, herbal remedies, NSAIDs,Â combined oral contraceptive pill (COCP), tacrolimus,Â ciclosporin,Â monoamine oxidase inhibitors (MAOIs), erythropoietin therapies</p>\n<ul>\n<li>Previous antihypertensive intolerances and allergies</li>\n<li>Diet,Â especially excessive salt intake</li>\n<li>Illicit drug use â€“ in particular amphetaminesÂ orÂ cocaine</li>\n<li>Caffeine intake, e.g.Â energy drinks</li>\n<li>Anabolic steroids,Â diet pills,Â liquorice use</li>\n<li>Alcohol and smoking history</li>\n</ul>\n<h3>Examine the patient</h3>\n<ul>\n<li>Take multipleÂ blood pressure (BP) measurements:</li>\n<li>EnsureÂ theÂ patient has emptiedÂ theirÂ bladder.</li>\n<li>Advise the patient to avoid caffeine, exercise,Â or smoking 30Â minutes prior to measurement.</li>\n<li>Ask the patientÂ to sitÂ for 5 minutesÂ before theÂ first measurement.</li>\n<li>UseÂ anÂ appropriate cuff size.</li>\n<li>Place the arm onÂ aÂ stable surfaceÂ for support.</li>\n<li>Ask the patientÂ to sitÂ upright with both feet onÂ theÂ floor (not cross legged).</li>\n</ul>\n<p>Measure blood pressure initially in both arms. If there is a difference in systolic pressureÂ moreÂ thanÂ 15Â mmHg,Â useÂ theÂ arm withÂ aÂ higher reading for subsequent measurements.</p>\n<ul>\n<li>Check 2Â readings in total onÂ theÂ same arm, 2Â minutes apart.</li>\n<li>DocumentÂ theÂ average of both readings.</li>\n<li>Avoid speaking toÂ theÂ patient, excessive noise,Â and mobile phone use during readings.</li>\n<li>In older adults andÂ patientsÂ with postural symptoms, perform lying and standing BP measurements.</li>\n<li>Be aware of theÂ classification of office blood pressure levels.</li>\n</ul>\n<h3>Classification of office blood pressure levels</h3>\n<strong>Classification 1:</strong>\n<h4>Stage 1 hypertension:</h4>\n<p>Clinic blood pressure ranges between 140/90Â toÂ 159/99Â mmHg, and</p>\n<p>Subsequent average daytime ambulatory blood pressure monitoring (ABPM), or home blood pressure monitoring (HBPM), ranges between 135/85Â toÂ 149/94Â mmHg</p>\n<h4>Stage 2 hypertension:</h4>\n<p>Clinic blood pressure of 160/100Â mmHg or higherÂ but less thanÂ 180/120Â mmHg, and</p>\n<p>Subsequent average daytime ABPM or HBPM blood pressure ofÂ 150/95Â mmHg orÂ higher</p>\n<p>Stage 3 or severe hypertension â€“ clinic blood pressure of 180/120Â mmHg orÂ higher</p>\n<p>The blood pressure (BP) category is defined by the highest level of BP, whether systolic or diastolic.</p>\n<p>Isolated systolic hypertensionÂ should be graded 1, 2, or 3 according to systolic BP values in the ranges indicated.</p>\n<h3>Isolated systolic hypertension</h3>\n<p>Occurs mostly in older patients</p>\n<p>Elevated pulse pressure is primarily due to diminished arterial compliance</p>\n<p>May also result from an increase in cardiac output due to anaemia, hyperthyroidism, aortic insufficiency, arteriovenous (AV) fistula, or Pagetâ€™s disease of bone</p>\n<p>Associated with a 2- to 4-fold increase in risk of myocardial infarction (MI), left ventricular hypertrophy (LVH), renal dysfunction, stroke, and cardiovascular mortality</p>\n<p>Patients who are actively taking anti-hypertensive medications are usually defined as having hypertension regardless of their observed blood pressure.</p>\n<p>Consider and address factors that may artificially elevate blood pressure, e.g. pain, anxiety,Â \"white coat\" hypertension.</p>\n<ul>\n<li>\"White coat\" hypertension is:</li>\n<li>very common</li>\n<li>not considered a benign condition</li>\n<li>defined as abnormally high blood pressure caused by being in a medical environment.</li>\n<li>Check weight and calculateÂ body mass index (BMI).</li>\n</ul>\n<h3>Body mass index (BMI)</h3>\n<h3>Body mass index = kg/m2Â (weight divided by height squared)</h3>\n<ul>\n<li>NHS has anÂ online calculator.</li>\n<li>Less thanÂ 18.5 â€“ underweight</li>\n<li>18.5 toÂ 24.9 â€“ healthy or normal weight</li>\n<li>25 toÂ 29.9 â€“ overweight</li>\n<li>OverÂ 30 â€“ obese</li>\n<li>For Black, Asian, and other minority ethnic groups (BAME) patients:</li>\n<li>Less thanÂ 18.5 â€“ underweight</li>\n<li>18.5 toÂ 22.9 â€“ healthy or normal weight</li>\n<li>23 toÂ 27.5 â€“ overweight</li>\n<li>OverÂ 27.5 â€“ obese</li>\n</ul>\n<strong>If confident and if one has not been done (check Meditech), perform a fundoscopy to exclude hypertensive retinopathy:</strong>\n<h4>Grade 1 â€“ tortuous retinal arteries, silver wiring</h4>\n<h4>Grade 2 â€“ arteriolar narrowing and arteriovenous nicking</h4>\n<h4>Grade 3 â€“ flame-shaped haemorrhages and cotton wool spots</h4>\n<h4>Grade 4 â€“ papilloedema</h4>\n<ul>\n<li>Perform cardiovascular andÂ respiratory examination.</li>\n<li>Palpate peripheral pulses including radio-radial and radio-femoral delay.</li>\n<li>Check for goitre.</li>\n<li>Look for evidence of peripheral oedema.</li>\n<li>Look for abdominalÂ orÂ renal bruit.</li>\n</ul>\n<h3>ArrangeÂ Investigations</h3>\n<ul>\n<li>FBC, LFTs, bone profile, CRP</li>\n<li>Urea and electrolytes</li>\n<li>When requesting urea and electrolytes, the laboratory will automatically test and provide:</li>\n<li>Sodium</li>\n<li>Potassium</li>\n<li>Bicarbonate</li>\n<li>Chloride</li>\n<li>Urea</li>\n<li>Creatinine</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n<li>Urine dip â€“ if positive for protein,Â send for urine microalbumin on V6</li>\n<li>Thyroid function tests</li>\n<li>Parathyroid hormone</li>\n</ul>\n<p>ECG</p>\n<ul>\n<li>HbA1cÂ andÂ serum glucose</li>\n<li>Lipid profile</li>\n<li>Renin:aldosterone ratio, if not currently on antihypertensive therapy</li>\n<li>Chest X-ray</li>\n<li>Pregnancy test, if appropriate</li>\n<li>CT brain if acute neurological signs</li>\n<li>Plasma metanephrines</li>\n<li>Be aware ofÂ medicationsÂ that couldÂ cause false positive plasma metanephrine results:</li>\n<li>Tricyclic antidepressants, e.g.Â amitriptyline, clomipramine, dosulepin</li>\n<li>Selective serotonin reuptake inhibitors, e.g.Â citalopram, fluoxetine, sertraline</li>\n<li>Serotonin/noradrenaline reuptake inhibitors, e.g.Â venlafaxine, duloxetine</li>\n<li>Î±-adrenergic receptor blockers, e.g.Â phenoxybenzamine, doxazosin, indoramin</li>\n<li>Î’-adrenergic receptor blockers, e.g.Â atenolol, labetolol, propranolol</li>\n<li>Calcium-channel blockers, e.g.Â amlodipine, diltiazem, nifedipine</li>\n<li>Monoamine-oxidase inhibitors, e.g.Â isocarboxazid, phenelzine, moclobaminde</li>\n<li>Dopa-related, e.g.Â levo(L)-Dopa, methyldopa</li>\n<li>StimulantÂ or sympathomimetic drugs, e.g.Â ephedrine, amphetamine, cocaine, nicotine, caffeine</li>\n</ul>\n<strong>If the patient is symptomatic or has severe hypertension (higherÂ thanÂ 180Â mmHg systolic and/or 110Â mmHg diastolic), consider whether this represents:</strong>\n<h3>Hypertensive emergency</h3>\n<strong>Hypertensive emergencies are situations in which severe hypertension is associated with acute hypertension-mediated organ damage, which is often life-threatening and requires immediate, but careful intervention to lower blood pressure (BP). Often oral therapy will suffice, but some patients may need intravenous therapy. Typical presentations include:</strong>\n<h3>Malignant hypertension</h3>\n<p>Malignant hypertension is aÂ rare, potentially life-threatening condition which requires immediate treatment.</p>\n<strong>It is severely elevated blood pressure (BP) with rapidly progressive end-organ damage, e.g. retinopathy, including papilloedema, acute left ventricular dysfunction, renal failure, and encephalopathy. Hypertensive encephalopathy:</strong>\n<p>In adults, this is usually associated with systolic blood pressure higherÂ thanÂ 200Â mmHg and diastolic higherÂ thanÂ 130Â mmHg.</p>\n<p>It can occur at lower levels if there has been a rapid rise in pressure.</p>\n<p>Symptoms include confusion, restlessness, convulsions, hypoventilation, and papilloedema.</p>\n<p>Symptoms include blurred vision, headaches, fits,Â acuteÂ confusionÂ orÂ delirium without alternative cause, weakness, numbness, nausea and vomiting, chest pain, shortness of breath.</p>\n<p>severe hypertension associated with a related acute clinical condition, e.g.Â aortic dissection,Â myocardial ischaemia,Â myocardial infarction,Â heart failure,Â stroke</p>\n<p>sudden severe hypertension due to phaeochromocytoma</p>\n<p>pregnancy with severeÂ hypertension or pre-eclampsia.</p>\n<h3>Hypertensive urgency</h3>\n<p>Very common scenario which presents as blood pressure (BP) higherÂ thanÂ 180/110Â mmHg in the absence of acute end-organ damage.</p>\n<ul>\n<li>It is much more common than malignant hypertension.</li>\n<li>The rate of change in BP may be more predictive of end-organ damage.</li>\n<li>It is commonly due to non-adherence with antihypertensive medication.</li>\n</ul>\n<strong>If the patient is asymptomatic and has mild-to-moderate (lower than 180/110Â mmHg) hypertension recorded in hospital that is unrelated to the presenting illness:</strong>\n<p>interpret measurements with caution as they may not accurately indicate the patient's BP when healthy.</p>\n<ul>\n<li>consider if the patient needs management and follow-up.</li>\n<li>ConsiderÂ secondary causesÂ looking for:</li>\n<li>ObstructiveÂ sleep apnoea</li>\n<li>Cushing's syndromeÂ orÂ exogenous glucocorticoid therapy</li>\n<li>Acromegaly</li>\n<li>Primary hyperaldosteronism</li>\n<li>Hyperthyroidism</li>\n<li>Coarctation of aorta</li>\n<li>ChronicÂ kidney disease</li>\n<li>Intrinsic renal diseaseÂ or glomerulonephritis</li>\n<li>Renal artery stenosis</li>\n<li>Valvular heart disease</li>\n<li>Primary hyperparathyroidism</li>\n<li>Phaeochromocytoma</li>\n<li>Features suggestive of secondary hypertension</li>\n</ul>\n<p>All patients youngerÂ thanÂ 40 years with hypertension, or those with onset of any grade of hypertension in childhood â€“ needs further investigation by specialist</p>\n<p>Acute onset hypertension in a patient with previously normal blood pressure</p>\n<h3>Resistant hypertension</h3>\n<p>This is defined as failure to lower blood pressure (BP) to less thanÂ 140/90Â mmHg despite appropriate lifestyle measures and 3Â antihypertensive medications.</p>\n<ul>\n<li>Causes of pseudo-resistant hypertension should be ruled out, e.g.:</li>\n<li>Poor adherence to prescribed medications</li>\n<li>White-coat phenomenon</li>\n<li>Poor BP measurement technique</li>\n<li>severe (grade 3) hypertension (at or greater than 180/110Â mmHg) or hypertensive emergency</li>\n<li>presence of extensive hypertension-mediated organ damage</li>\n</ul>\n<p>clinical or biochemical features suggestive of a secondary cause, e.g. cushingoid appearance, hypokalaemia, obstructive sleep apnoea.</p>\n<ul>\n<li>Check forÂ Symptoms of end-organ damage</li>\n<li>Headaches</li>\n<li>Transient weakness or blindness</li>\n<li>Loss of visual acuity</li>\n<li>Chest pain</li>\n<li>Dyspnoea</li>\n<li>Claudication</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<p>IfÂ the patient hasÂ accelerated orÂ malignant hypertension, requestÂ critical care outreach.</p>\n<h3>Malignant hypertension</h3>\n<p>Malignant hypertension is aÂ rare, potentially life-threatening condition which requires immediate treatment.</p>\n<strong>It is severely elevated blood pressure (BP) with rapidly progressive end-organ damage, e.g. retinopathy, including papilloedema, acute left ventricular dysfunction, renal failure, and encephalopathy. Hypertensive encephalopathy:</strong>\n<p>In adults, this is usually associated with systolic blood pressure higherÂ thanÂ 200Â mmHg and diastolic higherÂ thanÂ 130Â mmHg.</p>\n<p>It can occur at lower levels if there has been a rapid rise in pressure.</p>\n<p>Symptoms include confusion, restlessness, convulsions, hypoventilation, and papilloedema.</p>\n<p>Symptoms include blurred vision, headaches, fits,Â acuteÂ confusionÂ orÂ delirium without alternative cause, weakness, numbness, nausea and vomiting, chest pain, shortness of breath.</p>\n<p>If clinical deterioration or evidence of organ failure requiring support, consider requestingÂ intensive care assessment.</p>\n<ul>\n<li>Aim to reduce BP gradually to less thanÂ 180/100Â mmHgÂ over 6Â hours.</li>\n<li>Do not reduce blood pressure more rapidly asÂ itÂ can lead to significant complications.</li>\n<li>StartÂ Treatment</li>\n</ul>\n<h4>First-line â€“Â intravenousÂ labetalolÂ 0.5Â mg/min (1Â mg/mL):</h4>\n<p>Titrate up to maximumÂ 2Â mg/min untilÂ blood pressure (BP)Â goal is achieved.</p>\n<p>MaintainÂ infusion at 5Â toÂ 20Â mg/hour.</p>\n<strong>Avoid if acute pulmonary oedema, asthma, heart block, bradycardia,Â acute coronary syndrome,Â or inÂ drug-induced malignant hypertension.</strong>\n<h4>Second-line â€“Â glyceryl trinitrateÂ 5Â microgram/minute:</h4>\n<ul>\n<li>Titrate up every 5Â minutes to maximum ofÂ 200Â microgram/minuteÂ according to response.</li>\n<li>Note:</li>\n<li>Preferred first-line for acute pulmonary oedema andÂ acute coronary syndrome</li>\n<li>Onset of action less than 5Â minutes</li>\n<li>May cause headache or reflex tachycardia</li>\n</ul>\n<h4>Third-line:</h4>\n<p>IntravenousÂ sodium nitroprussideÂ 0.5Â micrograms/kg/minute adjusted in steps of 0.5Â micrograms/kg/minute every 5Â minutes up to maximum dose of 8Â micrograms/kg/minute.</p>\n<p>Contraindications â€“ raisedÂ intracranial pressure (ICP), renal or hepatic disease (risk of cyanide toxicity)</p>\n<strong>Special considerations:</strong>\n<h3>Acute aortic dissection:</h3>\n<p>Manage withÂ intravenousÂ labetalol rather thanÂ intravenous glyceryl trinitrateÂ or sodium nitroprusside.</p>\n<p>If there is a contraindication to B-blocker, seekÂ cardiology advice.</p>\n<p>Acute coronary syndrome orÂ aortic dissectionÂ â€“ ensure adequate pain relief asÂ it isÂ likely to improve BP control.</p>\n<p>IfÂ suspectedÂ phaeochromocytoma,Â requestÂ acute endocrinology assessmentÂ and start phenoxybenzamine 10Â mg twiceÂ aÂ dayÂ before initiation ofÂ intravenousÂ labetolol.</p>\n<p>If pregnant, requestÂ acute obstetric assessment.</p>\n<p>For inpatient management of severe hypertension, seekÂ general medicine adviceÂ orÂ nephrology advice.</p>\n<p>If in Emergency Department (ED) or Emergency Assessment Unit (EAU) and noÂ features of accelerated orÂ malignant hypertensionÂ inÂ patients with BPÂ more thanÂ 180/120Â mmHg,Â requestÂ acute general medicine assessmentÂ via Same Day Emergency Care (SDEC).</p>\n<ul>\n<li>If already on hypertensive therapy:</li>\n<li>Ensure compliance and increase current treatment dose to maximum tolerated.</li>\n<li>IfÂ alreadyÂ on maximum dose, add secondÂ orÂ third-line treatment according toÂ NICE guidelines.</li>\n<li>If new hypertension, or no medical therapy:</li>\n<li>Start antihypertensive treatment afterÂ arrangingÂ bloods.</li>\n<li>If no contraindication,Â prescribe nifedipineÂ modified releaseÂ 10Â mg twiceÂ aÂ day.</li>\n<li>Be aware:</li>\n<li>Combinations to avoid</li>\n<li>Avoid the combination of beta blocker and verapamil due to the risk of hypotension and asystole.</li>\n<li>Avoid sublingual and immediate-release preparations due to risk of sudden symptomatic hypotension.</li>\n</ul>\n<p>Be cautious using the combination of beta blocker and diltiazem â€“ watch for atrioventricular (AV) block and bradycardia.</p>\n<h3>Avoid:</h3>\n<p>angiotensin-converting enzyme (ACE) inhibitor plus angiotensin-II receptor blocker (ARB) â€“ increased risk of hypotensive symptoms, syncope, and renal dysfunction.</p>\n<ul>\n<li>NSAIDs with ACE inhibitors, ARB, and diuretics.</li>\n<li>most patients will need a combination of a least 2Â drugs</li>\n<li>compliance is often poor and difficult to manage</li>\n</ul>\n<p>monitoring of electrolytes, urea, and creatinine after 1Â week and repeated after 1Â month is required for patients taking ACE inhibitors or ARBs.</p>\n<strong>Reserve beta blockers for when there is inadequate BP control with the other 3Â main classes, or if specific indications e.g:</strong>\n<ul>\n<li>women of childbearing potential.</li>\n<li>patients with:</li>\n<li>evidence of increased sympathetic drive.</li>\n<li>intolerance of ACE inhibitors and ARBs.</li>\n<li>heart disease.</li>\n<li>ConsiderÂ effective combinations</li>\n</ul>\n<p>Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor blocker (ARB) and calcium channel blocker â€“ especially in the presence of diabetes or lipid abnormalities</p>\n<p>ACE inhibitor or ARB and thiazide diuretic â€“ especially in the presence of heart failure, or post-stroke</p>\n<p>ACE inhibitor or ARB and beta blocker â€“ recommended after myocardial infarction (MI) or in the presence of heart failure</p>\n<p>Beta blocker and dihydropyridine calcium channel blocker â€“ especially in the presence of heart disease</p>\n<strong>Consider starting anÂ antihypertensive medicationÂ in hospital:</strong>\n<h3>Oral antihypertensive medication</h3>\n<p>Consider in a stepwise fashion, taking into account potential adverse effects and contraindications to each medication.</p>\n<strong>Medications may be used preferentially if they have additional benefits, e.g. beta blocker used much earlier if coexisting ischaemic heart disease (IHD), thiazide used earlier if evidence of fluid overload:</strong>\n<h3>Step 1:</h3>\n<strong>If the patient is youngerÂ thanÂ 55Â years or has diabetes, startÂ angiotensin-converting enzyme (ACE) inhibitor, e.g.Â ramipril, or an angiotensinÂ II inhibitor (ARB), e.g.Â candesartanÂ orÂ losartan.</strong>\n<strong>If the patient is aged 55Â yearsÂ orÂ older or Afro-Caribbean, and does not have type 2Â diabetes mellitus, first-line is calcium channel blocker (e.g.Â amlodipine) or a thiazide-like diuretic, e.g.Â indapamide.</strong>\n<ul>\n<li>Step 2 â€“ if BP is not controlled, add:</li>\n<li>a calcium channel blocker or thiazide-like diuretic, e.g.Â indapamide, or</li>\n<li>an ACE or ARB.</li>\n</ul>\n<p>Step 3 â€“ if BP still not controlled, use an ACE or ARBÂ andÂ a calcium channel blockerÂ andÂ a thiazide-like diuretic, e.g.Â indapamide.</p>\n<p>Step 4 â€“ if patient is not controlled on 3Â or more agents, consider resistant hypertension. Check ambulatory or home records and addÂ spironolactoneÂ (start at 12.5Â mg once a day to minimise adverse effects), or a beta blocker or alpha blocker if the patient has renal impairment or hyperkalaemia.</p>\n<p>Step 5 â€“ seek specialist advice if BP is uncontrolled in patients taking optimal tolerated doses of 4 drugs.</p>\n<ul>\n<li>See also NICE Guidance â€“Â Hypertension</li>\n<li>Be aware Combinations to avoid</li>\n<li>Avoid the combination of beta blocker and verapamil due to the risk of hypotension and asystole.</li>\n<li>Avoid sublingual and immediate-release preparations due to risk of sudden symptomatic hypotension.</li>\n</ul>\n<p>Be cautious using the combination of beta blocker and diltiazem â€“ watch for atrioventricular (AV) block and bradycardia.</p>\n<h3>Avoid:</h3>\n<p>angiotensin-converting enzyme (ACE) inhibitor plus angiotensin-II receptor blocker (ARB) â€“ increased risk of hypotensive symptoms, syncope, and renal dysfunction.</p>\n<ul>\n<li>NSAIDs with ACE inhibitors, ARB, and diuretics.</li>\n<li>most patients will need a combination of a least 2Â drugs.</li>\n<li>compliance is often poor and difficult to manage.</li>\n</ul>\n<p>monitoring of electrolytes, urea, and creatinine after 1Â week and repeated after 1Â month is required for patients taking ACE inhibitors or ARBs.</p>\n<p>Trial each regimen change for 3Â months. Consider earlier review (e.g. 6Â weeks) if baseline BP is severely elevated.</p>\n<strong>Reserve beta blockers for when there is inadequate BP control with the other 3Â main classes, or if specific indications e.g:</strong>\n<ul>\n<li>women of childbearing potential.</li>\n<li>patients with:</li>\n<li>evidence of increased sympathetic drive.</li>\n<li>intolerance of ACE inhibitors and ARBs.</li>\n<li>heart disease.</li>\n<li>ConsiderÂ effective combinations</li>\n</ul>\n<p>Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor blocker (ARB) and calcium channel blocker â€“ especially in the presence of diabetes or lipid abnormalities</p>\n<p>ACE inhibitor or ARB and thiazide diuretic â€“ especially in the presence of heart failure, or post-stroke</p>\n<p>ACE inhibitor or ARB and beta blocker â€“ recommended after myocardial infarction (MI) or in the presence of heart failure</p>\n<p>Beta blocker and dihydropyridine calcium channel blocker â€“ especially in the presence of heart disease</p>\n<h3>If presenting with Hypertensive urgency</h3>\n<p>Very common scenario which presents as blood pressure (BP) higherÂ thanÂ 180/110Â mmHg in the absence of acute end-organ damage.</p>\n<ul>\n<li>It is much more common than malignant hypertension.</li>\n<li>The rate of change in BP may be more predictive of end-organ damage.</li>\n<li>It is commonly due to non-adherence with antihypertensive medication.</li>\n</ul>\n<h3>Hypertensive emergency</h3>\n<strong>Hypertensive emergencies are situations in which severe hypertension is associated with acute hypertension-mediated organ damage, which is often life-threatening and requires immediate, but careful intervention to lower blood pressure (BP). Often oral therapy will suffice, but some patients may need intravenous therapy. Typical presentations include:</strong>\n<h3>Malignant hypertension</h3>\n<p>Malignant hypertension is aÂ rare, potentially life-threatening condition which requires immediate treatment.</p>\n<strong>It is severely elevated blood pressure (BP) with rapidly progressive end-organ damage, e.g. retinopathy, including papilloedema, acute left ventricular dysfunction, renal failure, and encephalopathy. Hypertensive encephalopathy:</strong>\n<p>In adults, this is usually associated with systolic blood pressure higherÂ thanÂ 200Â mmHg and diastolic higherÂ thanÂ 130Â mmHg.</p>\n<p>It can occur at lower levels if there has been a rapid rise in pressure.</p>\n<p>Symptoms include confusion, restlessness, convulsions, hypoventilation, and papilloedema.</p>\n<p>Symptoms include blurred vision, headaches, fits,Â acuteÂ confusionÂ orÂ delirium without alternative cause, weakness, numbness, nausea and vomiting, chest pain, shortness of breath.</p>\n<p>severe hypertension associated with a related acute clinical condition, e.g.Â aortic dissection,Â myocardial ischaemia,Â myocardial infarction,Â heart failure,Â stroke</p>\n<ul>\n<li>sudden severe hypertension due to phaeochromocytoma</li>\n<li>pregnancy with severeÂ hypertension or pre-eclampsia.</li>\n<li>for secondary prevention related to their presenting illness, e.g. stroke, acute coronary syndrome.</li>\n<li>if evidence ofÂ Symptoms of end-organ damage</li>\n<li>Headaches</li>\n<li>Transient weakness or blindness</li>\n<li>Loss of visual acuity</li>\n<li>Chest pain</li>\n<li>Dyspnoea</li>\n<li>Claudication</li>\n</ul>\n<strong>Monitor for appropriate response with hourlyÂ BP measurementsÂ over 3Â hoursÂ and manage the patient depending on response:</strong>\n<ul>\n<li>Blood pressureÂ (BP)Â measurements</li>\n<li>EnsureÂ theÂ patient has emptiedÂ theirÂ bladder.</li>\n<li>Advise the patient to avoid caffeine, exercise,Â or smoking 30Â minutes prior to measurement.</li>\n<li>Ask the patientÂ to sitÂ for 5 minutesÂ before theÂ first measurement.</li>\n<li>UseÂ anÂ appropriate cuff size.</li>\n<li>Place the arm onÂ aÂ stable surfaceÂ for support.</li>\n<li>Ask the patientÂ to sitÂ upright with both feet onÂ theÂ floor (not cross legged).</li>\n</ul>\n<p>Measure blood pressure initially in both arms. If there is a difference in systolic pressureÂ moreÂ thanÂ 15Â mmHg,Â useÂ theÂ arm withÂ aÂ higher reading for subsequent measurements.</p>\n<ul>\n<li>Check 2Â readings in total onÂ theÂ same arm, 2Â minutes apart.</li>\n<li>DocumentÂ theÂ average of both readings.</li>\n<li>Avoid speaking toÂ theÂ patient, excessive noise,Â and mobile phone use during readings.</li>\n<li>In older adults andÂ patientsÂ with postural symptoms, perform lying and standing BP measurements.</li>\n<li>Be aware of theÂ classification of office blood pressure levels.</li>\n</ul>\n<h3>Classification of office blood pressure levels</h3>\n<strong>Classification 1:</strong>\n<h4>Stage 1 hypertension:</h4>\n<p>Clinic blood pressure ranges between 140/90Â toÂ 159/99Â mmHg, and</p>\n<p>Subsequent average daytime ambulatory blood pressure monitoring (ABPM), or home blood pressure monitoring (HBPM), ranges between 135/85Â toÂ 149/94Â mmHg</p>\n<h4>Stage 2 hypertension:</h4>\n<p>Clinic blood pressure of 160/100Â mmHg or higherÂ but less thanÂ 180/120Â mmHg, and</p>\n<p>Subsequent average daytime ABPM or HBPM blood pressure ofÂ 150/95Â mmHg orÂ higher</p>\n<p>Stage 3 or severe hypertension â€“ clinic blood pressure of 180/120Â mmHg orÂ higher</p>\n<p>The blood pressure (BP) category is defined by the highest level of BP, whether systolic or diastolic.</p>\n<p>Isolated systolic hypertensionÂ should be graded 1, 2, or 3 according to systolic BP values in the ranges indicated.</p>\n<h3>Isolated systolic hypertension</h3>\n<p>Occurs mostly in older patients</p>\n<p>Elevated pulse pressure is primarily due to diminished arterial compliance</p>\n<p>May also result from an increase in cardiac output due to anaemia, hyperthyroidism, aortic insufficiency, arteriovenous (AV) fistula, or Pagetâ€™s disease of bone</p>\n<p>Associated with a 2- to 4-fold increase in risk of myocardial infarction (MI), left ventricular hypertrophy (LVH), renal dysfunction, stroke, and cardiovascular mortality</p>\n<p>Patients who are actively taking anti-hypertensive medications are usually defined as having hypertension regardless of their observed blood pressure.</p>\n<p>Consider and address factors that may artificially elevate blood pressure, e.g. pain, anxiety,Â \"white coat\" hypertension.</p>\n<ul>\n<li>\"White coat\" hypertension is:</li>\n<li>very common</li>\n<li>not considered a benign condition</li>\n<li>defined as abnormally high blood pressure caused by being in a medical environment.</li>\n<li>IfÂ BPÂ less thanÂ 200/120Â mmHgÂ on 2Â consecutive readings, dischargeÂ the patient.</li>\n</ul>\n<p>If no response after 3 hours,Â addÂ lisinoprilÂ 5Â mgÂ over 24Â hoursÂ andÂ requestÂ acute general medicine assessmentÂ via SDECÂ to ensure response.</p>\n<p>If still no response at 24 hours,Â requestÂ acute nephrology assessment.</p>\n<p>If adequate response,Â requestÂ non-acute nephrology assessmentÂ via theÂ hypertension clinic.</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<ul>\n<li>RecommendÂ lifestyle modificationsÂ for all patients.</li>\n<li>Stopping smoking</li>\n<li>Diet modification (seeÂ DASHÂ approach)</li>\n<li>Limiting salt intakeÂ (less than 4Â g/day)</li>\n<li>Increasing physical activity</li>\n<li>Weight management</li>\n<li>DecreasingÂ alcohol intake</li>\n<li>Safety net advice to return if symptomatic.</li>\n<li>Consider providing medication advice using theÂ MaPPs tool.</li>\n</ul>\n<strong>Refer all patients back to their general practitioner for ongoing management and medication adjustment.</strong>\n<strong>If the patient is taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blocker (ARBs), requestÂ acute general medicine assessmentÂ via SDECÂ for monitoring of electrolytes, urea, and creatinine after 1 week. Advise the patient to repeat tests after 1 month with their general practitioner. Specify 1 month in the discharge letter to the general practitioner.</strong>\n<ul>\n<li>If a specific secondary cause is suspected or confirmed as:</li>\n<li>endocrine, requestÂ non-acute endocrinology assessment.</li>\n<li>renal,Â requestÂ non-acute nephrology assessment.</li>\n</ul>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<strong>If the patient has accelerated orÂ malignant hypertension, requestÂ critical care outreach. If clinical deterioration or evidence of organ failure requiring support, consider requestingÂ intensive care assessment.</strong>\n<h3>Malignant hypertension</h3>\n<p>Malignant hypertension is aÂ rare, potentially life-threatening condition which requires immediate treatment.</p>\n<strong>It is severely elevated blood pressure (BP) with rapidly progressive end-organ damage, e.g. retinopathy, including papilloedema, acute left ventricular dysfunction, renal failure, and encephalopathy. Hypertensive encephalopathy:</strong>\n<p>In adults, this is usually associated with systolic blood pressure higherÂ thanÂ 200Â mmHg and diastolic higherÂ thanÂ 130Â mmHg.</p>\n<p>It can occur at lower levels if there has been a rapid rise in pressure.</p>\n<p>Symptoms include confusion, restlessness, convulsions, hypoventilation, and papilloedema.</p>\n<p>Symptoms include blurred vision, headaches, fits,Â acuteÂ confusionÂ orÂ delirium without alternative cause, weakness, numbness, nausea and vomiting, chest pain, shortness of breath.</p>\n<ul>\n<li>If suspected phaeochromocytoma, requestÂ acute endocrinology assessment</li>\n<li>If pregnant, requestÂ acute obstetric assessment.</li>\n<li>RequestÂ acute general medicine assessmentÂ via SDECÂ if:</li>\n</ul>\n<p>in ED or EAU andÂ no features of accelerated orÂ malignant hypertensionÂ in patients with BP more thanÂ 180/120Â mmHg.</p>\n<h3>Malignant hypertension</h3>\n<p>Malignant hypertension is aÂ rare, potentially life-threatening condition which requires immediate treatment.</p>\n<strong>It is severely elevated blood pressure (BP) with rapidly progressive end-organ damage, e.g. retinopathy, including papilloedema, acute left ventricular dysfunction, renal failure, and encephalopathy. Hypertensive encephalopathy:</strong>\n<p>In adults, this is usually associated with systolic blood pressure higherÂ thanÂ 200Â mmHg and diastolic higherÂ thanÂ 130Â mmHg.</p>\n<p>It can occur at lower levels if there has been a rapid rise in pressure.</p>\n<p>Symptoms include confusion, restlessness, convulsions, hypoventilation, and papilloedema.</p>\n<p>Symptoms include blurred vision, headaches, fits,Â acuteÂ confusionÂ orÂ delirium without alternative cause, weakness, numbness, nausea and vomiting, chest pain, shortness of breath.</p>\n<ul>\n<li>no response after 3 hours.</li>\n<li>at discharge, the patient is taking ACE inhibitors or ARBs.</li>\n<li>If a specific secondary cause is suspected or confirmed as:</li>\n<li>endocrine, requestÂ non-acute endocrinology assessment.</li>\n<li>renal, requestÂ non-acute nephrology assessment.</li>\n<li>If there is a contraindication to B-blocker, seekÂ cardiology advice.</li>\n<li>For inpatient management of severe hypertension, seekÂ general medicine adviceÂ orÂ nephrology advice.</li>\n</ul>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<p>NICE Guidance â€“Â Hypertension in Adults: Diagnosis and Management</p>\n<h4>For patients</h4>\n<p>British Heart Foundation â€“Â High Blood Pressure</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nAcute Hypertension","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Acute Kidney Injury","filename":"Acute Kidney Injury Draft V.1.docx","category":"Acute Medicine","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<p>Urine dipstick significantly positive for blood and protein</p>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Acute Kidney Injury</h3>\n<p>Acute kidney injury (AKI), formerly known as acute renal failure (ARF), is common and is independently and strongly associated with morbidity and mortality.</p>\n<p>AKI is not a single disease, but a complex clinical syndrome that may arise in response to many aetiologies, such as circulatory shock, sepsis, and nephrotoxins.</p>\n<ul>\n<li>The underlying pathophysiology of AKI is not fully understood.</li>\n<li>Early detection and treatment of AKI may improve outcomes.</li>\n<li>AKI is defined as any of the following:</li>\n<li>Increase in serum creatinine level by more than 26Â micromol/L within 48Â hours</li>\n<li>Increase in serum creatinine level by 1.5Â times baseline or more within the previous 7Â days</li>\n<li>Urine volume less than 0.5Â mL/kg/hour for 6Â hours or more</li>\n</ul>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<h3>Take a history â€“ ask about:</h3>\n<p>SymptomÂ with the presence of risk factors.</p>\n<h4>Risk factors</h4>\n<ul>\n<li>Older thanÂ 65Â years</li>\n<li>Chronic kidney disease (CKD)</li>\n<li>Heart failure</li>\n<li>Liver disease</li>\n<li>Diabetes</li>\n<li>ACE inhibitor or ARB in combination with diuretic medication and an NSAID (the triple whammy)</li>\n<li>Past history of acute kidney injury</li>\n<li>Hypovolaemia, e.g. burns, trauma, circulatory shock, patients with ileostomy</li>\n</ul>\n<p>Neurological or cognitive impairment or disability (which may limit fluid intake because of reliance on a carer)</p>\n<ul>\n<li>Use of nephrotoxic drugs in the last week, e.g. NSAIDs, aminoglycosides</li>\n<li>Recent contrast or angiogram</li>\n<li>History of urological obstruction</li>\n<li>Sepsis</li>\n<li>Anaemia</li>\n</ul>\n<h4>Symptoms</h4>\n<ul>\n<li>Nausea and vomiting, or diarrhoea.</li>\n<li>Evidence of dehydration.</li>\n<li>Reduced urine output or changes to urine colour.</li>\n<li>Confusion, fatigue, and drowsiness.</li>\n</ul>\n<h4>Medications</h4>\n<p>DrugsÂ withÂ direct toxic effects on kidneys and can causeÂ acute kidney injury (AKI), e.g. NSAIDS, gentamicin, amphotericin,Â and iodinated radio-contrast agents</p>\n<p>DrugsÂ thatÂ can exacerbate AKI,Â especially during acute illness or hypovolaemia, e.g. all anti-hypertensive drugs (ACE inhibitors, angiotensin receptor blockers, andÂ diuretics)</p>\n<p>DrugsÂ that canÂ accumulate during AKI and effects of drug accumulationÂ that canÂ cause further patient harm, e.g.Â metforminÂ andÂ other diabetic drugs (sulfonylureas), opiates, gabapentin, andÂ digoxin</p>\n<p>Suspect any new drugs which have recently been started, especiallyÂ proton pump inhibitors (PPI)Â or antibiotics.</p>\n<ul>\n<li>Consider AKI if warning alerts received from the laboratory.</li>\n<li>Perform Examine for:</li>\n<li>Achycardia</li>\n<li>Postural hypotension â€“ perform supine and standing blood pressure measurements</li>\n<li>Fluid status</li>\n<li>Tachypnoea â€“ respiratory rate may be increased due to sepsis or acidosis</li>\n<li>Anaemia</li>\n</ul>\n<p>Urinalysis â€“ assume that patients with blood and protein in the urine, and without other indications of UTI, have glomerular disease until proven otherwise</p>\n<h3>Abdomen for palpable bladder or masses</h3>\n<p>ArrangeÂ initial investigationsÂ as appropriate. Exclude bladder outflow obstruction and upper urinary tract obstruction.</p>\n<ul>\n<li>Initial investigations</li>\n<li>Take urine dipstick.</li>\n<li>Urine:</li>\n</ul>\n<p>Albumin/creatinine ratio if there is significant protein on urinalysis (greater than 1+ on dipstick). ACR is not a reliable measure in active urinary tract infection and must be repeated once infection is fully treated.</p>\n<ul>\n<li>Microscopy and culture if urinary tract infection is suspected on urinalysis.</li>\n<li>Blood tests:</li>\n<li>Urea and electrolytes</li>\n<li>When requesting urea and electrolytes, the laboratory will automatically test and provide:</li>\n<li>Sodium</li>\n<li>Potassium</li>\n<li>Bicarbonate</li>\n<li>Chloride</li>\n<li>Urea</li>\n<li>Creatinine</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n</ul>\n<p>FBC</p>\n<ul>\n<li>Bone profile</li>\n<li>Liver function test.</li>\n<li>Use creatinine levels to diagnose AKI using Acute kidney injuryÂ diagnosis and staging</li>\n</ul>\n<p>Acute kidney injury (AKI)Â diagnosisÂ andÂ staging is based upon changes to either serum creatinine and/or urine output. It isÂ assessed by clinician review and compared to defined internationalÂ Kidney Disease Improving Global Outcome (KDIGO)Â AKI criteria.</p>\n<p>Baseline creatinine is considered as the usual creatinine for a patient prior to their current illness.</p>\n<ul>\n<li>Assess potassium levels in context of presentation and patient:</li>\n<li>Levels greater or equal to 6.5Â mmol/L â€“ class as severe.</li>\n<li>Levels of 5.5 to 6.5Â mmol/L â€“ recheck.</li>\n</ul>\n<p>SeveralÂ external factorsÂ can give â€˜falseâ€™ increase in potassium levels â€“ if suspected, recheck urgently.</p>\n<ul>\n<li>External factors</li>\n<li>Can include:</li>\n<li>Delay in transit to the laboratory</li>\n<li>Excess tourniquet time during venepuncture</li>\n<li>Contamination of EDTA tube</li>\n<li>Abnormal platelets, red or white bloods cells</li>\n</ul>\n<p>Patients with existing CKD can often tolerate higher levels of potassium and may habitually run slightly higher than normal â€“ if stable CKD and creatinine levels, consider repeating levels.</p>\n<p>ConsiderÂ Potential causes of AKI</p>\n<h3>Prerenal â€“ due to reduced perfusion of the kidneys</h3>\n<p>Postrenal â€“ due to acute obstruction of the flow of urine resulting in increased intratubular pressure</p>\n<ul>\n<li>Intrinsic renal disease:</li>\n<li>Rapidly progressive glomerulonephritis</li>\n<li>Rhabdomyolysis</li>\n<li>Acute interstitial nephritis</li>\n<li>Myeloma</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<ul>\n<li>Request emergency assessmentÂ if:</li>\n<li>bladder outflow obstruction and upper urinary tract obstruction.</li>\n<li>serum potassium levels greater thanÂ 6.5Â mmol/L.</li>\n<li>AKI with development of complications or any other concerning features.</li>\n</ul>\n<h4>Concerning features</h4>\n<ul>\n<li>New onset severe AKI with creatinine level greater thanÂ 300Â micromol/L</li>\n<li>AKI with creatinine levels 2Â times the baseline or greater</li>\n<li>Urine dipstick significantly positive for blood and protein (potentially intrinsic kidney disease)</li>\n<li>Initial creatinine level 1.5Â toÂ 2Â times baseline, and rising when rechecked</li>\n<li>RequestÂ acute nephrology assessmentÂ if:</li>\n<li>acutely unwell dialysis or transplant patient.</li>\n<li>kidney transplant recipients with acute intercurrent illness.</li>\n</ul>\n<strong>If the patient has multi-organ failure due to AKI requiring blood pressure or respiratory support, orÂ urgent dialysis,Â requestÂ critical care outreachÂ assessment.</strong>\n<h4>Urgent dialysis</h4>\n<ul>\n<li>Consider dialysis if:</li>\n<li>refractory hyperkalaemia (6.5Â mmol/LÂ or greater)Â despite medical therapy.</li>\n<li>refractory fluid overload with anuria, despite intervention for obstruction.</li>\n<li>refractory acidosis (pH less thanÂ 7.15), despite medical therapy.</li>\n<li>uraemic pericarditis or encephalopathy.</li>\n<li>SeekÂ nephrology adviceÂ if dialysisÂ is indicated and clinically appropriate.</li>\n<li>If obstruction:</li>\n<li>requestÂ acute urology assessmentÂ and seekÂ nephrology adviceÂ if dialysis is indicated.</li>\n<li>considerÂ treatingÂ with nephrostomy or stenting if indicated.</li>\n<li>StopÂ medications that may increase the risk of AKI.</li>\n<li>Medications that may increase risk of acute kidney injury (AKI)</li>\n<li>Non-steroidal anti-inflammatory drugs (NSAIDs)</li>\n<li>Angiotensin converting enzyme (ACE) inhibitors</li>\n<li>Angiotensin receptor blockers</li>\n<li>Intravenous and intra-arterial contrast</li>\n</ul>\n<h3>Antibiotics, e.g. aminoglycosides, beta lactams, sulphonamides</h3>\n<ul>\n<li>Diuretics</li>\n<li>Fibrates</li>\n<li>Cisplatin</li>\n<li>Amphotericin</li>\n<li>Alcohol</li>\n<li>Ensure that all prescribed medicationsÂ are clinically appropriate.</li>\n</ul>\n<strong>Ensure drug doses are appropriate for level of renal function,Â and levelsÂ areÂ monitoredÂ andÂ adjustedÂ as needed.</strong>\n<p>AvoidÂ radiographicÂ contrastÂ agents, unless deemed necessary by a senior clinician.</p>\n<h3>Radiographic contrast agents</h3>\n<strong>IfÂ intravenousÂ contrastÂ isÂ necessary, consider delayingÂ use untilÂ acute kidney injury (AKI) isÂ resolved and:</strong>\n<p>assess fluidsÂ â€“Â ifÂ the patient has depletedÂ fluids,Â carefully resuscitate to euvolaemia,Â (e.g. 1Â mL/kg/hour 0.9%Â salineÂ intravenouslyÂ for 12Â hoursÂ before and afterÂ contrast) with care to avoid fluid overload.</p>\n<p>minimise contrast volume and use low or iso-osmolar contrast â€“ reviewÂ and/orÂ suspend other drugs as per general AKI medication guidance.</p>\n<p>monitor renal function daily post-contrast and consider renal opinion if oliguria or creatinineÂ areÂ still rising 72Â hours post-contrast (or other indication).</p>\n<p>Manage fluid status, i.e.Â fluid depletionÂ orÂ fluid overload.Â Seek advice from a senior clinicianÂ ifÂ unsureÂ about fluid status or prescription.</p>\n<h3>Fluid overloadÂ (euvolaemia)</h3>\n<p>Consider maintenanceÂ intravenousÂ fluids (avoiding fluid overload),Â ifÂ theÂ patientÂ isÂ unable to drink adequately.</p>\n<strong>Aim to match estimated daily fluid loss plus 500Â mL over 24Â hoursÂ andÂ setÂ aÂ daily fluid balance target.</strong>\n<ul>\n<li>Adjust the fluid type toÂ theÂ clinical contextÂ andÂ biochemistry.</li>\n<li>Aim to revertÂ the patientÂ to oral fluids at earliest opportunity.</li>\n<li>See NICE Guidance â€“Â Algorithms for IV Fluid Therapy in Adults</li>\n<li>Fluid depletionÂ (hypovolaemia)</li>\n<li>Identify any underlying cause of fluid deficit and treat accordingly.</li>\n</ul>\n<p>GiveÂ intravenousÂ fluid bolus challenges of 250Â toÂ 500Â mL over 15Â toÂ 30Â minutes,Â with regular review of response.</p>\n<strong>Ensure the fluid typeÂ isÂ tailored to clinical contextÂ andÂ biochemistryÂ â€“Â typically crystalloid with Na+Â 130Â toÂ 154Â mmol/L.</strong>\n<p>Conduct a middle grade review if 2Â L or more fluid challenge given and patientÂ isÂ still hypovolaemicÂ and/orÂ oliguric.</p>\n<p>If hypotensiveÂ orÂ shocked despite fluid resuscitation,Â considerÂ requestingÂ critical care opinionÂ forÂ blood pressureÂ support.</p>\n<p>Consider maintenance fluids once fluid replete ifÂ theÂ patientÂ isÂ unable to drinkÂ anÂ adequate volume.</p>\n<ul>\n<li>Monitor and manage complications of AKI including:</li>\n<li>Hyperkalaemia</li>\n<li>Acidosis</li>\n<li>Acidosis</li>\n<li>Manage acidosis using sodium bicarbonate therapy:</li>\n<li>If venous bicarbonateÂ isÂ 16Â mmol/LÂ or less,Â consider giving sodium bicarbonate as:</li>\n</ul>\n<p>500Â toÂ 1000Â mg orallyÂ four times a day. Stop if bicarbonate rises toÂ more thanÂ 22Â mmol/L or fluid overload.</p>\n<ul>\n<li>500Â mL of 1.26% sodium bicarbonateÂ intravenouslyÂ over 1Â hour.</li>\n<li>If pHÂ isÂ 7.15Â or less:</li>\n<li>consider early critical care input and dialysis if acidosisÂ isÂ refractory to medical interventions.</li>\n<li>ensure other causes of metabolic acidosis are identified and treated.</li>\n<li>Be aware that:</li>\n</ul>\n<p>bicarbonate therapy can worsen fluid overload andÂ decreaseÂ iCa2+. Avoid if either parameterÂ isÂ present.</p>\n<ul>\n<li>intravenous bicarbonate and intravenous calcium should not be given via sameÂ intravenousÂ cannula.</li>\n<li>Pulmonary oedema</li>\n<li>Sit the patient up and give oxygen â€“ 60Â toÂ 100% unless contraindicated.</li>\n</ul>\n<p>If haemodynamically stable, give intravenousÂ furosemide 80Â mg and considerÂ glyceryl trinitrateÂ infusion 1Â toÂ 10Â mg/hour.</p>\n<strong>Do not use furosemide duringÂ acute kidney injury (AKI)Â to expedite renal recoveryÂ as there isÂ no proven benefit.</strong>\n<p>Be aware that furosemideÂ isÂ mainly reserved for pulmonary oedema in non-oliguric AKI without hypotension.</p>\n<p>If haemodynamically unstable, ensureÂ early critical care inputÂ andÂ consideration of respiratory support.</p>\n<p>Hypocalcaemia</p>\n<h3>Hypoglycaemia</h3>\n<p>IfÂ intrinsic renal diseaseÂ is suspected, e.g. significant protein or blood on urine dipstick, consider seekingÂ nephrology advice.</p>\n<h3>Intrinsic renal disease</h3>\n<p>Intrinsic renal diseaseÂ is aÂ relatively uncommon cause ofÂ acute kidney injury (AKI)Â (less thanÂ 5% of cases).</p>\n<p>Be awareÂ not to miss diagnoses asÂ the patientÂ may benefit from early intervention.Â SeekÂ nephrology adviceÂ if unsure.</p>\n<p>Consider intrinsic renal disease screeningÂ ifÂ theÂ urine dipstickÂ isÂ positive for blood and protein, and no obvious cause for AKI, or clinical suspicion of nephritis or systemic disease-causing AKI.</p>\n<ul>\n<li>Consider transferring the patient to a renal unit if:</li>\n<li>discussed with a renal specialty registrar or consultant.</li>\n<li>referred by a registrarÂ orÂ consultant familiar with clinical details of the patient.</li>\n<li>theyÂ have an appropriateÂ indication for renal referral.</li>\n<li>Indication for renal referral</li>\n<li>RequestÂ acute nephrology assessmentÂ if:</li>\n</ul>\n<p>stage 3Â acute kidney injury (AKI),Â unless obviousÂ cause andÂ imminent recovery likely with standard AKI care pathway.</p>\n<h4>stage 2 AKIÂ andÂ not responding to standard AKI care pathway after 48Â hours.</h4>\n<ul>\n<li>AKI complicationsÂ andÂ not responding to medical treatment orÂ if theyÂ meet indicationsÂ for dialysis.</li>\n<li>suspected nephritis or systemic disease-causing AKI.</li>\n<li>the patient is aÂ renal transplant recipient with AKI.</li>\n<li>theÂ patientÂ hasÂ poisoning and AKI.</li>\n<li>stable for safe transfer and suitable for ward-based care.</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<strong>Ensure drug information and advice is given on discharge.</strong>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<ul>\n<li>RequestÂ emergency assessmentÂ if:</li>\n<li>bladder outflow obstruction and upper urinary tract obstruction.</li>\n<li>serum potassium levels greater thanÂ 6.5Â mmol/L.</li>\n<li>AKI with development of complications or any otherÂ concerning features.</li>\n</ul>\n<h4>Concerning features</h4>\n<ul>\n<li>New onset severe AKI with creatinine level greater thanÂ 300Â micromol/L</li>\n<li>AKI with creatinine levels 2Â times the baseline or greater</li>\n<li>Urine dipstick significantly positive for blood and protein (potentially intrinsic kidney disease)</li>\n<li>Initial creatinine level 1.5Â toÂ 2Â times baseline, and rising when rechecked</li>\n<li>RequestÂ critical care outreach assessmentÂ if:</li>\n</ul>\n<p>the patient has multi-organ failure due to AKI requiring blood pressure or respiratory support, or urgent dialysis.</p>\n<ul>\n<li>hypotensive or shocked despite fluid resuscitation, for blood pressure support.</li>\n<li>RequestÂ acute nephrology assessmentÂ if:</li>\n<li>acutely unwell dialysis or transplant patient.</li>\n<li>kidney transplant recipients with acute intercurrent illness.</li>\n</ul>\n<h4>stage 3 AKI, unless obvious cause and imminent recovery likely.</h4>\n<h4>stage 2 AKI and not responding to standard AKI care pathway after 48Â hours.</h4>\n<ul>\n<li>AKI complications and not responding to medical treatment or meet indications for dialysis.</li>\n<li>suspected nephritis or systemic disease-causing AKI.</li>\n<li>poisoning.</li>\n</ul>\n<p>If obstruction, and dialysis is indicated, requestÂ acute urology assessmentÂ and seekÂ nephrology advice.</p>\n<p>SeekÂ nephrology adviceÂ if intrinsic renal disease is suspected.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<ul>\n<li>Further information</li>\n<li>NICE Guidance â€“Â Acute Kidney Injury</li>\n<li>UK Kidney Association</li>\n</ul>\n<h4>For patients</h4>\n<p>National Kidney Federation â€“Â Acute Kidney Injury</p>\n<p>NHS â€“Â Acute Kidney Injury</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nAcute kidney Injury","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Death of an adult","filename":"Death of an adult Draft V.1.docx","category":"End of Life Care","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Confirming Death","content":"<p>ClinicallyÂ confirm the deathÂ following the correctÂ procedure. Death must be verified byÂ a registered healthcare professional.</p>\n<ul>\n<li>Procedure</li>\n<li>Feel for a major (carotid or femoral) pulse for at least 1Â minute.</li>\n<li>Listen for heart sounds over the cardiac apex for at least 1Â minute.</li>\n<li>Watch the chest wall for any movement.</li>\n<li>Listen to the chest for breath sounds for 3Â minutes.</li>\n<li>Watch for any spontaneous movement during the examination.</li>\n<li>Check there is no motor response to supraorbital pressure.</li>\n<li>Check that both pupils are fixed and dilated.</li>\n<li>Check the corneal reflexes are absent.</li>\n<li>Confirm death</li>\n</ul>\n<p>Death has occurred if there is no spontaneous cardiac function, no spontaneous respiratory effort, and no central nervous system activity, including no pupillary response to light.</p>\n<ul>\n<li>Collate theÂ information to be recordedÂ in the patient's medical notes.</li>\n<li>Information to be recorded</li>\n<li>Date and time of examination of body</li>\n<li>No heartbeat heard over 1Â minute</li>\n<li>No carotid pulse felt over 1Â minute</li>\n<li>No breath sounds heard, and no chest movement seen over 1Â minute</li>\n<li>Pupils fixed and dilated</li>\n<li>Corneal reflex absent</li>\n<li>Patient verified as dead</li>\n<li>Signature, name, and designation of verifier</li>\n<li>Following confirmation of death, complete the \"verificationÂ of deathÂ â€“ adult\" inÂ Meditech V6.</li>\n<li>Support the nursing staff to:</li>\n<li>ensure the next of kin or carers are informed if they are not present when the patient dies.</li>\n<li>If possible, allow time for the kin or carers to visit the patient before transfer to the mortuary.</li>\n</ul>\n<p>If it is not possible for the kin or carers to visit before the transfer, give contact information by phone for mortuary advice in case they would like to view the deceased after discharge from the ward.</p>\n<p>provide the next of kin or carer with a bereavement pack which provides relevant post-death information. If the next of kin or carer are not present on the ward, seek bereavement advice and support and provide the service with the kin or carers contact information.</p>\n<p>discuss any religious or cultural needs with the next of kin or carers to ensure that the patientâ€™s wishes are respected.</p>\n<p>If family members are not available, seek mortuary advice or chaplaincy advice.</p>\n<p>If the death is to be referred to the coroner, the patient cannot be released, regardless of religious or cultural wishes. If necessary,Â contact theÂ medical examiner's officeÂ for advice.</p>\n<h3>Medical examiner's office</h3>\n<ul>\n<li>Location:Â Harton Wing, South Tyneside Hospital</li>\n<li>Phone:Â (71) 4006</li>\n<li>Email:Â stsft.meoffice@nhs.net</li>\n<li>Available Monday to Friday, 8:00 am to 4:00 pm</li>\n</ul>\n<p>discuss the possibility of eye and tissue donation with the next of kin. See the Organ and Tissue Donation pathway.</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Medical Examiner Scrutiny and Certifying Death","content":"<strong>Seek consultant's adviceÂ to agree on aÂ proposed cause of deathÂ and to consider whetherÂ the death should be reported to theÂ coronerÂ by:</strong>\n<ul>\n<li>Coroner</li>\n<li>Independent judicial officers, usually a doctor or solicitor.</li>\n<li>Each must have a deputy and one or the other must be available at all times.</li>\n<li>Are helped by their officers, who receive the reports of deaths and make enquiries on their behalf.</li>\n<li>Enquire into those deaths reported to them.</li>\n<li>Offer advice on death certification to general practitioners.</li>\n</ul>\n<p>Have a duty to determine the medical cause of the death, if it is not known, and to enquire about the cause of it if it was due to violence or was otherwise unnatural.</p>\n<ul>\n<li>Proposed cause of death</li>\n<li>State the cause(s) of death accurately and fully.</li>\n<li>Avoid:</li>\n<li>the use of abbreviations, e.g. COPD, question marks, and vague terms such as \"probably\".</li>\n</ul>\n<p>giving \"frailty of old age\" or \"senility\" as the only cause of death. Only use if you cannot give a more specific cause of death and the deceased was aged 80Â years or older.</p>\n<p>giving a mode of dying, e.g. \"heart failure\", \"shock\", or \"uraemia\" unless you also give the underlying causal sequence. Do not give the mode of dying as the only cause on the death certificate as this will not be accepted by the registrar.</p>\n<p>SeeÂ guidance for doctorsÂ completing Medical Certificate of Cause of Death (MCCD) in England and Wales, and Royal College ofÂ PathologistsÂ â€“Â Cause of Death List.</p>\n<ul>\n<li>determining if the cause of death is known and due to natural causes,</li>\n<li>ruling out otherÂ significant findingsÂ not reflecting reported cause of death.</li>\n<li>Significant findings</li>\n</ul>\n<p>For example, an elderly person thought to have died from a myocardial infarction (MI) but, on further examination of the body, there are signs of a fall and fractured hip.</p>\n<p>establishing that the cause of death was not due to a condition on theÂ notification of deaths regulations.</p>\n<p>If all of these conditions are met then the death does not need to be reportedÂ to the coroner.</p>\n<strong>SendÂ aÂ medical examiner (ME)Â referral via Orders on V6, providing:</strong>\n<h3>Medical examiner (ME)</h3>\n<p>Medical examiners are senior medical doctors trained in the legal and clinical elements of death certification processes.</p>\n<ul>\n<li>Their role is to:</li>\n<li>Review the medical records</li>\n<li>Liaise with the doctor who treated the patient in their final illness</li>\n</ul>\n<p>Agree the proposed cause of death and help with the quality and accuracy of the Medical Certificate of Cause of Death (MCCD)</p>\n<p>Discuss the proposed cause of death with the next of kin, ensuring that they understand any medical terms and providing an opportunity for them to discuss</p>\n<ul>\n<li>Ensure that any concerns about the care of the deceased are acted on appropriately</li>\n<li>theÂ proposed cause of death.</li>\n<li>Proposed cause of death</li>\n<li>State the cause(s) of death accurately and fully.</li>\n<li>Avoid:</li>\n<li>the use of abbreviations, e.g. COPD, question marks, and vague terms such as \"probably\".</li>\n</ul>\n<p>giving \"frailty of old age\" or \"senility\" as the only cause of death. Only use if you cannot give a more specific cause of death and the deceased was aged 80Â years or older.</p>\n<p>giving a mode of dying, e.g. \"heart failure\", \"shock\", or \"uraemia\" unless you also give the underlying causal sequence. Do not give the mode of dying as the only cause on the death certificate as this will not be accepted by the registrar.</p>\n<p>SeeÂ guidance for doctorsÂ completing Medical Certificate of Cause of Death (MCCD) in England and Wales, and Royal College ofÂ PathologistsÂ â€“Â Cause of Death List.</p>\n<p>confirmation if direct referral to the coroner is being made.</p>\n<p>any concerns regarding the death.</p>\n<strong>Advise the next of kin that the medical examinerâ€™s office will contact them. Information about the role of the medical examiner is included in theÂ Trust Bereavement Booklet. This can be delegated to ward staff.</strong>\n<strong>Use theÂ online portalÂ to notify a reportable death to the coroner, after which the following steps will be undertaken:</strong>\n<h3>Online portal</h3>\n<p>Be aware that a coroner referral is made to the coroner in whose jurisdiction the body is located, and is not dependent on the address of the deceased.</p>\n<ul>\n<li>South Tyneside coroner referral</li>\n<li>Sunderland coroner referral</li>\n<li>When accessing the portals, use the referrer code H01.</li>\n</ul>\n<p>The coroner will decide whether the cause of death is likely to be natural or unnatural, based on the information that they have received.</p>\n<strong>Once reviewed by the coroner, a coronerâ€™s officer will be back in touch with theÂ attending doctorÂ with a view to progressing the case dependent on whether:</strong>\n<p>.</p>\n<p>the death was natural andÂ no further investigation is required.</p>\n<h3>Attending doctor</h3>\n<p>The legal definition of who qualifies as an attending doctor is a registered doctor who has attended the deceased before their death.</p>\n<p>In order to complete the Medical Certificate and Cause of Death (MCCD) they must also have access to and be familiar with the person's medical records.</p>\n<p>For more information, see The National Archives â€“Â The Medical Certificate of Cause of Death Regulations 2024</p>\n<h3>No further investigation is required</h3>\n<p>The coroner may decide that the death was natural and that there is a doctor to certify this. If so, the medical examiner's office will receive a CN1A form giving a reason as to why further investigation is not needed.Â Medical examinerÂ scrutiny will start as soon as a proposed cause of death is offered by the attending practitioner.</p>\n<strong>Check that the medical examiner referral (V6 Orders) has been fully completed and aÂ proposed cause of deathÂ has been offered.</strong>\n<ul>\n<li>Proposed cause of death</li>\n<li>State the cause(s) of death accurately and fully.</li>\n<li>Avoid:</li>\n<li>the use of abbreviations, e.g. COPD, question marks, and vague terms such as \"probably\".</li>\n</ul>\n<p>giving \"frailty of old age\" or \"senility\" as the only cause of death. Only use if you cannot give a more specific cause of death and the deceased was aged 80Â years or older.</p>\n<p>giving a mode of dying, e.g. \"heart failure\", \"shock\", or \"uraemia\" unless you also give the underlying causal sequence. Do not give the mode of dying as the only cause on the death certificate as this will not be accepted by the registrar.</p>\n<p>SeeÂ guidance for doctorsÂ completing Medical Certificate of Cause of Death (MCCD) in England and Wales, and Royal College ofÂ PathologistsÂ â€“Â Cause of Death List.</p>\n<ul>\n<li>Further investigation is required</li>\n<li>The coroner may ask a pathologist to examine the body. If so:</li>\n<li>The examination must be done as soon as possible.</li>\n<li>The coronerâ€™s officer will contact the family of the deceased to:</li>\n<li>advise them of the need for the coronerâ€™s enquiry.</li>\n<li>advise them regarding funeral arrangements.</li>\n<li>keep them updated until enquiries are complete and death registration can proceed.</li>\n</ul>\n<p>The coroner will also give notice of the arrangements to the deceasedâ€™s usual doctor and the nominated funeral director.</p>\n<p>Doctors involved in the deceasedâ€™s care or treatment may be required to submit any relevant information to the coroner as part of the enquiry, and may be asked to attend any subsequent inquest to give evidence.</p>\n<strong>When the proposed cause of death has been agreed with the medical examiner, issue the appropriate certificate:</strong>\n<p>For deaths in adults, children, or infants aged 28Â days or older, issue aÂ Medical Certificate and Cause of Death (MCCD).</p>\n<ul>\n<li>Medical Certificate Cause of Death (MCCD)</li>\n<li>When completing a Medical Certificate Cause of Death (MCCD):</li>\n<li>Write legibly.</li>\n<li>Ensure that the cause of deathÂ exactlyÂ matches that agreed with the medical examiner (ME).</li>\n<li>Ensure that you have completed the sections on ethnicity, implants, and pregnancy.</li>\n</ul>\n<p>Always state your qualifications. If qualified abroad, state qualifications and town or university where you qualified.</p>\n<p>Scan and email the MCCD back to theÂ medical examiner's office. The MCCD will be countersigned by the ME and will be sent to the Registrar.</p>\n<h3>Medical examiner's office</h3>\n<ul>\n<li>Location:Â Harton Wing, South Tyneside Hospital</li>\n<li>Phone:Â (71) 4006</li>\n<li>Email:Â stsft.meoffice@nhs.net</li>\n<li>Available Monday to Friday, 8:00 am to 4:00 pm</li>\n</ul>\n<p>AnyÂ attending doctorÂ has a legal responsibility to issue a death certificate where they can establish a cause of death and if there is no indication for referral to the coroner.</p>\n<h3>Attending doctor</h3>\n<p>The legal definition of who qualifies as an attending doctor is a registered doctor who has attended the deceased before their death.</p>\n<p>In order to complete the Medical Certificate and Cause of Death (MCCD) they must also have access to and be familiar with the person's medical records.</p>\n<p>For more information, see The National Archives â€“Â The Medical Certificate of Cause of Death Regulations 2024.</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Certifying a Death in Special Circumstances","content":"<strong>Be aware, different cultures and faiths have varying traditions when someone dies and can include the need for an immediate burial. For aÂ predictableÂ death that is likely to occur over a weekend or public holiday:</strong>\n<strong>For a predictable death that is likely to occur over a weekend or public holiday:</strong>\n<p>If possible,Â phoneÂ theÂ medical examiner's officeÂ during working hours to discuss an imminent and expected death that does not need reporting to the coroner.</p>\n<h3>Medical examiner's office</h3>\n<ul>\n<li>Location:Â Harton Wing, South Tyneside Hospital</li>\n<li>Phone:Â (71) 4006</li>\n<li>Email:Â stsft.meoffice@nhs.net</li>\n<li>Available Monday to Friday, 8:00 am to 4:00 pm</li>\n</ul>\n<p>The medical examiner can provide a \"pre-scrutiny\" allowing the MCCD to be done immediately after death. The MCCD will still need to be countersigned by an ME.</p>\n<strong>For deaths that occur without pre-scrutiny and family require urgent release for faith reasons:</strong>\n<p>MondayÂ toÂ Friday â€“ phone theÂ medical examiner's officeÂ to advise of urgency immediately after completion of the V6 Order (or at 8.00Â am the next morning for deaths occurring weekdays out of hours)</p>\n<h3>Medical examiner's office</h3>\n<ul>\n<li>Location:Â Harton Wing, South Tyneside Hospital</li>\n<li>Phone:Â (71) 4006</li>\n<li>Email:Â stsft.meoffice@nhs.net</li>\n<li>Available Monday to Friday, 8:00 am to 4:00 pm</li>\n</ul>\n<p>For natural deaths, a body may be removed from the mortuary early by undertakers using the Out-of-Hours Release from Mortuary form. The body will not be altered until the MCCD is issued. Contact the mortuary technician on call (via switchboard) if this is required.</p>\n<p>If the death needs to be referred to the coroner,Â a body cannot be released until approved by the coroner regardless of religious or cultural wishes.</p>\n<p>If necessary, contact theÂ medical examiner's officeÂ for advice.</p>\n<h3>Medical examiner's office</h3>\n<ul>\n<li>Location:Â Harton Wing, South Tyneside Hospital</li>\n<li>Phone:Â (71) 4006</li>\n<li>Email:Â stsft.meoffice@nhs.net</li>\n<li>Available Monday to Friday, 8:00 am to 4:00 pm</li>\n</ul>\n<p>Out of hours,Â phone the on-call coronerâ€™s officerÂ for the relevant jurisdiction (via police switchboard â€“Â 101) to ensure they are made aware of family wishes.</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Registering a Death","content":"<p>The medical examiner's office will now send the Death Certificate to the Registrar, and will update the family throughout the process.</p>\n<strong>Deaths involving cremation:</strong>\n<p>There is no longer any need to complete a cremation form.</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Transferring the Deceased Patient to the Mortuary","content":"<p>Support the nursing staff in preparing the patient for transfer to the mortuary using a Care after Death pack.</p>\n<ul>\n<li>If the pack is unavailable on the ward, requestÂ a pack from theÂ mortuary.</li>\n<li>Mortuary</li>\n<li>South Tyneside District Hospital â€“ ext.Â 4164</li>\n<li>Sunderland Royal Hospital â€“ ext.Â 49042</li>\n<li>If the next of kin request that jewellery is not removed, document in the patient valuables book.</li>\n<li>Choose the appropriate procedure:</li>\n<li>Procedure if no coroner involvement</li>\n<li>Lie the deceased patient on their back and leave 1 pillow under the head.</li>\n<li>Straighten all limbs.</li>\n<li>Ensure legible correct name band is in situ on the right wrist.</li>\n<li>Close their eyes â€“ gently apply light pressure for 30Â seconds.</li>\n<li>Close mouth (apply mask).</li>\n<li>Let the deceased patient rest for 30Â minutes â€“ open a window.</li>\n<li>If a urinary catheter, deflate balloon with syringe and remove.</li>\n<li>Remove all intravenous lines and medical devices and apply gauze.</li>\n</ul>\n<p>Two people to wash and dry the patient and ensure dignity is maintained, including mouth and dentures, comb hair.</p>\n<ul>\n<li>Do not shave as this may leave bruising.</li>\n<li>Dress the patient in their own nightwear or shroud.</li>\n<li>Dispose of all waste in an orange clinical waste bag.</li>\n</ul>\n<p>Two people to roll the patient onto their side, sheet under patient rolled under patient, bed wiped clean with antibacterial wipes,Â and envelope bag placed in situ.</p>\n<p>Two people roll the patient to the other side, remove sheet, wipe the bed clean with antibacterial wipes,Â and unroll the envelope bag under the patient.</p>\n<p>Following transfer from the bed, the nursing staff should ensure the patient has not rotated during transfer and remains on their back.</p>\n<p>Wrap the envelope bag around the patient, no tape is required.</p>\n<p>Place the patient's property in a property bag and record items.</p>\n<p>If belongings are not collected by the next of kin or carers, advise them to contact the bereavement team.</p>\n<ul>\n<li>Procedure if coroner involvement</li>\n<li>Lie the deceased patient on their back and leave 1 pillow under the head.</li>\n<li>Straighten all limbs.</li>\n<li>Ensure legible correct name band is in situ on the right wrist.</li>\n<li>Close their eyes â€“ gently apply light pressure for 30Â seconds.</li>\n<li>Close mouth (apply mask).</li>\n<li>Let the deceased patient rest for 30Â minutes â€“ open a window.</li>\n<li>If a urinary catheter, leave in place.</li>\n<li>Leave all intravenous lines and medical devices in place, do not remove.</li>\n</ul>\n<p>Two people to wash and dry the patient and ensure dignity is maintained, including mouth and dentures, comb hair.</p>\n<ul>\n<li>Do not shave as this may leave bruising.</li>\n<li>Dress the patient in their own nightwear or shroud.</li>\n<li>Dispose of all waste in an orange clinical waste bag.</li>\n</ul>\n<p>Two people to roll the patient onto their side, sheet under patient rolled under patient, bed wiped clean with antibacterial wipes,Â and envelope bag placed in situ.</p>\n<p>Two people roll the patient to the other side, remove sheet, wipe the bed clean with antibacterial wipes,Â and unroll the envelope bag under the patient.</p>\n<p>Wrap the envelope bag around the patient, no tape is required.</p>\n<p>Place the patient's property in a property bag and record items.</p>\n<p>If belongings are not collected by the next of kin or carers, advise them to contact the bereavement service.</p>\n<p>Support the nursing staff to discharge the deceased patient to the mortuary via theÂ porters.</p>\n<h3>Porters</h3>\n<p>InÂ the hospital, phoneÂ 0Â to talk to automated switchboard or hold to speak to a person and ask for the porters.</p>\n<strong>Document all post-death care in theÂ Meditech \"Care After Death\" checklistÂ and \"Care of the Dying\" document if relevant.</strong>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Advice and Referrals","content":"<p>SendÂ aÂ medical examiner (ME)Â referral via Orders on Meditech V6 for all deaths.</p>\n<h3>Medical examiner (ME)</h3>\n<p>Medical examiners are senior medical doctors trained in the legal and clinical elements of death certification processes.</p>\n<ul>\n<li>Their role is to:</li>\n<li>Review the medical records</li>\n<li>Liaise with the doctor who treated the patient in their final illness</li>\n</ul>\n<p>Agree the proposed cause of death and help with the quality and accuracy of the Medical Certificate of Cause of Death (MCCD)</p>\n<p>Discuss the proposed cause of death with the next of kin, ensuring that they understand any medical terms and providing an opportunity for them to discuss</p>\n<ul>\n<li>Ensure that any concerns about the care of the deceased are acted on appropriately</li>\n<li>Use theÂ online portalÂ to notify a reportable death to the coroner.</li>\n<li>Online portal</li>\n</ul>\n<p>Be aware that a coroner referral is made to the coroner in whose jurisdiction the body is located, and is not dependent on the address of the deceased.</p>\n<ul>\n<li>South Tyneside coroner referral</li>\n<li>Sunderland coroner referral</li>\n<li>When accessing the portals, use the referrer code H01.</li>\n</ul>\n<p>If a deathÂ andÂ needs to be immediately referred to the coroner, phone the police onÂ 101Â to be put in contact with the on-call coronerâ€™s officer.</p>\n<strong>If the patient's kin or carer are not present on the wardÂ when a death occurs, seek bereavement advice and support.</strong>\n<p>SeekÂ mortuary adviceÂ orÂ chaplaincy adviceÂ to discuss any religious or cultural needs with the next of kin or carers to ensure that the patientâ€™s wishes are respected if family members are not available.</p>\n<p>IfÂ expectingÂ a death in circumstances where the family will request immediate burial, and it's possible, phone theÂ medical examiner's officeÂ during working hours to discuss an imminent death that does not need reporting to the coroner.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<p>Further information</p>\n<h4>For health professionals</h4>\n<p>Department of Health and Social CareÂ â€“Â Guidance for Doctors Completing Medical Certificates of Cause of Death in England and Wales</p>\n<p>NHS England â€“Â Overview Process for Death Certification</p>\n<p>STSFT Intranet â€“Â Medical Examiner Service</p>\n<h4>For patients</h4>\n<ul>\n<li>GOV.UK â€“Â What To Do When Someone Dies: Step by Step</li>\n<li>South Tyneside Council â€“Â Deaths</li>\n<li>Sunderland City Council â€“Â Registration of Deaths</li>\n</ul>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nDeath of an Adult","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Delirium","filename":"Delirium Draft V.1.docx","category":"Mental Health & Cognition","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<ul>\n<li>History of fever</li>\n<li>Any recent fall</li>\n<li>Hypoactive presentation</li>\n<li>Poor fluid intake</li>\n</ul>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Delirium</h3>\n<p>Delirium is an acute change in mental status that tends to fluctuate during the day and is characterised by a disturbance of consciousness, attention, cognition, and perception thatÂ oftenÂ develops over a short period of time, usually hours to a few days.Â It can be triggered by multiple problems such as medical illness, surgery or medications.</p>\n<ul>\n<li>The burden associated with delirium is high. Patients with delirium have:</li>\n<li>an increased risk of death.</li>\n<li>an increased length of hospital stay.</li>\n<li>an increased risk of fallsÂ and pressure ulcers.</li>\n<li>a greater chance of being discharged to a higher dependency of care.</li>\n<li>a greater chance of developing dementia.</li>\n</ul>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<h3>Screen patients promptly</h3>\n<p>All patients with risk factors for delirium should be screened within 24Â hours of admission,Â or at point of clinical suspicion,Â using the 4AT assessment tool.</p>\n<h3>Take a History considering:</h3>\n<ul>\n<li>Ask about:</li>\n<li>any acute change in cognitive function or change in behaviour:</li>\n<li>Confusion</li>\n<li>Worsened concentration</li>\n<li>Agitation</li>\n<li>Restlessness</li>\n<li>Altered level of consciousness</li>\n<li>Less communicative or responsive</li>\n<li>Difficulty cooperating with reasonable requests</li>\n<li>Alterations in mood or emotions</li>\n<li>Altered sleep patterns</li>\n<li>changes or fluctuation in condition over hours to days.</li>\n<li>any other symptoms or complaintsÂ to suggest underlying illness,Â injury,Â or infection.</li>\n<li>recent falls.</li>\n<li>the use of hearing aids or glasses.</li>\n<li>any changes to medication within the last month.</li>\n<li>alcohol use or risk of withdrawal.</li>\n</ul>\n<p>Obtain a collateral history, including pre-morbid cognitive function, from both the patient's family and general practice team.</p>\n<h4>Risk factors</h4>\n<ul>\n<li>Predisposing factors:</li>\n<li>Being age 65 years or older</li>\n<li>Existing cognitive impairment (e.g. dementia)</li>\n<li>Previous episode of delirium</li>\n<li>Altered functional status (e.g. immobility, falls)</li>\n<li>Hearing or vision impairment</li>\n<li>Dehydration or malnutrition</li>\n<li>Polypharmacy</li>\n<li>Alcohol or other drug misuse</li>\n<li>Co-existing medicalÂ or mental healthÂ disorders</li>\n<li>Precipitating factors:</li>\n<li>Drugs (e.g. anticholinergic, opioid, benzodiazepine)Â â€“Â CalculateÂ anticholinergic burden (ACB)</li>\n<li>Addition of three or more new medications</li>\n<li>Compliance with medications</li>\n<li>Alcohol or other drug withdrawal</li>\n<li>Stroke or other neurological conditions</li>\n<li>Infection</li>\n<li>Severe acute illness (e.g. renal failure, hepatic failure, respiratory failure)</li>\n<li>Pain</li>\n<li>Metabolic derangements (electrolytes, especially sodium, acid base)</li>\n<li>Surgery (especially orthopaedic or cardiac)</li>\n<li>Dehydration and/or malnutrition (including Wernicke encephalopathy)</li>\n<li>Urinary retention or faecal impaction, constipation</li>\n<li>Sleep deprivation, stress, ITU admission</li>\n<li>Change of environment</li>\n<li>Wide range of presentation noteÂ that these areÂ often mixed.</li>\n</ul>\n<p>Medications (including non-prescription and other) which may decrease cognition and worsen confusion</p>\n<ul>\n<li>Anticholinergic, e.g.:</li>\n<li>Hyoscine</li>\n<li>Atropine</li>\n<li>Tricyclic antidepressants</li>\n<li>Antiepileptics, e.g.:</li>\n<li>Carbamazepine</li>\n<li>Phenytoin</li>\n<li>Sodium valproate</li>\n<li>Alcohol</li>\n<li>Antipsychotics, e.g.:</li>\n<li>Haloperidol</li>\n<li>Olanzapine</li>\n<li>Quetiapine</li>\n<li>Risperidone</li>\n<li>Clozapine</li>\n<li>Opioids, e.g.:</li>\n<li>Codeine</li>\n<li>Oxycodone</li>\n<li>Morphine</li>\n<li>Benzodiazepines, e.g.:</li>\n<li>Temazepam</li>\n<li>Oxazepam</li>\n<li>Lorazepam</li>\n<li>Diazepam</li>\n<li>Corticosteroids at high doses</li>\n<li>Zopiclone</li>\n<li>Cardiovascular medications, e.g.:</li>\n<li>Digoxin</li>\n<li>Metoprolol</li>\n<li>Propranolol</li>\n<li>Antibacterials and antivirals, e.g.:</li>\n<li>Aciclovir</li>\n<li>Ciprofloxacin</li>\n<li>Trimethoprim with sulfamethoxazole</li>\n</ul>\n<strong>Check nursing documentationÂ and ensure screening is completed within 24 hours of admission.Â Cognitive assessmentÂ isÂ mandated to be done as part of admission documentation.Â If not previously done, perform a:</strong>\n<p>4AT (assessment test for delirium and cognitive impairment).</p>\n<strong>full physical examination (including respiratory, cardiac, abdominal and neurological). Check:</strong>\n<p>vital signsÂ â€“ consider adding RADAR (Recognising Acute Delirium As part of your Routine) score toÂ NEWS2Â vital signs documentation.</p>\n<ul>\n<li>Vital signs</li>\n<li>The physiological observation for adults at a minimum is:</li>\n<li>respiratory rate.</li>\n<li>oxygen saturations.</li>\n<li>blood pressure,Â lying and standing.</li>\n<li>heart rate.</li>\n<li>temperature.</li>\n<li>level of consciousness.</li>\n<li>blood glucose level.</li>\n</ul>\n<p>for pain. If the patient has difficulty describing their pain, consider using theÂ Pain Assessment in Advanced Dementia Scale (PAINAD).</p>\n<ul>\n<li>for urinary retention.</li>\n<li>for dehydration.</li>\n<li>for signs of infection.</li>\n<li>for constipation and faecal impaction.</li>\n<li>Be aware, it's important to examine for these, not just ask the patient about them.</li>\n<li>Investigation:</li>\n<li>Arrange:</li>\n<li>Full blood count</li>\n<li>liver function test</li>\n<li>calcium, magnesium,</li>\n<li>phosphate</li>\n<li>blood glucose level</li>\n<li>CRP.</li>\n</ul>\n<strong>Urea and electrolytes, when requesting urea and electrolytes, the laboratory will automatically test and provide:</strong>\n<ul>\n<li>Sodium</li>\n<li>Potassium</li>\n<li>Bicarbonate</li>\n<li>Chloride</li>\n<li>Urea</li>\n<li>Creatinine</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n<li>MSU.</li>\n<li>ECG.</li>\n<li>Chest X-ray.</li>\n<li>Consider arranging:</li>\n<li>thyroid function tests, vitamin B12, folate, lactate, ammonia.</li>\n<li>venous or arterial blood gas if indicated.</li>\n<li>blood cultures if an infection is suspected.</li>\n<li>drug levels if toxicity is suspected, e.g. digoxin, lithium, phenytoin, alcohol.</li>\n<li>bladder scan post-void.</li>\n<li>CT head if focal neurologic signs are present or there is a possible head injury.</li>\n<li>ConsiderÂ Differential features of the 3Ds (delirium, dementia, and depression)</li>\n<li>Copyright permission adapt #G50</li>\n<li>AssessÂ capacity</li>\n</ul>\n<p>The clinical team should assessÂ the patient'sÂ mental capacity to consent to investigations and management. The treatment plan should then be discussed with the patientâ€™s carer or representative. If there is no patient representative then contact patientâ€™s general practitioner, social worker, orÂ care home, or consider requestingÂ independent mental capacity advocateÂ (IMCA) input.</p>\n<p>ConsiderÂ theÂ Deprivation of Liberty Safeguards (DOLS).</p>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<ul>\n<li>Treat any underlying causes:</li>\n<li>Correct fluid and electrolyte imbalances:</li>\n<li>Commence fluid balance chart and monitor input and output including bladder obstruction.</li>\n</ul>\n<p>Encourage oral hydration and diet. Consider IV or subcutaneous fluids if the patient is unable to tolerate oral intake.</p>\n<strong>Ensure safe swallow â€“ consider requestingÂ speech and language therapyÂ (SALT)Â assessment.</strong>\n<strong>If the patient is malnourished or has a history of ethanol abuse, give vitamin B (Pabrinex) to address a likely vitamin B deficiency.</strong>\n<p>Correct metabolic imbalances.</p>\n<p>Consider discontinuing medications that may be impacting on delirium in consultation with a senior clinician.</p>\n<ul>\n<li>Follow theÂ SepsisÂ pathway if indicated.</li>\n<li>Correct hypoxia or hypercapniaÂ (be extra cautious if the patient has COPD).</li>\n<li>Monitor the patient's bowel habits on a bowel chart and prevent or treatÂ constipation.</li>\n<li>For positive MSU results, consider antibiotics if the patient is symptomatic.</li>\n<li>EnsureÂ supportive measuresÂ are in place. These alone can prevent delirium and improve function.</li>\n<li>Supportive measures</li>\n<li>Ensure:</li>\n<li>hearing aids are working and in place.</li>\n<li>glasses are clean and in use.</li>\n<li>Provide:</li>\n<li>a clock and other aids that assist in orientating the patient.</li>\n<li>verbal orientation on a regular basis.</li>\n<li>uninterrupted periods of sleep at night.</li>\n<li>Introduce yourself each time you enter the room.</li>\n<li>Encourage mobility.</li>\n<li>Attend to activities of daily living when the patient is less agitated and support self-care.</li>\n<li>Discourage napping during the day.</li>\n<li>Avoid tubing, such as urinary catheter, cannula, oxygen, wherever possible.</li>\n<li>Consider theÂ ward environment.</li>\n<li>Ward environment</li>\n<li>Ensure an appropriate level of:</li>\n</ul>\n<p>supervisionÂ appropriate to enhanced therapeutic observation and care (ETOC) level as assessed in nursing admission documentation.</p>\n<p>stimulation, e.g. low stimulus environment with minimal noise and clutter in hyperactive delirium.</p>\n<p>Minimise room and staff changes.</p>\n<p>Nursing staff will carry out a risk assessment to assess whether bed rails should or should not be used â€“ follow the recommendations ofÂ theÂ assessment.Â Where possible,Â physical restraints including bed railsÂ should be avoidedÂ as in some cases these have not been shown to prevent falls and can increase risk of injury. It may be preferable to nurse the patient on a low bed. If this is not feasible, use a mattress or protective mat on the floor.</p>\n<strong>Enable family and friends, who may be able to calm the patient, to visit:</strong>\n<strong>Ensure nursing staff and family know that the patient requires open visiting for their own safety. This will not always be possible if the ward is closed for infection. Carers can get aÂ carerâ€™s passport.</strong>\n<p>Ask family members to complete aÂ â€˜This is Meâ€™Â form from a nurse in the ward, to provide background information about the patient.</p>\n<p>Explain the cause of confusion to family members and encourage them to bring in familiar objects and pictures and to participate in rehabilitation (e.g. by helping with feeding and drinking).</p>\n<strong>Request acute delirium and dementia assessment from theÂ Delirium and Dementia Outreach TeamÂ (DDOT)Â for advice, support, and cognitive stimulation therapy.</strong>\n<strong>ConsiderÂ short-term drug treatmentÂ only if other measuresÂ are exhausted and patient at risk of harming themselves or others:</strong>\n<ul>\n<li>Short-term drug treatment</li>\n<li>Use 1 medication</li>\n<li>Start slow, go low</li>\n<li>Review every 24 hours</li>\n</ul>\n<strong>There is no evidence that antipsychotics or sedatives improve prognosis, and they haveÂ significant adverse effects. Consider drug treatment if:</strong>\n<h3>Significant adverse effects</h3>\n<p>Increased risk of stroke â€“ second-generation antipsychotics have been associated with an increased risk of stroke in older adults with dementia</p>\n<p>Extrapyramidal side-effects â€“ antipsychotics (especially haloperidol) may worsen symptoms in Parkinson'sÂ disease and Lewy body dementiaÂ and are contraindicated</p>\n<p>Lewy body dementia â€“ even low dose antipsychotics (especially first generation) may increase agitation and worsen motor function</p>\n<p>Prolonged QT interval â€“ especially with haloperidol</p>\n<h3>Postural hypotension</h3>\n<p>the patient's degree of agitation and/or aggression interferes with the ability to provide vital nursing or medical care.</p>\n<p>the patient's behaviour threatens the safety of themselves or others.</p>\n<p>anxiety, delusions and/or hallucinations are causing significant distress to the patient.</p>\n<h3>Pharmacological options for initial management</h3>\n<p>A single dose is usually sufficient. Onset of action can be delayed for 30Â toÂ 60Â minutes after administration.</p>\n<strong>Do not use antipsychotic medication (e.g. haloperidol, risperidone, olanzapine) or sedatives for insomnia, restlessness, wandering, or disruptive behaviour.</strong>\n<p>Keep use of sedatives to a minimum.</p>\n<p>Tailor the dose depending on age, body size, and degree of agitation.</p>\n<strong>Start at the lowest clinically appropriate dose and titrate cautiously every 2Â hours according to symptoms.</strong>\n<h3>If absolutely necessary, consider sedation with:</h3>\n<p>First-line â€“Â haloperidolÂ 0.5Â toÂ 1Â mg orally as required or regularly (usually twice a day) and as required to a maximum of 2Â mgÂ inÂ 24Â hours.</p>\n<p>If haloperidol is contraindicated (e.g. Lewy body dementia, Parkinsonâ€™s disease or Parkinson's-plus syndrome, prolonged QTc on ECG, or hypokalaemia) useÂ lorazepamÂ 0.5Â orally as required to a maximum of 2Â mgÂ inÂ 24Â hours.</p>\n<ul>\n<li>Use one drug only, starting at the lowest possible dose.</li>\n<li>ReviewÂ the patientÂ daily withÂ multidisciplinary teamÂ (MDT) input:</li>\n<li>Consult with a senior clinician.</li>\n<li>Ensure clinical handover andÂ clear documentation.</li>\n<li>Clear documentation</li>\n</ul>\n<strong>When there is use of antipsychotics or benzodiazepines to treat delirium, including immediate and when required doses, clinical documentation should include:</strong>\n<p>any non-drug measures attempted.</p>\n<p>consent for their use or, if the patient did not have capacity to give consent, that the decision was made in their best interest.</p>\n<p>the specific behaviours being managed.</p>\n<p>the patient's response to specific medications.</p>\n<strong>Ensure that the patient has been reassessed forÂ ETOC,Â falls riskÂ (including updated assessment for use of bed rails), andÂ pressure injuriesÂ following diagnosis of delirium.</strong>\n<h3>Consider requesting:</h3>\n<ul>\n<li>occupational therapy assessment for assistance with assessment to assist with discharge planning.</li>\n<li>physiotherapy assessmentÂ to encourage mobilisation.</li>\n<li>pharmacyÂ for medication reconciliation and assistance.</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<ul>\n<li>Before considering discharge, consult with a senior clinician and allied health teams to ensure:</li>\n<li>the patient can care for themselves, or carer and family support is available and accessible.</li>\n<li>medication safety has been considered.</li>\n<li>living arrangements are adequate.</li>\n</ul>\n<p>Assess the patient's current cognition and function to ensure the safety of discharge planning. Delirium and associated deconditioning may be slow to resolve.</p>\n<p>In the discharge summary, clearly document the episode of delirium, underlying factors, and the patient's current condition.</p>\n<p>If a regular sedativeÂ orÂ antipsychotic has been started, ensure review by specialist team (PLT) prior to discharge.</p>\n<strong>Do not prescribe antipsychotic medication long-term for the management of difficult behaviour or aggression. Such use is unlicensed and increases mortality in patients with dementia:</strong>\n<p>RequestÂ acute mental health assessmentÂ from the psychiatricÂ liaisonÂ teamÂ if ongoing drug treatment is required.Â Any treatment continued past discharge must be managed by PLT including plan for reducing and stopping.</p>\n<p>If treatment with haloperidol or atypical antipsychotic agents is continued past discharge, inform the patient and their relatives about the unlicensed use of the drug and risk of death and stroke.</p>\n<p>Communicate a clear plan for reducing and eventually stopping the drug to the patient, their family, and their general practitioner.</p>\n<strong>If the patient has established dementia, advise relatives or carers on how to requestÂ carer supportÂ orÂ mental health community support.</strong>\n<strong>If the patient had delirium as an inpatient but was not previously known to have had dementia, in the discharge summary advise their general practitioner:</strong>\n<p>of planned follow up by Delirium and Dementia Outreach TeamÂ (DDOT).</p>\n<p>that aÂ memory clinic referral will be made by DDOT if dementia is suspected.</p>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<p>RequestÂ acute mental health assessmentÂ from the psychiatricÂ liaisonÂ team if ongoing drug treatment is required.</p>\n<strong>Request acute delirium and dementia assessment from theÂ Delirium and Dementia Outreach TeamÂ (DDOT)Â for advice, support, and cognitive stimulation therapy.</strong>\n<ul>\n<li>Consider requestingÂ speech and language therapyÂ (SALT)Â assessment.</li>\n<li>Consider requesting:</li>\n<li>occupational therapy assessment for assistance with assessment.</li>\n<li>physiotherapy assessmentÂ to encourage mobilisation.</li>\n<li>pharmacyÂ for medication reconciliation and assistance.</li>\n</ul>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<h3>Further information</h3>\n<p>NICE Guidance â€“Â Delirium: Prevention, Diagnosis and Management in Hospital and Long-Term Care</p>\n<h4>For patients</h4>\n<p>Alzheimer's Society â€“Â Delerium: Symptoms, Diagnosis and Treatment</p>\n<p>NHS â€“Â Sudden Confusion (Delerium)</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nDelirium","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Hyponatraemia","filename":"Hyponatraemia Draft V.1.docx","category":"Metabolic & Endocrine","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<ul>\n<li>Serum sodium less than 120 mmol/L in a patient with previously normal sodium levels.</li>\n<li>Acutely decreasing sodium levels.</li>\n<li>Systemically unwell.</li>\n<li>Neurological symptoms, e.g. tremor, altered conscious state, seizures, new onset falls.</li>\n<li>Persistent vomiting or diarrhoea.</li>\n</ul>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Hyponatraemia</h3>\n<p>Chronic hyponatraemia with serum sodium levels 120 to 130Â mmol/L is not uncommon in patients with chronic liver, cardiac, or renal disease.</p>\n<p>Neurological symptoms are more important than absolute serum sodium level.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<h3>Immediate assessment</h3>\n<p><strong>1. Use theÂ ABCDE approachÂ to rapidly assess the patient. If they are seriously unwell:</strong></p>\n<ul>\n<li>contact a senior clinician or activate aÂ clinical emergencyÂ as appropriate.</li>\n<li>do not delay immediate management steps (below), commence in parallel with assessment.</li>\n</ul>\n<p><strong>2. If the patient is haemodynamically unstable, attach a cardiac monitor for continuous monitoring.</strong></p>\n<p><strong>3. InsertÂ intravenous (IV) cannulaÂ and takeÂ bloods.</strong></p>\n<ul>\n<li>Bloods</li>\n<li>Venous blood gas if the patient is haemodynamically unstable</li>\n<li>Full blood count</li>\n<li>Urea and electrolytes</li>\n<li>Serum calcium, albumin, and adjusted calcium</li>\n<li>Liver function tests</li>\n<li>Serum magnesium</li>\n<li>Serum phosphate</li>\n<li>Blood glucose level</li>\n<li>Coagulation screen</li>\n</ul>\n<p><strong>4. Obtain and interpret a 12 leads ECG in haemodynamically unstable patients.</strong></p>\n<p><strong>5. Consider the possibility of cerebral oedema ifÂ there areÂ any neurological symptoms or signs.</strong></p>\n<ul>\n<li>This requires urgent treatment. RequestÂ critical care outreach assessmentÂ if seizures or decliningÂ Glasgow Coma Scale (GCS).</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Secondary Assessment","content":"<p><strong>1. Check for previous low sodium results.</strong></p>\n<p><strong>2. Exclude potential confounding causes of hyponatraemia:</strong></p>\n<ul>\n<li>Markedly increased lipids and protein (pseudohyponatraemia)</li>\n<li>Moderate to severe hyperglycaemia, including hyperosmolar hyperglycaemic state (HHS) or diabetic ketoacidosis (DKA)</li>\n</ul>\n<p><strong>3. Check signs and symptoms.</strong></p>\n<ul>\n<li>These are usually related to the underlying cause, rate of onset, and degree of hyponatraemia.</li>\n<li>Mild or chronic hyponatraemia â€“ often no or non-specific symptoms, e.g. headache, nausea, tiredness, gait disturbance, muscle cramps, new onset falls.</li>\n<li>Severe or acute onset hyponatraemia â€“ disorientation, drowsiness, agitation, seizure, headache.</li>\n</ul>\n<p><strong>4. Assess Volume status â€“ this is crucial to determining the cause of hyponatraemia.</strong></p>\n<ul>\n<li>Volume status</li>\n<li>Examine:</li>\n<li>Jugular venous pressure (JVP)</li>\n<li>Mucous membranes and skin turgor</li>\n<li>Lying and standing blood pressure (a fall greater than 20/10 on standing suggests volume depletion)</li>\n<li>Heart rate</li>\n<li>Peripheral oedema</li>\n<li>Ascites</li>\n<li>Weight</li>\n</ul>\n<p><strong>5. Determine type of hyponatraemia:</strong></p>\n<ul>\n<li>Hypovolaemic/volume depletion</li>\n<li>Defined as a decrease in body water with a greater decrease in body sodium.</li>\n<li>Probably the most common cause of hyponatraemia.</li>\n<li>Signs and investigations include:</li>\n<li>Jugular venous pressure (JVP) â€“ not visible supine, or just visible with hepatojugular reflex</li>\n<li>Hypotension or postural hypotension (a fall of greater than 20/10 on standing)</li>\n<li>Tachycardia</li>\n<li>Normal or raised uric acid, urea, creatinine,</li>\n<li>Causes include:</li>\n<li>Urine sodium less than 20 mmol/L</li>\n<li>Decreased fluid intake</li>\n<li>Diarrhoea and vomiting</li>\n<li>Fluid shifts e.g. pancreatitis</li>\n<li>Burns</li>\n<li>Urine sodium greater than 20 mmol/L</li>\n<li>Salt-losing nephropathy</li>\n<li>Diuretics</li>\n<li>Adrenal insufficiency</li>\n<li>Patients with undiagnosed adrenal insufficiency may present with isolated hyponatraemia as the presenting feature. For all patients with suspected adrenal insufficiency, check morning plasma cortisol levels.</li>\n<li>If known adrenal insufficiency and hyponatraemia is an incidental finding, there is no need to re-measure plasma cortisol. Seek acute endocrinology advice about excluding other causes.</li>\n<li>Hypervolaemic/volume overload</li>\n<li>Defined as an increase in total body water with a lesser increase in body sodium. Causes include:</li>\n<li>Congestive heart failure</li>\n<li>Cirrhosis</li>\n<li>Nephrotic syndrome</li>\n<li>Euvolemic</li>\n<li>Defined as having normal volume of blood or fluids in the body.</li>\n<li>Increase in total body water with normal body sodium.</li>\n<li>Examination â€“ no postural blood pressure fall, jugular venous pressure (JVP) not low.</li>\n<li>Usually:</li>\n<li>urine sodium greater than 20 mmol/L.</li>\n<li>normal uric acid, urea, creatinine.</li>\n<li>Causes include:</li>\n<li>Acute water overload (urine sodium less than 20 mmol/L)</li>\n<li>Chronic water overload (urine sodium greater than 20 mmol/L but urine osmolality less than 100 mOsm/kg)</li>\n<li>Syndrome of inappropriate anti-diuretic hormone (SIADH) secretion</li>\n<li>Chronic renal failure</li>\n<li>Hypothyroidism</li>\n<li>Adrenal insufficiency</li>\n</ul>\n<p><strong>6. Assess neurological status. Consider performing a brief neurological examination.</strong></p>\n<p><strong>7. Arrange additional investigations:</strong></p>\n<ul>\n<li>TSH</li>\n<li>Triglycerides â€“ to exclude artefactual causes (pseudohyponatraemia) if significantly elevated</li>\n<li>Paired plasma osmolality, urine osmolality, and urine sodium:</li>\n<li>Plasma osmolality greater than 275 mmol/kg â€“ hypertonic hyponatraemia. Consider hyperglycaemia (e.g. HHS).</li>\n<li>Plasma osmolality less than 275 mmol/kg and urine osmolality greater than 100 mmol/kg â€“ consider hypotonic hyponatraemia.</li>\n<li>Urine sodium greater than 20 mmol/L â€“ consider syndrome of inappropriate anti-diuretic hormone (SIADH).</li>\n<li>Urine osmolality less than 100 mmol/kg â€“ consider primary polydipsia.</li>\n<li>9:00 am cortisol level if the patient is not on exogenous steroids.</li>\n</ul>\n<p><strong>8. Consider likely causes of hyponatraemia:</strong></p>\n<ul>\n<li>Drugs causing hyponatraemia</li>\n<li>Thiazide diuretics are a common cause, particularly in the elderly and in those who are also on ACE inhibitors, or angiotensin II receptor blockers.</li>\n<li>Many other drugs can also cause or contribute to hyponatraemia through various mechanisms. Examples include:</li>\n<li>selective serotonin reuptake inhibitors (SSRIs)</li>\n<li>antipsychotics</li>\n<li>nonsteroidal anti-inflammatory drugs (NSAIDs)</li>\n<li>carbamazepine</li>\n<li>sodium valproate</li>\n<li>tricyclic antidepressants (TCAs)</li>\n<li>proton pump inhibitors (PPIs)</li>\n<li>sulphonylureas</li>\n<li>some chemotherapeutic agents</li>\n<li>opioids</li>\n<li>amiodarone.</li>\n<li>Consider any new agents, or agents that were commenced at the time of onset of hyponatraemia, and review fluid chart.</li>\n<li>Syndrome of inappropriate anti-diuretic hormone (SIADH) secretion</li>\n<li>Patients produce an inappropriately concentrated urine in the absence of an appropriate stimulus for the release of antidiuretic hormone.</li>\n<li>Diagnostic criteria:</li>\n<li>Clinically euvolaemic</li>\n<li>Urine osmolality exceeds 100 mmoL/kg in the absence of diuretics</li>\n<li>Urine sodium greater than 20 mmol/L</li>\n<li>Plasma osmolality less than 275 mmol/kg</li>\n<li>Normal renal function with no hypokalaemia and no acid base disturbance</li>\n<li>Adrenal insufficiency and hypothyroidism have been excluded</li>\n<li>Causes of SIADH include:</li>\n<li>Drugs, e.g. carbamazepine, sodium valproate, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), haloperidol</li>\n<li>Pulmonary conditions, e.g. neoplasm, infection including tuberculosis (TB), asthma</li>\n<li>Central nervous system pathology, e.g. infection, bleed, mass, delirium tremens (DTs)</li>\n<li>Malignancy, e.g. lung, mesothelioma, gastrointestinal, lymphoma, and urinary tract</li>\n<li>Postoperative pain</li>\n<li>Idiopathic â€“ more common in the elderly.</li>\n<li>Adrenal insufficiency</li>\n<li>Water intoxication (often associated with unstable mental health) â€“ typically low urine osmolality less than 100 mmol/kg</li>\n<li>Severe hypothyroidism</li>\n</ul>\n<p><strong>9. Consider further investigations depending on likely cause:</strong></p>\n<ul>\n<li>Short synacthen stimulation test (SST) if 9:00 am cortisol level is less than 400.</li>\n<li>Chest X ray.</li>\n<li>CT chest â€“ may help determine the cause of syndrome of inappropriate anti-diuretic hormone (SIADH).</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<h3>Immediate management</h3>\n<p><strong>1. Stop dextrose infusion and any medications known to cause hyponatraemia.</strong></p>\n<p><strong>2. Seek acuteÂ general medicine adviceÂ for admission for symptomatic patients, along with starting initial treatment.</strong></p>\n<p><strong>3. Manage depending on the presence ofÂ Red FlagsÂ and the patient's clinical state, symptoms, and duration of hyponatraemia.</strong></p>\n<ul>\n<li>Severely symptomatic (usually sodium less than 120 mmol/L)</li>\n<li>If severe hyponatraemia with seizure or coma, consider usingÂ sodium chlorideÂ 1.8%, 150Â mL intravenously (IV) or via central venous access device over 15 minutes. SeekÂ urgent intensive care adviceÂ about whether to transfer the patient to the ICU.</li>\n<li>Sodium chloride 1.8% has a high osmolarity (hypertonic) and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is not available, administer via a large peripheral vein. Concentrations exceeding 1.8% should always be administered via a central venous access device. See Medusa â€“Â NHS Injectable Medicines Guide.</li>\n</ul>\n<p>Arrange urgentÂ intensive care assessment,Â if advised,Â but do not delay initiating further treatment.</p>\n<p>Manage patient in an environment where close biochemical and clinical monitoring can be provided.</p>\n<strong>Aim to improve symptoms, not to correct sodium level back to normal.</strong>\n<p>Repeat serum sodium after 20Â minutes if no clinical improvement (venous sample on blood gas analyser, if available).</p>\n<p>If sodium level remains the same, a repeat bolus dose of hypertonic saline can be given.</p>\n<p>Recheck serum sodium at 6, 12, 24, and 48Â hours. Sodium should not rise greater thanÂ 6Â mmol/L in first 6Â hours or greater thanÂ 10Â mmol/l in first 24 hours and 8 mmol/L in subsequent 24 hours. If rapid overcorrection, use IV 5% dextrose or consider desmopressin to reduce risk of osmotic demyelination, and seekÂ endocrinology advice.</p>\n<h3>Non-severe symptoms or asymptomatic</h3>\n<p>Cause-specific treatment is recommended, rather than aiming to increase sodium level. If thought to be drug induced, this may be all that is required.</p>\n<p>If hypovolaemic, restore volume with an initialÂ intravenous (IV)Â fluid challenge of 1Â L isotonic saline over 8 hours</p>\n<h3>If hypervolaemic,Â startÂ fluid restriction</h3>\n<p>If thought to be drug induced, then stopping the causative drug may be all that is required â€“ there is no need to do fluid restriction unless sodiumÂ isÂ not improving.</p>\n<strong>IfÂ SIADH secretionÂ isÂ suspected or diagnosticÂ criteria are met:</strong>\n<p>Syndrome of inappropriate anti-diuretic hormone (SIADH) secretion</p>\n<p>Patients produce an inappropriately concentrated urine in the absence of an appropriate stimulus for the release of antidiuretic hormone.</p>\n<ul>\n<li>Diagnostic criteria:</li>\n<li>Clinically euvolaemic</li>\n<li>Urine osmolality exceeds 100 mmoL/kg in the absence of diuretics</li>\n<li>UrineÂ sodiumÂ greater thanÂ 20Â mmol/L</li>\n<li>Plasma osmolalityÂ less thanÂ 275Â mmol/kg</li>\n<li>Normal renal function with no hypokalaemia and no acid base disturbance</li>\n<li>Adrenal insufficiency and hypothyroidism have been excluded</li>\n<li>Causes of SIADH include:</li>\n</ul>\n<p>Drugs, e.g. carbamazepine, sodium valproate, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), haloperidol</p>\n<ul>\n<li>Pulmonary conditions, e.g. neoplasm, infection including tuberculosis (TB), asthma</li>\n<li>Central nervous system pathology, e.g. infection, bleed, mass, delirium tremens (DTs)</li>\n<li>Malignancy, e.g. lung, mesothelioma, gastrointestinal, lymphoma, and urinary tract</li>\n<li>Postoperative pain</li>\n<li>Idiopathic â€“ more common in the elderly.</li>\n<li>startÂ fluid restriction</li>\n<li>considerÂ seekingÂ endocrinology advice.</li>\n<li>BeginÂ monitoring:</li>\n<li>Strict fluid input and output charting with regular fluid balance is required</li>\n<li>Urea and electrolytes must be checked every 24 hours initially.</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Ongoing Management","content":"<p><strong>1. Treat any underlying cause identified.</strong></p>\n<p><strong>2. Ensure the rates of sodium correction stay within the safe limit (10Â mmol/L in first 24 hours, 8 mmol/L in subsequent 24 hours). Over-rapid sodium replacement in chronic hyponatraemia can cause central pontine myelinolysis.</strong></p>\n<p><strong>3. If hypovolaemia, restore extracellular volume withÂ intravenous (IV)Â infusion 0.9% saline at 0.5Â toÂ 1.0Â mL/kg per hour</strong></p>\n<p><strong>4. If euvolaemia or hypervolaemia continue orÂ startÂ fluid restriction if needed. Be guided by the fluid balance chart</strong></p>\n<p><strong>5. In all cases, aim to restore plasma sodium to 125Â toÂ 130Â mmol/L.</strong></p>\n<p><strong>6. IfÂ SIADH secretionÂ diagnosed or suspected, seekÂ endocrinology adviceÂ for consideration ofÂ tolvaptanÂ or demeclocycline hydrochloride if poor response after 24 to 48 of fluid restriction.</strong></p>\n<ul>\n<li>Tolvaptan</li>\n<li>Prescription is authorised by an endocrinology consultant only and reviewed daily (including weekends).</li>\n<li>Remove any fluid restriction.</li>\n<li>Allow the patient to drink to thirst response.</li>\n<li>Repeat serum sodium 6Â hours later.</li>\n<li>Repeat doseÂ after discussion with endocrinologyÂ if no improvement after 24Â hours (and if no improvement after second dose, reconsider diagnosis).</li>\n<li>StopÂ as soon sodiumÂ isÂ greater than 125Â mmol/L.</li>\n</ul>\n<strong>Do not use forÂ ongoing control of chronic hyponatraemia.</strong>\n<p><strong>7. If knownÂ Adrenal insufficiencyÂ and hyponatraemia is an incidental finding, seekÂ endocrinology adviceÂ about glucocorticoid dosage.</strong></p>\n<p><strong>8. If the cause of hyponatraemia has not been identified, seekÂ endocrinology advice.</strong></p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up.","content":"<ul>\n<li>Complete the patient's discharge summary:</li>\n<li>provide clear information to the general practitioner about the patient's:</li>\n<li>diagnosis</li>\n<li>treatment given, alterations to medications</li>\n<li>follow up arrangements.</li>\n</ul>\n<p>arrangeÂ repeat sodium levelÂ via phlebotomy hub after clinically appropriate interval (2Â toÂ 6 weeks).</p>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<p>If severely symptomaticÂ with seizure or coma, seekÂ urgent intensive care adviceÂ and arrange urgentÂ intensive care assessmentÂ if advised.</p>\n<strong>Seek acuteÂ general medicine adviceÂ for admission for symptomatic patients, along with starting initial treatment.</strong>\n<ul>\n<li>SeekÂ endocrinology advice:</li>\n<li>for glucocorticoid dosageÂ in patients with adrenal insufficiency.</li>\n<li>for consideration ofÂ tolvaptanÂ orÂ demeclocycline hydrochlorideÂ to treat SIADH.</li>\n</ul>\n<p>for consideration of desmopressin to reduce risk of osmotic demyelination in severely symptomatic patients.</p>\n<p>if the cause of hyponatraemia has not been identified.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<p>Health Care Professionals</p>\n<h3>Further information</h3>\n<p>European Journal of Endocrinology â€“Â Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia</p>\n<p>GGC Medicines Adult Therapeutics Handbook â€“Â Flowchart 1: Investigations of Hyponatraemia in Adults</p>\n<h3>NICE Clinical Knowledge Summaries (CKS) â€“Â Hyponatraemia</h3>\n<p>North Cumbria Integrated Care NHS Foundation Trust â€“Â Clinical Guideline: Hyponatraemia â€“ Management of Adult Hospital Inpatient</p>\n<p>Patients</p>\n<p>Patient â€“Â Hyponatraemia</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nHyponatraemia Assessment & Treatment Algorithm","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Inflammatory Bowel Disease (IBD)","filename":"Inflammatory Bowel Disease (IBD) Draft V.1.docx","category":"Gastroenterology","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<ul>\n<li>Fever</li>\n<li>Signs of shock, e.g. tachycardia or hypotension</li>\n<li>More thanÂ 4Â bowel motions a day</li>\n<li>Significant abdominal pain</li>\n<li>Imaging suggestive of toxic megacolon, perforation, bowel obstruction, or intra-abdominal abscess</li>\n</ul>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About inflammatory bowel disease (IBD)</h3>\n<p>Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). All are characterised by inflammation of the gut mucosa with symptoms including diarrhoea, rectal bleeding, abdominal pain, and weight loss.</p>\n<p>Acute severe ulcerative colitis (ASC) is a potentially life-threatening condition, characterised by clinical and laboratory assessment using the modified Truelove and Witts criteria.</p>\n<p>Toxic megacolon is a devastating complication of severe colitis, characterised by radiographic distension of the colon often with fever, tachycardia, neutrophil leucocytosis, and anaemia.</p>\n<p>Between 15% and 25% of patients with UC will require hospitalisation for an acute severe flare of disease at some stage in the natural history of their disease, often as the index presentation. ASC can more rarely be associated with Crohn's disease, viral and parasitic infections, and medications such as immune checkpoint-inhibitors.</p>\n<strong>The location and type of inflammation distinguishes CD from UC:</strong>\n<p>UC is a chronic inflammatory disease characterised by mucosal inflammation starting distally in the rectum, with continuous extension proximally for a variable distance, often with an abrupt demarcation between inflamed and non-inflamed mucosa. Typically, patients with UC experience periods of relapse and remission.</p>\n<p>CD can affect any part of the gastrointestinal tract from the mouth to the anus, but most commonly the terminal ileum. It causes transmural inflammation and can be patchy. Crohnâ€™s disease is a complex chronic inflammatory gastrointestinal condition with variable age of onset, disease location and behaviour.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<ul>\n<li>Consider inflammatory bowel disease if a patient presents with:</li>\n<li>diarrhoea with urgency, rectal bleeding, abdominal pain, weight loss, and anaemia.</li>\n<li>frequency of bowel motions and the presence of blood in the stool.</li>\n</ul>\n<p>nocturnal symptoms such as diarrhoea or abdominal pain which wake the patient. Functional diarrhoea (e.g. irritable bowel syndrome) usually stops at night.</p>\n<p>Consider acute severe colitis (ASC) early if a patient presents with moreÂ thanÂ 6Â stools aÂ day and signs of systemic toxicity. Calculate Truelove and Witts Severity Index.</p>\n<ul>\n<li>Truelove and Witts Severity Index</li>\n<li>Use theÂ Truelove and Witts Severity Index calculator. Diagnosis is:</li>\n<li>mild when all six criteria are satisfied.</li>\n<li>moderate when variables fall between these criteria.</li>\n</ul>\n<p>severe when criteria for frequency of bowel movement and â‰¥1 features of systemic upset (bolded) are satisfied.</p>\n<ul>\n<li>Truelove and Witts Severity Index criteria:</li>\n<li>Ask about:</li>\n<li>Family history, drugs, smoking, travel</li>\n<li>Family history of IBD, colorectal cancer, coeliac disease, autoimmune disease.</li>\n</ul>\n<p>Drugs, especially nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. NSAID enteropathy), antibiotics, laxatives.</p>\n<strong>Smoking â€“ check the timing relative to IBD symptoms as there is a paradoxical relationship between smoking and IBD:</strong>\n<p>Smoking increases the risk of developing Crohn's disease and disease activity.</p>\n<p>Smoking reduces the risk of ulcerative colitis. Smoking cessation can precipitate ulcerative colitis.</p>\n<ul>\n<li>Travel history.</li>\n<li>Extra-intestinal manifestations of IBD</li>\n<li>Skin, e.g. erythema nodosum, pyoderma gangrenosum</li>\n<li>Arthropathy</li>\n<li>Eye conditions, e.g. episcleritis, iritis</li>\n<li>Mouth ulcers</li>\n<li>Night sweats</li>\n<li>Primary sclerosing cholangitis (PSC)</li>\n<li>Perform examination:</li>\n<li>Check physiological observations and calculate the patient's NEWS2 score. Record onÂ Meditech v6.</li>\n<li>Examine abdomen for tenderness, distension, and masses.</li>\n<li>Examine rectum for blood, masses, and perianal disease, e.g. abscesses, fistula, fissures.</li>\n</ul>\n<h3>ArrangeÂ Initial investigations</h3>\n<p>Full blood count</p>\n<p>CRP</p>\n<h3>liver function tests including albumin</h3>\n<strong>Urea and electrolytes, when requesting urea and electrolytes, the laboratory will automatically test and provide:</strong>\n<ul>\n<li>Sodium</li>\n<li>Potassium</li>\n<li>Bicarbonate</li>\n<li>Chloride</li>\n<li>Urea</li>\n<li>Creatinine</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n<li>Ferritin, vitamin B12</li>\n<li>Anti-tissue transglutaminase antibodies and IgA (coeliac serology)</li>\n<li>Faecal culture and sensitivity</li>\n<li>Stool â€“ ova, cysts, and parasites if appropriate, e.g. overseas travel</li>\n<li>Clostridium difficileÂ antigen test (via stoop test), if appropriate</li>\n<li>Faecal calprotectin if patient is younger than 50Â years. Before ordering a calprotectin:</li>\n<li>confirm faecal culture and sensitivity is negative.</li>\n<li>stop NSAIDs for at least 4 weeks.</li>\n</ul>\n<p>Maintain an accurate stool chart, recording frequency, consistency and the presence of blood. Patients can be instructed to keep this record if they are able to do so.</p>\n<ul>\n<li>CalculateÂ Truelove and Witts Severity Index calculatorÂ if not done as part of ASC work-up above.</li>\n<li>Truelove and Witts Severity Index</li>\n<li>Use theÂ Truelove and Witts Severity Index calculatorÂ calculator. Diagnosis is:</li>\n<li>mild when all six criteria are satisfied.</li>\n<li>moderate when variables fall between these criteria.</li>\n</ul>\n<p>severe when criteria for frequency of bowel movement and â‰¥1 features of systemic upset (bolded) are satisfied.</p>\n<h3>Truelove and Witts Severity Index criteria:</h3>\n<p>Arrange urgent CT abdomen and pelvis in patients with moderate or severe UC to look for high risk features such as toxic mega-colon or perforation even in the absence of other signs (e.g. abdominal pain). Arrange non-contrast CT in patient where IV contrast is contraindicated.</p>\n<h3>If suspectedÂ Acute severe ulcerative colitis (ASC)</h3>\n<strong>Acute severe ulcerative colitis (ASC) is definedÂ in patients with suspected or established ulcerative colitisÂ by the modified Truelove and Witts criteria as:</strong>\n<ul>\n<li>more than 6Â stools per day</li>\n<li>systemic toxicity with at least one of:</li>\n<li>temperature greater thanÂ 37.8ÂºC</li>\n<li>pulse greater than 90Â beats per minute</li>\n<li>haemoglobin less than 105Â g/L</li>\n<li>CRP greater than 12Â mg/L</li>\n</ul>\n<h3>arrange urgent inpatient assessment</h3>\n<h3>arrange additionalÂ blood tests magnesium, cytomegalovirus (CMV)Â serology.</h3>\n<p>consider pre-biologics screening for all ASC patients on admission (ICE panel \"anti-TNF workup\"), as nearly half are likely to fail intravenous corticosteroids.</p>\n<p>obtain a stool culture and microscopy as soon as practicable, to exclude pathogenic bacteria including testing forÂ C. difficileÂ toxin (CDT).</p>\n<p>considerÂ arrangingÂ repeatÂ CT abdomen and pelvis inÂ clinically deterioratingÂ patients withÂ ASCÂ to look for high risk features such as toxic megacolon or perforation even in the absence of other signs (e.g. abdominal pain). Arrange non-contrast CT in patient where IV contrast is contraindicated.</p>\n<h3>arrange early flexible sigmoidoscopy to:</h3>\n<ul>\n<li>confirm diagnosis</li>\n<li>obtain histologyÂ (sample in formalin)</li>\n<li>evaluateÂ for CMV inÂ (sample inÂ saline)</li>\n<li>informÂ prognosis.</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<p>Acute Severe Colitis (ASC)</p>\n<h3>Immediate management</h3>\n<p>SeekÂ gastroenterology adviceÂ as soon as possibleÂ to discuss the indication and timing of flexible sigmoidoscopy.</p>\n<p>Insert intravenous cannula.</p>\n<p>Complete the Acute Colitis Bundle in Meditech (found under documents and named 'Gastro Acute Colitis Bundle').</p>\n<p>Begin intravenous corticosteroids,Â hydrocortisoneÂ 100Â mgÂ every 6 hours.Â Do not delay while waiting for stool culture and CDT results.</p>\n<strong>If the patient is on steroids, prescribe Adcal-D3 for bone protection.</strong>\n<p>Begin prophylactic subcutaneousÂ low molecular weight heparinÂ unless contraindicated. Risk of venous thromboembolism (VTE) is 2 to 3 times higher compared with inpatients without IBD.</p>\n<p>Monitor weight and fluid balance.</p>\n<p>Correct anyÂ dehydration and electrolyte abnormalities.</p>\n<p>IfÂ C. difficileÂ is detected or strongly suspected, treat with oralÂ vancomycinÂ and discuss with infection prevention regarding isolation. Do not withhold corticosteroids.</p>\n<p>If deep ulceration is present, there is a 93% risk of steroid failure.Â Consider requestingÂ acute gastroenterology assessmentÂ for early treatment escalation (ciclosporin or infliximab).</p>\n<p>If evidence of bowel perforation or toxic megacolon, requestÂ acute general surgery assessment.</p>\n<p>RequestÂ non-acute gastroenterology assessmentÂ from IBD nurses.</p>\n<p>After flexible sigmoidoscopy has been performed, calculateÂ ADMIT-ACS scoreÂ and document the score in the patient notes. If score is greater than or equal to 2,Â requestÂ acute gastroenterology assessmentÂ for consideration for early escalation of medical therapy.</p>\n<ul>\n<li>ADMIT-ACS score</li>\n<li>CRPÂ greater than or equal toÂ 100mg/L (1 point)</li>\n<li>AlbuminÂ less than or equal toÂ 25g/L (1 point)</li>\n<li>UCEISÂ greater than or equal toÂ 7Â (2 points), orÂ greater than or equal toÂ 4 (1 point).</li>\n<li>Document the patient'sÂ Travis indexÂ 72Â hours after the first dose of IV steroids.</li>\n<li>If results show high-risk of IV steroid failure, requestÂ acute general surgery assessment.</li>\n<li>Consider arrangingÂ repeatÂ CT scan, if not already done.</li>\n</ul>\n<p>RequestÂ acute anaesthesia assessmentÂ via V6 order if doubt about the patient's suitability for surgery.</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Ongoing Management","content":"<h3>If cytomegalovirus (CMV) reactivation in the colonic mucosa</h3>\n<p>treat withÂ intravenous ganciclovirÂ 5â€‰mg/kg twice a day while continuing conventional therapy with corticosteroids or rescue medication.</p>\n<p>In rare cases with systemic disease (meningo-encephalitis, pneumonitis, hepatitis, or oesophagitis), stop all immunosuppressive therapy while CMV is treated.</p>\n<p>Repeat blood tests as per initial management, except CMV serology.</p>\n<p>ArrangeÂ acute gastroenterology assessmentÂ for daily review throughout inpatient admission.</p>\n<p>Senior gastroenterology review is the gold standard, but it may not be achievable given current staffing situation within the IBD service.</p>\n<p>Where there is diagnostic uncertainty, or the ongoing management of the patient is unclear, a review from a consultant gastroenterologist is important.</p>\n<p>Arrange daily abdominal x-ray in patients scoring moderate or severe on the Truelove and Witts scoring system, unless advised that this is unnecessary by consultant surgeon or gastroenterologist.</p>\n<h3>Arrange transfer to gastroenterology ward as soon as possible.</h3>\n<p>Assess response to treatment through number of bowel movements and presence and absence of rectal bleeding.</p>\n<p>Consider switch to oral treatment if symptoms improved or continuing IV hydrocortisone if there is some response.</p>\n<strong>If the patient is failing to respond to treatment after 3 days,Â requestÂ acute gastroenterology assessmentÂ toÂ consider second line \"rescue\" therapyÂ in the form of intravenousÂ infliximabÂ (5Â mgÂ toÂ 10Â mg/kg).</strong>\n<p>ConsiderÂ ciclosporinÂ as an alternative in patients who have not previously failed thiopurine therapy.</p>\n<p>Be aware that there is a high-risk of the patient needing a colectomy, requestÂ acute general surgery assessmentÂ if not already done.</p>\n<p>Discuss the possibility of surgery with the patient, offer involvement of stoma care nurses and reassure the patient.</p>\n<p>If no response to treatment 2 to 3 days after the firstÂ infliximabÂ infusion,Â a gastroenterologist mayÂ consider a second dose of 5Â mg/kg in patients who have received an initial dose of 5Â mg/kg on day 3Â orÂ 4 of admission.</p>\n<strong>If the patient has received medical treatment for more than 6Â days, consider requestingÂ acute colorectal surgery assessmentÂ instead of another dose of infliximab.</strong>\n<strong>If the patient fails to improve, e.g. CRP remains over 45, ongoing diarrhoea, ongoing, significant or severe abdominal pain, requestÂ acute colorectal surgery assessmentÂ orÂ acute general surgery assessmentÂ for consideration ofÂ surgical resectionÂ unless deemed a palliative care decision.</strong>\n<p>Have a low threshold for repeat CT abdomen if clinical deterioration.</p>\n<p>If any incidental surgical pathology on CT abdomen and pelvis scan, or if no clinical, biochemical, or radiological improvement by dayÂ 3, consider requesting acute colorectal surgery assessment.</p>\n<p>Be aware surgery in ASC is indicated when the disease is medically resistant, there are intolerable side-effects of medication, or when there is life-threatening haemorrhage, toxic megacolon, or perforation.</p>\n<strong>Request stoma care assessment, even if surgery is only being considered.</strong>\n<strong>Ensure multidisciplinary team involvement with gastroenterologist, colorectal surgeon, and stoma nurse.</strong>\n<strong>If managing the patient on the weekend, ensure a management plan is in place. The gastroenterology consultant should:</strong>\n<p>refer ASC patients to the on-call general medicine team over the weekend.</p>\n<p>put a clear plan in place and document this in the clinical notes for the on-call medicine team to review over the weekend. The plan should state that if there is failed medical management of the patient, the on-call surgical consultant must be contacted and opinion sought.</p>\n<p>inform the on-call surgical consultant of the patient by lunchtime on FridayÂ afternoon so they have knowledge of the patient if the patient requires surgical input over the weekend.</p>\n<p>If Proctitis</p>\n<h3>Immediate management</h3>\n<p>RequestÂ non-acute gastroenterology assessmentÂ from IBD nurses.</p>\n<p>Begin 5-aminosalicylic acid (5-ASA) suppositories or enemas e.g.Â SalofalkÂ 1Â g per day.</p>\n<p>Begin steroid suppositories, e.g.Â budesonideÂ 2Â mg (Budenofalk), in patients who either do not tolerate or do not respond to 5-ASA suppositories.</p>\n<h3>Ongoing management</h3>\n<p>If starting steroid therapy or if any associated risk factors, e.g. low BMI or smoking, consider usingÂ FRAXÂ scoring to assess the patientâ€™s risk of osteoporosis.</p>\n<strong>Address specific issues:</strong>\n<h3>Nutrition</h3>\n<p>In active Crohn's disease, under-nutrition, protein deficiency, and specific deficiencies in vitamins, minerals, and trace elements are common. Calculate the patient'sÂ Malnutrition Universal Screening Tool (MUST)Â score and request anÂ acute adult nutrition and dietitian assessmentÂ if appropriate.</p>\n<strong>As under-nutrition has a negative impact on clinical course, rate of postoperative complications, and mortality:</strong>\n<p>encourage a healthy balanced diet.</p>\n<p>consider and treat any nutritional deficiencies, e.g. iron, vitamin B12, vitaminÂ D. Less common are vitamin K, zinc, and folate deficiencies.</p>\n<p>Fragility fracture risk â€“ monitor, as there is a risk of osteoporosis with repeated or prolonged (longer than 3Â months) courses of steroids (prednisoloneÂ orÂ budesonide) or low vitamin D levels.</p>\n<h3>Risk of opportunistic infections</h3>\n<p>There is a possibility of varicella and other infections due to immunosuppression â€“ increased by immunomodulators, steroids, and biologics, especially if on more than one medication. Advise patients to present early if they become unwell.</p>\n<p>Confidence and self-image â€“ be aware that depression is more frequent in IBD due to factors such as the impact on the patient's quality of life.</p>\n<ul>\n<li>Extra-intestinal manifestations of IBD</li>\n<li>Skin, e.g. erythema nodosum, pyoderma gangrenosum</li>\n<li>Arthropathy</li>\n<li>Eye conditions, e.g. episcleritis, iritis</li>\n<li>Mouth ulcers</li>\n<li>Night sweats</li>\n<li>Primary sclerosing cholangitis (PSC)</li>\n<li>If Undifferentiated colitis</li>\n</ul>\n<h3>Immediate management</h3>\n<strong>If the patient has anyÂ high acuity features, arrange immediate CT abdomen and pelvis and follow theÂ Acute Abdominal PainÂ pathway.</strong>\n<ul>\n<li>High acuity features</li>\n<li>NEWS score more than 5</li>\n<li>WCC more than 20</li>\n<li>CRP more than 200</li>\n<li>Lactate more than 5</li>\n<li>Clinical suspicion of perforation or other life-threatening pathology</li>\n</ul>\n<strong>If the patient has diarrhoea (with or without blood) and does not have anyÂ high acuity featuresÂ orÂ systemic factors, consider discharge or conservative management.</strong>\n<ul>\n<li>Systemic factors</li>\n<li>Temperature greater than 37.8Â°C</li>\n<li>Heart rate greater than 90Â beats per minute</li>\n<li>Haemoglobin less than 105Â g/L</li>\n<li>CRP greater thanÂ 30</li>\n<li>High acuity features</li>\n<li>NEWS score more than 5</li>\n<li>WCC more than 20</li>\n<li>CRP more than 200</li>\n<li>Lactate more than 5</li>\n<li>Clinical suspicion of perforation or other life-threatening pathology</li>\n<li>If the patient is not suitable for discharge, admit them to Acute Medical Take.</li>\n</ul>\n<strong>If the patient fits theÂ criteriaÂ below or CT results show potential acute severe colitis, requestÂ acute general surgery assessmentÂ orÂ acute gastroenterology assessment.</strong>\n<ul>\n<li>Potential acute severe colitis criteria</li>\n<li>Temperature greater than 37.8Â°C</li>\n<li>Heart rate greater than 90 beats per minute</li>\n<li>Haemoglobin less than 105Â g/L</li>\n<li>CRP greater than 30</li>\n<li>RequestÂ acute general surgery assessmentÂ ifÂ CT scan results show:</li>\n<li>a perforation</li>\n<li>a colonic abscess</li>\n<li>ischaemic colitis as the most likely diagnosis</li>\n<li>gas in the bowel wall</li>\n<li>a large or small bowel fistula</li>\n<li>acute diverticulitis.</li>\n</ul>\n<strong>If the patient presents with any other form of colitis, requestÂ acute general surgery assessmentÂ orÂ acute gastroenterology assessment.</strong>\n<p>Begin oral 5-aminosalicylic acid (5-ASA), e.g.Â OctasaÂ 2.4Â g to 4.8Â g per day (over 2.4Â g per day as divided dose only).</p>\n<p>Consider topical 5-ASA in the form of enema treatment in combination with oral 5-ASA, e.g.Â mesalazineÂ 1Â g enema at bedtime.</p>\n<p>Consider oralÂ prednisoloneÂ for patients who fail to respond or are intolerant to oral or rectal 5-ASA.</p>\n<p>Consider topically acting oral corticosteroids, e.g.Â budesonide MMXÂ orÂ beclometasone dipropionateÂ for those wishing to avoid systemic corticosteroids.</p>\n<h3>Ongoing management</h3>\n<p>Use maintenance 5-ASA therapy to decrease the risk and frequency of flares. If distal ulcerative colitis, use rectal 5-ASA maintenance therapy.</p>\n<strong>If starting steroid therapy or if any associated risk factors, e.g. low BMI or smoking:</strong>\n<p>consider usingÂ FRAXÂ scoring to assess the patientâ€™s risk of osteoporosis.</p>\n<p>monitor fragility fracture risk, as there is a risk of osteoporosis with repeated or prolonged (longer than 3 months) courses of steroids (prednisoloneÂ orÂ budesonide) or low vitamin D levels.</p>\n<strong>Address specific issues:</strong>\n<h3>Risk of opportunistic infections</h3>\n<p>There is a possibility of varicella and other infections due to immunosuppression â€“ increased by immunomodulators, steroids, and biologics, especially if on more than one medication. Advise patients to present early if they become unwell.</p>\n<p>Confidence and self-image â€“ be aware that depression is more frequent in IBD due to factors such as the impact on the patient's quality of life.</p>\n<ul>\n<li>Extra-intestinal manifestations of IBD</li>\n<li>Skin, e.g. erythema nodosum, pyoderma gangrenosum</li>\n<li>Arthropathy</li>\n<li>Eye conditions, e.g. episcleritis, iritis</li>\n<li>Mouth ulcers</li>\n<li>Night sweats</li>\n<li>Primary sclerosing cholangitis (PSC)</li>\n<li>Crohn's disease</li>\n</ul>\n<h3>Immediate management</h3>\n<p>Treat ileocaecal Crohnâ€™s disease with Ileal-releaseÂ budesonideÂ 9Â mg once a day for eightÂ weeks.</p>\n<p>Treat mild, moderate, and severe colonic Crohnâ€™s disease with systemic corticosteroids (40Â mgÂ prednisoloneÂ once a day tapering by 5Â mg a week). If mild to moderate Crohn's disease and avoidance of corticosteroids is desired, consider exclusive enteral nutrition.</p>\n<strong>Consider early use of biological therapy in those with an aggressive disease course or high risk factors, e.g.:</strong>\n<ul>\n<li>complex (stricturing or penetrating) disease at presentation.</li>\n<li>perianal fistulising disease.</li>\n<li>aged youngerÂ than 40Â years at diagnosis.</li>\n<li>need for steroids to control the index flare.</li>\n</ul>\n<p>Consider biological therapy in patients refractory to immunomodulator therapy despite dose optimisation.</p>\n<h3>Ongoing management</h3>\n<ul>\n<li>Consider for the maintenance of remission:</li>\n<li>azathioprineÂ orÂ mercaptopurineÂ as monotherapy, or</li>\n<li>subcutaneousÂ methotrexate.</li>\n</ul>\n<p>AdviseÂ smoking cessationÂ as smoking significantly worsens the course of Crohn's disease and smoking cessation can significantly improve patientâ€™s symptoms.</p>\n<p>If starting steroid therapy or if any associated risk factors, e.g. low BMI or smoking, consider usingÂ FRAXÂ scoring to assess the patientâ€™s risk of osteoporosis.</p>\n<strong>Address specific issues:</strong>\n<h3>Nutrition</h3>\n<p>n active Crohn's disease, under-nutrition, protein deficiency, and specific deficiencies in vitamins, minerals, and trace elements are common. Calculate the patient'sÂ Malnutrition Universal Screening Tool (MUST)Â score and request anÂ acute adult nutrition and dietitian assessmentÂ if appropriate.</p>\n<strong>As under-nutrition has a negative impact on clinical course, rate of postoperative complications, and mortality:</strong>\n<p>encourage a healthy balanced diet.</p>\n<p>consider and treat any nutritional deficiencies, e.g. iron, vitamin B12, vitaminÂ D. Less common are vitamin K, zinc, and folate deficiencies.</p>\n<p>Fragility fracture risk â€“ monitor, as there is a risk of osteoporosis with repeated or prolonged (longer than 3 months) courses of steroids (prednisoloneÂ orÂ budesonide) or low vitamin D levels.</p>\n<h3>Risk of opportunistic infections</h3>\n<p>There is a possibility of varicella and other infections due to immunosuppression â€“ increased by immunomodulators, steroids, and biologics, especially if on more than one medication. Advise patients to present early if they become unwell.</p>\n<p>Confidence and self-image â€“ be aware that depression is more frequent in IBD due to factors such as the impact on the patient's quality of life.</p>\n<ul>\n<li>Extra-intestinal manifestations of IBD</li>\n<li>Skin, e.g. erythema nodosum, pyoderma gangrenosum</li>\n<li>Arthropathy</li>\n<li>Eye conditions, e.g. episcleritis, iritis</li>\n<li>Mouth ulcers</li>\n<li>Night sweats</li>\n<li>Primary sclerosing cholangitis (PSC)</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<strong>Ensure patients have follow-up and a plan for ongoing therapy arranged with the gastroenterology team. When discharge occurs over the weekend or during bank holidays, this should be arranged at the next available opportunity.</strong>\n<ul>\n<li>Complete the patient's discharge summary with clear information to their general practitioner on:</li>\n<li>the diagnosis and results of any investigations.</li>\n<li>speech and language therapy and dietitian management plans.</li>\n<li>medication therapy and duration of treatment.</li>\n<li>details of nutritional supplements or thickeners, if they are to continue.</li>\n<li>any follow-up arrangements.</li>\n</ul>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<ul>\n<li>If ASC,Â proctitis, or UC:</li>\n<li>requestÂ non-acute gastroenterology assessmentÂ from IBD nurses.</li>\n<li>If ASC:</li>\n<li>seekÂ gastroenterology adviceÂ as soon as possible.</li>\n<li>requestÂ acute gastroenterology assessment:</li>\n<li>after flexible sigmoidoscopy has been performed and ADMIT-ACS score is greater than or equal to 2.</li>\n<li>for daily review throughout inpatient admission.</li>\n<li>if the patient is failing to respond to treatment after 3 days.</li>\n</ul>\n<p>consider requestingÂ acute gastroenterology assessmentÂ if deep ulceration is present, there is a 93% risk of steroid failure for early treatment escalation.</p>\n<ul>\n<li>requestÂ acute general surgery assessmentÂ if:</li>\n<li>and any evidence of bowel perforation or toxic megacolon.</li>\n<li>Travis index results show high-risk of IV steroid failure.</li>\n<li>there is a high-risk of the patient needing a colectomy and it has not already been done.</li>\n</ul>\n<p>requestÂ acute anaesthesia assessmentÂ via V6 order if doubt about the patient's suitability for surgery.</p>\n<p>consider requestingÂ acute colorectal surgery assessmentÂ if no response to infliximab infusion after 6 days.</p>\n<p>requestÂ acute colorectal surgery assessmentÂ orÂ acute general surgery assessmentÂ for consideration of surgical resection unless deemed a palliative care decision.</p>\n<strong>and any incidental surgical pathology on CT abdomen and pelvis scan, or if no clinical, biochemical, or radiological improvement by dayÂ 3:</strong>\n<ul>\n<li>consider requesting acute colorectal surgery assessment.</li>\n<li>request stoma care assessment, even if surgery is only being considered.</li>\n<li>If UC:</li>\n</ul>\n<p>requestÂ acute general surgery assessmentÂ orÂ acute gastroenterology assessmentÂ if the patient fits theÂ criteriaÂ or CT results show potential acute severe colitis.</p>\n<ul>\n<li>Potential acute severe colitis criteria</li>\n<li>Temperature greater than 37.8Â°C</li>\n<li>Heart rate greater than 90 beats per minute</li>\n<li>Haemoglobin less than 105Â g/L</li>\n<li>CRP greater than 30</li>\n<li>requestÂ acute general surgery assessmentÂ if CT scan results show:</li>\n<li>a perforation</li>\n<li>a colonic abscess</li>\n<li>ischaemic colitis as the most likely diagnosis</li>\n<li>gas in the bowel wall</li>\n<li>a large or small bowel fistula</li>\n<li>acute diverticulitis.</li>\n</ul>\n<p>requestÂ acute general surgery assessmentÂ orÂ acute gastroenterology assessmentÂ if the patient presents with any other form of colitis.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<h3>Further information</h3>\n<p>British Society of Gastroenterology â€“Â BSG Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults</p>\n<ul>\n<li>MD Calc â€“Â Truelove and Witts Severity Index for Ulcerative Colitis</li>\n<li>South Tyneside and Sunderland NHS Foundation Trust:</li>\n<li>Clinical Guideline: Acute Severe Ulcerative Colitis Protocol</li>\n<li>Clinical Guideline: Undifferentiated Colitis Pathway (including Acute Severe Colitis)</li>\n<li>Protocols and procedures</li>\n<li>Northern Treatment Advisory Group â€“Â Shared Care Guidelines</li>\n</ul>\n<h4>For patients</h4>\n<strong>Crohn's and Colitis UK:</strong>\n<h3>About Crohnâ€™s and Colitis</h3>\n<p>Pregnancy and BreastfeedingÂ [includes information on medication and breastfeeding]</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nInflammatory Bowel Disease (IBD)","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Last days of life","filename":"Last days of life Draft V.1.docx","category":"End of Life Care","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Background","content":"<h3>About Last Days of Life</h3>\n<p>Refers to the period when a person's death is thought to be imminent and they may have hours or days to live.</p>\n<p>The recognition and diagnosis of dying is complex. Uncertainty is an integral factor in the dying process and there are occasions when a person thought to be dying lives longer or dies sooner than expected.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<ul>\n<li>Determine if the patient isÂ dying â€“ look forÂ signs of the terminal phase.</li>\n<li>Signs of the terminal phase</li>\n<li>Profound weakness</li>\n<li>Reduced intake of food and fluids</li>\n<li>Increased drowsiness, diminished consciousness, delirium, terminal restlessness</li>\n<li>Incontinence</li>\n</ul>\n<p>Cardiac and respiratory changes, e.g. changing patterns of breathing, rattling or noisy breathing, tachycardia, bradycardia</p>\n<ul>\n<li>Peripheral shut-down (cold hands and feet)</li>\n<li>Ensure there are noÂ reversible factorsÂ that require treatment or investigation.</li>\n<li>Reversible factors</li>\n<li>Opioid toxicity</li>\n<li>Renal failure</li>\n<li>Hypercalcaemia</li>\n<li>Infection</li>\n<li>Hypoglycaemia</li>\n</ul>\n<p>Missing drugs, e.g. Parkinson's disease,Â myastheniaÂ gravis, ?? add following feedback: Thyroid medications</p>\n<p>Ask the patient or family about current symptoms, e.g. pain, agitation, restlessness, nausea, dyspnoea, or confusion.</p>\n<ul>\n<li>ExamineÂ the patient,Â including:</li>\n<li>mouth condition and the need forÂ mouth care.</li>\n<li>bowels â€“Â episodic pain may suggest colic.</li>\n<li>bladder,Â e.g. retention and catheter care.</li>\n<li>skin, including any pressure areas.</li>\n<li>Review anyÂ Advance Care Plan.</li>\n<li>ConsiderÂ the patient'sÂ spiritual and cultural needs.</li>\n<li>AssessÂ theÂ family'sÂ concerns, priorities, expectations, and understanding.</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<p>National guidance advocates the use ofÂ 5 priorities for care of the dying person.</p>\n<strong>Inform the patient and family that the patient is dying and in the last days or hours of life. Agree on a plan of care:</strong>\n<ul>\n<li>Allow time for wishes, fears, and concerns around dying to be addressed.</li>\n<li>Focus on patient comfort and family support.</li>\n<li>Provide and maintain dignity, respect, and privacy.</li>\n<li>Provide advice onÂ what to expect and what may be needed.</li>\n<li>What to expect and what may be needed</li>\n<li>Discuss theÂ signs of the terminal phaseÂ and the common symptoms expected.</li>\n<li>Signs of the terminal phase</li>\n<li>Profound weakness</li>\n<li>Reduced intake of food and fluids</li>\n<li>Increased drowsiness, diminished consciousness, delirium, terminal restlessness</li>\n<li>Incontinence</li>\n</ul>\n<p>Cardiac and respiratory changes, e.g. changing patterns of breathing, rattling or noisy breathing, tachycardia, bradycardia</p>\n<h3>Peripheral shut-down (cold hands and feet)</h3>\n<p>Provide written information about what to expect and any medications that may be required.</p>\n<strong>Advise the patient and family that the priorities of care are to reduce non-essential interventions and maintain comfort and dignity.</strong>\n<p>Educate the family about mouth, bowel, and bladder care, as necessary.</p>\n<p>Determine the preferred place of death. If the patient wishes to die somewhere other than their current location,Â followÂ theÂ rapid discharge checklist.</p>\n<p>Address any spiritual and cultural needs.</p>\n<strong>Ensure the familyÂ contact details (names and phone numbers) or up to date on Meditech.</strong>\n<strong>Use the Care of the Dying Patient document in Meditech to record your actions and facilitate necessary information sharing:</strong>\n<ul>\n<li>Select patient orders â€“ EOL Medical Assessment.</li>\n<li>Click onto Medical Assessment and Edit.</li>\n<li>Manage medicationsÂ in the terminal phase:</li>\n</ul>\n<p>.</p>\n<h3>Simplify drug regimens</h3>\n<p>Consider issues of potential withdrawal.Â This may include medications for Parkinson's disease,Â medications forÂ epilepsyÂ (including gabapentinoids), steroids, antidepressants, and benzodiazepines.</p>\n<p>Consider and discuss parenteral alternatives with your team (including pharmacist).</p>\n<p>SeekÂ palliative care adviceÂ if necessary.</p>\n<strong>Stop all non-essential medications. This may include anti-hypertensives, oral hypoglycaemics, diuretics, antibiotics,Â and others.</strong>\n<strong>Start appropriate medications for existing symptoms as needed.Â Consider nicotine patches for heavy smokers.</strong>\n<p>Consider the risks and benefits of administering hydration by parenteral route beforeÂ startingÂ or stopping intravenous or subcutaneous fluids.</p>\n<h3>ArrangeÂ anticipatory medications.</h3>\n<p>Anticipate common problems that may arise requiring symptom management.</p>\n<p>PrescribeÂ as-required medications for management of symptoms that may arise after hours or at the weekend.Â These may be subcutaneous or oral (if still able to swallow) and, if necessary, via continuous subcutaneous infusion.</p>\n<p>Change essential orÂ anticipatory medicationsÂ to the subcutaneous route.</p>\n<p>Use Meditech medication set Care of the Dying or Care of the Dying (Renal).</p>\n<p>Provide symptom management and anticipatory prescribing for the 5 most common symptoms. For non-complex patients, prescribe fromÂ Meditech.</p>\n<p>Pain â€“ useÂ morphine or other appropriate opioid</p>\n<h3>Morphine or other appropriate opioid</h3>\n<p>MorphineÂ is commonly used as first-line in anticipatory prescribing for pain and dyspnoea in palliative care.</p>\n<h3>If reduced eGFR, consider:</h3>\n<p>using a lower dose or longer-dosing interval with frequent review â€“ particularly in a patient whose renal function has gradually deteriorated, and they have already been prescribed and are tolerating morphine, or</p>\n<ul>\n<li>in opiate-naive patients, prescribe an alternative opioid:</li>\n<li>If less thanÂ 60, useÂ oxycodone.</li>\n<li>If less thanÂ 30, useÂ alfentanil.</li>\n</ul>\n<p>To convert opioids to the subcutaneous route, see NENC Palliative and End of Life Care Symptom Control Guidelines â€“Â Opioid Dose Conversion Chart.</p>\n<ul>\n<li>Be aware that:</li>\n<li>the subcutaneous dose of morphine is half the oral dose.</li>\n<li>the subcutaneous dose of oxycodone is approximately half of the oral oxycodone dose.</li>\n<li>subcutaneous doses of morphine or another appropriate opioid can be given up to every hour.</li>\n<li>For additional drug options, see:</li>\n<li>theÂ Pain in Palliative CareÂ pathway.</li>\n<li>NENC Palliative and End of Life Care Symptom Control Guidelines â€“Â Pain in the Last Days of Life.</li>\n<li>Agitation, delirium, or restlessness</li>\n<li>Be aware thatÂ terminal agitationÂ is very common in dying patients.</li>\n<li>Terminal agitation</li>\n</ul>\n<p>Also known as terminal restlessness.Â Often has underlying causes which should be carefully considered and addressed.</p>\n<ul>\n<li>Symptoms include:</li>\n<li>Agitation</li>\n<li>impaired consciousness</li>\n<li>distressed vocalising</li>\n<li>muscle twitching.</li>\n<li>Causes include:</li>\n<li>fearÂ andÂ anxiety,</li>\n<li>pain</li>\n<li>faecal impactionÂ andÂ urinary retention</li>\n<li>prescribed drug withdrawal</li>\n<li>withdrawal from nicotine, alcohol, or elicit drugs.</li>\n<li>Holistic assessment is vital to methodically and proportionately address contributory causes.</li>\n<li>Sedation can be complex to manage. ConsiderÂ seekingÂ palliative care advice.</li>\n<li>See also theÂ Anxiety, Distress, and Agitation in Palliative CareÂ pathway.</li>\n<li>ExcludeÂ orÂ manage pain, urinary retention, faecal impaction, or spiritual distress as a cause.</li>\n<li>Consider proportionate sedation usingÂ one of:</li>\n<li>Midazolam</li>\n<li>Subcutaneous dose:</li>\n</ul>\n<p>If a crisis, e.g. massive bleedÂ orÂ seizures, giveÂ midazolamÂ 5Â toÂ 10Â mg subcutaneously up to every 15Â minutesÂ if needed.</p>\n<p>Be aware thatÂ the bolus anticipatory for terminal agitation isÂ 2.5Â toÂ 5Â mg subcutaneously up to every hour if required.</p>\n<p>If multiple doses (3 or more) given in 24Â hours, consider increasing subcutaneous dose orÂ startingÂ syringe driver.</p>\n<p>The initial syringe driver dose of midazolam will depend on whether the patient is already having as-required bolusesÂ ofÂ midazolam.</p>\n<p>If not, consider starting at 10Â mg to 20Â mg over 24Â hours.</p>\n<p>Much higher doses can sometimes be needed.Â If unsure, consider seekingÂ palliative care advice.</p>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<h3>Haloperidol</h3>\n<p>is primarily indicated forÂ nausea and vomitingÂ (centrally acting and very effective for opioid-induced nausea) but is also used for agitatedÂ delirium, acute crises, and last days of life.</p>\n<ul>\n<li>can be used in bowel obstruction.</li>\n<li>can be used forÂ hiccups.</li>\n<li>Haloperidol hasÂ calmingÂ rather than sedating properties.</li>\n<li>Extrapyramidal side-effects are less likely when given subcutaneously.</li>\n<li>Contraindicated in ParkinsonismÂ and Lewy body dementia.</li>\n<li>Doses vary depending on the indication:</li>\n<li>Agitated deliriumÂ â€“Â treatÂ hypoactive delirium with non-pharmacological measures.</li>\n<li>Agitated delirium</li>\n</ul>\n<p>GiveÂ haloperidolÂ 0.5Â mg subcutaneously immediately. If necessary,Â repeat up to hourly to a maximum of 3Â mg over 24 hours.</p>\n<p>It isÂ preferable, to sedate with a benzodiazepine with or without levomepromazine rather thanÂ increase haloperidol above 3mgÂ overÂ 24Â hours.</p>\n<p>Aim for a regular dose twice a day, or a continuous subcutaneous infusion.</p>\n<h3>Nausea</h3>\n<p>Haloperidol is a potent, centrally acting antiemetic. It is very effective for nausea and vomiting caused by hypercalcaemia, renal failure, and opioids.</p>\n<h3>GiveÂ haloperidol:</h3>\n<p>orally 0.5Â toÂ 3Â mg every night. Oral therapy can also be divided into two daily doses.</p>\n<p>subcutaneously as a 0.5Â mg bolus every sixÂ hours, or as an infusion of 1Â toÂ 3Â mg everyÂ 24Â hours.</p>\n<p>If concerned about side-effects, start at 0.5Â mg every eight to twelveÂ hours, as required. Extrapyramidal side-effects are less likely with a subcutaneous dose.</p>\n<ul>\n<li>Avoid doses above 3Â mg, as these do not offer any benefit.</li>\n<li>Hiccups</li>\n<li>GiveÂ haloperidolÂ either orally or subcutaneously.</li>\n<li>Give 0.5Â mg twiceÂ a day, or 1.5Â mg at night, orÂ asÂ a continuous subcutaneous infusion.</li>\n<li>If ongoing distress, seekÂ palliative care advice.</li>\n</ul>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<h3>Levomepromazine</h3>\n<p>Levomepromazine is a phenothiazine antipsychotic used for managing nausea as well as pain and terminal restlessness.</p>\n<ul>\n<li>Dose:</li>\n<li>LevomepromazineÂ 6.25Â to 25Â mg orally or subcutaneously atÂ night</li>\n<li>Syringe driver 12.5Â to 25Â mg over 24Â hours</li>\n<li>Postural hypotension and sedation are common.</li>\n<li>Can be used during the day but warn that this can be very sedating.</li>\n<li>For higher dosesÂ orÂ long-term use,Â consider seekingÂ palliative care advice.</li>\n</ul>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<p>See theÂ Anxiety, Distress, and Agitation in Palliative CareÂ andÂ Delirium in Palliative CareÂ pathways.</p>\n<ul>\n<li>Nausea and vomiting</li>\n<li>Consider current antiemetics and whether effective. Continue these parenterally.</li>\n<li>Useful options are:</li>\n<li>Cyclizine</li>\n<li>Use withÂ caution in patients with advanced heart failure.</li>\n<li>Avoid in porphyria.</li>\n<li>IsÂ antihistaminic, anticholinergic,Â andÂ antiemetic.</li>\n</ul>\n<p>Theoretically, the anticholinergic effects of cyclizine antagonise the prokinetic effects of metoclopramide â€“Â do notÂ routinely combine.</p>\n<ul>\n<li>Be aware thatÂ it may cause cognitive impairment or drowsiness.</li>\n<li>Dose â€“Â giveÂ cyclizine:</li>\n<li>25Â toÂ 50Â mg orallyÂ or subcutaneouslyÂ as required every 6 to 8 hours.</li>\n<li>Syringe driver, 75 to 150Â mg per 24 hours.</li>\n</ul>\n<p>If subcutaneous use causes skin irritation, dilute to maximum possible volume with water for injection.</p>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<h3>Haloperidol</h3>\n<p>is primarily indicated forÂ nausea and vomitingÂ (centrally acting and very effective for opioid-induced nausea) but is also used for agitatedÂ delirium, acute crises, and last days of life.</p>\n<ul>\n<li>can be used in bowel obstruction.</li>\n<li>can be used forÂ hiccups.</li>\n<li>Haloperidol hasÂ calmingÂ rather than sedating properties.</li>\n<li>Extrapyramidal side-effects are less likely when given subcutaneously.</li>\n<li>Contraindicated in ParkinsonismÂ and Lewy body dementia.</li>\n<li>Doses vary depending on the indication:</li>\n<li>Agitated delirium</li>\n<li>treatÂ hypoactive delirium with non-pharmacological measures.</li>\n</ul>\n<p>GiveÂ haloperidolÂ 0.5Â mg subcutaneously immediately. If necessary,Â repeat up to hourly to a maximum of 3Â mg over 24 hours.</p>\n<p>It isÂ preferable, to sedate with a benzodiazepine with or without levomepromazine rather thanÂ increase haloperidol above 3mgÂ overÂ 24Â hours.</p>\n<p>Aim for a regular dose twice a day, or a continuous subcutaneous infusion.</p>\n<h3>Nausea</h3>\n<p>Haloperidol is a potent, centrally acting antiemetic. It is very effective for nausea and vomiting caused by hypercalcaemia, renal failure, and opioids.</p>\n<h3>GiveÂ haloperidol:</h3>\n<p>orally 0.5Â toÂ 3Â mg every night. Oral therapy can also be divided into two daily doses.</p>\n<p>subcutaneously as a 0.5Â mg bolus every sixÂ hours, or as an infusion of 1Â toÂ 3Â mg everyÂ 24Â hours.</p>\n<p>If concerned about side-effects, start at 0.5Â mg every eight to twelveÂ hours, as required. Extrapyramidal side-effects are less likely with a subcutaneous dose.</p>\n<ul>\n<li>Avoid doses above 3Â mg, as these do not offer any benefit.</li>\n<li>Hiccups</li>\n<li>GiveÂ haloperidolÂ either orally or subcutaneously.</li>\n<li>Give 0.5Â mg twiceÂ a day, or 1.5Â mg at night, orÂ asÂ a continuous subcutaneous infusion.</li>\n<li>If ongoing distress, seekÂ palliative care advice.</li>\n</ul>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<h3>Levomepromazine</h3>\n<p>Levomepromazine is a phenothiazine antipsychotic used for managing nausea as well as pain and terminal restlessness.</p>\n<ul>\n<li>Dose:</li>\n<li>LevomepromazineÂ 6.25Â to 25Â mg orally or subcutaneously atÂ night</li>\n<li>Syringe driver 12.5Â to 25Â mg over 24Â hours</li>\n<li>Postural hypotension and sedation are common.</li>\n<li>Can be used during the day but warn that this can be very sedating.</li>\n<li>For higher dosesÂ orÂ long-term use,Â consider seekingÂ palliative care advice.</li>\n</ul>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<h3>Metoclopramide</h3>\n<p>Metoclopramide is an upper gastrointestinal prokinetic with weak central effects via dopamine receptors. It is indicated forÂ nausea and vomiting, gastrointestinal gastroparesis, and functional bowel obstruction (commonly caused by opioids), and for GORD.</p>\n<ul>\n<li>Avoid if the patient has:</li>\n<li>suspected complete bowel obstruction.</li>\n<li>Parkinsonism â€“ use domperidone instead.</li>\n</ul>\n<p>GiveÂ metoclopramideÂ 10Â mg orally three to four times a day, or subcutaneously, or intravenously every 4Â toÂ 6Â hours. AdviseÂ theÂ patient to take 20 to 30Â minutes before meals if gastric stasis.</p>\n<p>Watch for akathisiaÂ orÂ agitation, particularly in higher doses and in youngÂ patients, especially women.</p>\n<p>Monitor olderÂ patients, who are at increased risk of extrapyramidal side-effects.</p>\n<p>In palliative care, doses, indications, and routes of administration may beÂ off-label or unlicensed.</p>\n<p>SeeÂ Nausea and Vomiting in Palliative Care.</p>\n<p>For further information see NENC Palliative and End of Life Care Symptom Control Guidelines â€“Â Nausea and/or Vomiting in the Last Days of Life.</p>\n<h3>Excessive secretions (death rattle)</h3>\n<p>Commonly seen inÂ aÂ dying patient when they are too weak to expectorate and are unable to clear their oral and upper airway secretions.</p>\n<p>ProvideÂ anÂ explanation toÂ theÂ family.</p>\n<p>Be aware thatÂ repositioning can be rapidly effective.</p>\n<p>Focus on oral hygiene. Avoid suction, as gentle mouth swabbing is usually well-tolerated and effective â€“ remove and add â€“ as gentle mouth care, using 360-degree soft bristle toothbrushes, is usually well tolerated and effective. (following feedback from Karen Crammond)</p>\n<p>Medications are effective only about half the time. If needed, useÂ hyoscine butylbromideÂ (Buscopan).</p>\n<h3>Hyoscine butylbromide</h3>\n<p>Is anÂ anticholinergicÂ medication, used for excessive or retained secretions inÂ aÂ dying patient.</p>\n<p>GiveÂ hyoscine butylbromideÂ 20Â mg subcutaneouslyÂ (can be repeated up to every hour) and 40Â toÂ 120Â mg every 24Â hours via syringe driver.</p>\n<p>For more information, see NENC Palliative and End of Life Care Symptom Control Guidelines â€“Â Respiratory Tract Secretions in the Last Days of Life.</p>\n<ul>\n<li>Dyspnoea</li>\n<li>This may be distressing for the patient or the family.</li>\n<li>Consider repositioning the patient.</li>\n<li>If medication is needed, considerÂ low-dose opiates via syringe driver according to renal function.</li>\n<li>SeeÂ theÂ Dyspnoea in Palliative CareÂ pathway.</li>\n</ul>\n<p>For more information, see NENC Palliative and End of Life Care Symptom Control Guidelines â€“Â Breathlessness in the Last Days of Life.</p>\n<ul>\n<li>Manage any physical needs:</li>\n<li>Pressure care</li>\n<li>If the patient can tolerate it, advise turning regularly.</li>\n</ul>\n<strong>Ensure use of a pressure-relieving mattress if the patientÂ cannot tolerate turning, e.g. due to pain.</strong>\n<p>Manage any emerging pressure ulcers.</p>\n<strong>?? to replace the above with the following statement from Pressure area care policy:</strong>\n<p>Positional changes must continue as part of end-of-life care. However, where patients or their family express concern that positional changes are causing too much distress or pain to the individual and express a preference not to be repositioned, this will be discussed and documented on the positional change/care chart and recorded in the patientâ€™s nursing records/end-of-life care documentation.</p>\n<p>(Following feedback from Claire Morris)</p>\n<h3>Continence care</h3>\n<p>For many patients, urine output will diminish.Â TheÂ patient may require incontinence pads orÂ aÂ urinary catheter.</p>\n<p>Individualise managementÂ for theÂ patient, taking into consideration factors such as pressure damage.</p>\n<p>The frequency of bowel motions reduces at the end of life â€“ manage with incontinence pads.</p>\n<p>IfÂ theÂ patient is agitated, restless, or distressed, consider urinary retention or faecal impaction.</p>\n<ul>\n<li>Oral care â€“ follow theÂ Oral Care in Palliative CareÂ pathway</li>\n<li>ManageÂ other non-prescribed interventions:</li>\n<li>Consider stopping routine phlebotomy.</li>\n</ul>\n<p>Limit finger-prick blood glucose monitoring for diabetes â€“Â use onlyÂ ifÂ the patientÂ remains on insulin.</p>\n<p>If an implantable cardiac defibrillator (ICD) requires deactivation, requestÂ implantable cardiac defibrillator (ICD) deactivation.</p>\n<ul>\n<li>Ensure close collaboration between all palliative care providers. SeekÂ palliative care advice:</li>\n<li>if symptoms persist.</li>\n<li>for patient review or support.</li>\n</ul>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow Up","content":"<p>If theÂ patient'sÂ preference is to die at home, start discharge planning immediately to minimise any potential delays.</p>\n<p>Involve theÂ patientÂ and their familyÂ orÂ carer in the discharge details and the plan of care.</p>\n<p>Use the Rapid Discharge checklist â€“ add: Please see Rapid Discharge SOP (following feedback from Karen Crammond)</p>\n<p>If a dying patient is being transferred home or to a hospice to enable them to die in their place of choice, arrange theÂ palliative care ambulance service.</p>\n<h3>Palliative care ambulance service</h3>\n<p>Dying patients have a dedicated service that does not rely on using core NEAS vehicles. This is to enable these patients to die in their place of choice and get there in a timely manner.</p>\n<ul>\n<li>Operating times:</li>\n<li>Monday to Friday betweenÂ 9Â amÂ toÂ 7Â pmÂ (including bank holidays).</li>\n<li>The shifts for each of the 3 vehicles are:</li>\n<li>9Â amÂ toÂ 5Â pm</li>\n<li>10Â amÂ toÂ 6Â pm</li>\n<li>11Â amÂ toÂ 7Â pm</li>\n<li>Call the urgent line onÂ 0191Â 414Â 3144Â to book an End of Life Vehicle.</li>\n<li>This line is open Monday to FridayÂ 8Â amÂ toÂ 5Â pmÂ (including Bank Holidays).</li>\n</ul>\n<p>Bookings can be made outside of these hours using normal NEAS urgent booking processes, but will require a core NEAS vehicle so may be more subject to delay</p>\n<strong>If the patient wishes to be discharged to a hospice, requestÂ hospice services:</strong>\n<p>Note that any patient being transferred from hospital wards to hospice need to arrive by 1Â pm as there are no doctors on site at the hospice out of hours. If this is not achieved, then the transfer may be cancelled.</p>\n<strong>Do not delay ward transfers to hospice because of waiting for medications. If needed, these can be couriered to the hospice later that day.</strong>\n<strong>If the patient is being discharged home:</strong>\n<p>RequestÂ community palliative care servicesÂ in good time.</p>\n<p>Where appropriate, ensure sufficientÂ anticipatoryÂ subcutaneous medications are prescribed and available in the home, with theÂ appropriate documentation.</p>\n<ul>\n<li>Appropriate documentation</li>\n<li>Current practice:</li>\n<li>South Tyneside Community Service â€“ green Kardex</li>\n<li>Sunderland Community service â€“ MAR chart</li>\n<li>Durham â€“ MAR chart</li>\n</ul>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<ul>\n<li>Seek or consider seekingÂ palliative care advice:</li>\n<li>if unsure of any medication issues.</li>\n<li>if ongoing distress.</li>\n<li>if symptoms persist.</li>\n<li>for patient review or support.</li>\n<li>if higher doses of midazolam are required.</li>\n<li>if higher doses or long-term use of levomepromazine are required.</li>\n<li>If the patient wishes to be discharged to a hospice, requestÂ hospice services.</li>\n</ul>\n<p>If an implantable cardiac defibrillator (ICD) requires deactivation, requestÂ implantable cardiac defibrillator (ICD) deactivation.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<ul>\n<li>Education</li>\n<li>e-Learning for Healthcare â€“Â End-of-life Care for All (e-ELCA)</li>\n<li>Further information</li>\n</ul>\n<p>General Medical Council â€“Â Treatment and Care Towards the End of Life: Good Practice in Decision Making</p>\n<p>NHS North East and North Cumbria Clinical Networks â€“Â Palliative and End of Life Care Symptom Control Guidelines</p>\n<ul>\n<li>Northern Cancer Alliance:</li>\n<li>Caring for the Dying Patient</li>\n<li>Professional Guidance and Resources</li>\n</ul>\n<h4>For patients</h4>\n<h3>Marie Curie â€“Â What to Expect at the End of Someone's Life</h3>\n<p>Northern Cancer Alliance â€“Â Understanding What Happens When Someone is Dying: Information for Relatives, Friends and Carers</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nLast days of life","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Mental Capacity","filename":"Mental Capacity Draft V.1.docx","category":"Mental Health & Cognition","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Background","content":"<h3>About Mental Capacity</h3>\n<p>The Mental Capacity Act (MCA) is designed to protect and empower people who may lack the mental capacity to make their own decisions about their care and treatment. It applies to people agedÂ 16Â years or older.</p>\n<p>Young people agedÂ 16Â orÂ 17Â yearsÂ are presumed in UK law, like adults, to have the capacity to consent to medical treatment. However, unlike adults, their refusal of treatment can, in some circumstances be overridden by a parent, someone with parental responsibility, or a court.</p>\n<p>ChildrenÂ youngerÂ thanÂ 16Â years may be competent to consent to treatment (Gillick competence and Fraser guidelines in relation to sexual health) however this should be assessed before starting treatment.</p>\n<p>The MCA is designed to empower those in health and social care to assess capacity themselves, rather than rely on expert testing â€“ good professional training is key.</p>\n<strong>Mental capacity is time-specific, decision-specific, and situation-specific. It can be temporary, permanent, or it can fluctuate. A lack of capacity could be due to:</strong>\n<ul>\n<li>a brain injury or stroke</li>\n<li>a mental health problem</li>\n<li>confusion or drowsiness related to a physical illness</li>\n<li>medications, including substance and alcohol misuse</li>\n<li>dementia</li>\n<li>a learning disability.</li>\n</ul>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<strong>Ensure assessment adheres to theÂ Five key principles of the Mental Capacity Act (MCA)</strong>\n<p>A person must be assumed to have capacity unless it is established that they lack capacity.</p>\n<p>A person is not to be treated as unable to make a decision unless all practicable steps to help them to do so have been taken without success.</p>\n<p>A person is not to be treated as unable to make a decision merely because they make an unwise decision.</p>\n<p>An act done, or decision made, under this Act for or on behalf of a person who lacks capacity must be done, or made, in their best interests.</p>\n<p>Before the act is done, or the decision is made, regard must be had to whether the purpose for which it is needed can be as effectively achieved in a way that is less restrictive of the person's rights and freedom of action.</p>\n<ul>\n<li>Prepare for the assessment:</li>\n<li>Determine if there is evidence to doubt the patient's capacity.</li>\n<li>Determine what has prompted a capacity assessment. ConsiderÂ common triggers.</li>\n<li>Common triggers for a capacity assessment</li>\n<li>Urgent clinical care</li>\n<li>Routine clinical care â€“ consent to medical treatment</li>\n<li>Covert administration of medications</li>\n<li>Covert administration of medications</li>\n<li>his is when medications are given in a disguised format without the knowledge of the patient.</li>\n<li>Medication should only be given covertly when all of:</li>\n<li>the patient refuses to take their medication</li>\n<li>the patient lacks the capacity to understand the consequences of refusing their medication</li>\n<li>the medicine is considered essential to their health and well-being.</li>\n<li>For further information,Â see The Care Quality Commission â€“Â Covert Administration of Medicines.</li>\n</ul>\n<p>Advance care planning â€“Â lasting power of attorney (LPA),Â advance decision to refuse treatment (ADRT)</p>\n<ul>\n<li>Advance Decision to Refuse Treatment (ADRT)</li>\n<li>Usually written but can be given verbally.</li>\n<li>Must be written and comply with legal requirements when refusing life-sustaining treatment.</li>\n</ul>\n<p>Documents an adult patientâ€™s decision to refuse a specific treatment and applies in all settings for peopleÂ agedÂ 18Â yearsÂ orÂ older.</p>\n<p>The patient must be deemed to have mental capacity to refuse treatmentÂ when makingÂ anÂ ADRT. Use theÂ Checking Advance Decisions checklistÂ to ensure the validity and applicability of an ADRT.</p>\n<p>If refusing treatment of a mental illness,Â thisÂ can be over-ruled by detention under the Mental Health Act.</p>\n<p>Printable ADRT form.</p>\n<h3>Lasting power of attorney (LPA)</h3>\n<p>A lasting power of attorney (LPA) is a legal document that lets the patient (\"donor\") appoint one or more people (\"attorneys\") to help make decisions or to make decisions on their behalf.</p>\n<p>A person must be 18 years or older and have mental capacity, i.e. the ability to make their own decisions, when making an LPA.</p>\n<p>An LPA gives the patient more control over their treatment if, through accident or illness, they lack mental capacity.</p>\n<p>There are 2 types of LPA â€“ health and welfare, and property and financial affairs. The patient can choose to make one type or both.</p>\n<p>Enduring powersÂ of attorney (EPA)Â put in place before 2007Â may still exist,Â butÂ theyÂ can only be used for financial decisions and do not cover health and welfare related issues.</p>\n<p>If a patient lacks capacity, they will not be able to appoint an LPA but family or carers can apply to become someone's \"deputy\" if they lack mental capacity and cannot make a decision for themselves at the time it needs to be made, e.g. following brain injury, dementia sufferers, or those with severe learning disabilities. The \"deputy\" will be appointed by the Court of Protection to make decisions on the patient's behalf.</p>\n<strong>Online resources:</strong>\n<h3>Make a Lasting Power of Attorney</h3>\n<p>Deputies: Make Decisions for Someone who Lacks CapacityMake, Register, or End a Lasting Power of Attorney</p>\n<ul>\n<li>Dying Matters</li>\n<li>Concerns from others â€“ family member, lawyer, service provider</li>\n<li>Adolescents younger thanÂ 16Â years when providing care without parents' consent or knowledge</li>\n<li>Concerns about self-neglect</li>\n</ul>\n<p>Identify the particular decision the patient is seeking to make. Capacity is time- and decision-specific.</p>\n<p>Consider what questions the patient needs to be asked to ascertain their ability to understand the salient points â€“ what do we need the patient to know, understand, and retain?</p>\n<strong>Ensure the patient has been given all the relevant informationÂ on all viable optionsÂ to make an informed decision and record theÂ options andÂ decision in the medical notes.</strong>\n<ul>\n<li>GatherÂ information to inform assessment.</li>\n<li>Information to inform assessment</li>\n<li>Consider:</li>\n<li>past medical and psychiatric history</li>\n<li>specialist letters, e.g. geriatrician, psychiatrist</li>\n<li>collateral history from family and carers.</li>\n</ul>\n<strong>If the patient's condition is temporary,Â assess the risk of delay andÂ consider whether the decision can be put off until the patient regains capacity.</strong>\n<p>Determine whether a substitute decision-maker, e.g. lasting power of attorney, has already been appointed, or if anÂ advance decision to refuse treatment (ADRT)Â is in place.</p>\n<ul>\n<li>Consider what reasonable adjustments can be made to enable a patient to make a decision.</li>\n<li>Allocate sufficient time with the patient andÂ support people.</li>\n<li>Support people</li>\n</ul>\n<p>Support people may be able to help communicate with the patient and provide information about their wishes.</p>\n<strong>Advise the support people that they are not able to answer the capacity questions on behalf of the patient. They can re-word, re-frame the question to make it easier to understand for the patient and/or ask the assessing practitioner to re-word the question.</strong>\n<p>Consider professionals, e.g. learning disability support, dementia support, speech and language therapist.</p>\n<p>If support people are invited, also make time to see the patient alone, to avoid subtle coercion from supporters.</p>\n<h3>Arrange anÂ interpreterÂ if required.</h3>\n<p>Consider the need for visual aids.</p>\n<p>Use the mental capacity assessment templateÂ (MCA1Â andÂ MCA2)Â available onÂ MeditechÂ to record the capacity assessment process and outcome.</p>\n<p>In adolescents youngerÂ thanÂ 16Â years who are requesting or refusing treatment without parental consent or knowledge, assessÂ Gillick competency.</p>\n<h3>Check understanding:</h3>\n<strong>Check the patient's understanding of the decision being made and theirÂ understanding of choices available.</strong>\n<ul>\n<li>Understanding of choices available</li>\n<li>Check whether the patient understands that they have a choice, including:</li>\n<li>the decision that needs to be made</li>\n<li>that they have different options to choose from</li>\n</ul>\n<p>the consequences, i.e. how treatment or non-treatment will affect them, the advantages and benefits, and the disadvantages and risks of the proposed treatment</p>\n<p>why the decision needs to be made, that there is a problem, and that the problem will affect them.</p>\n<p>Where possible, provideÂ education and supportÂ about the available options. Do not mistake a lack of knowledge for incapacity.</p>\n<p>Education and support</p>\n<h3>To minimise communication difficulties:</h3>\n<p>Use simple terminology to clearly explain the significance of the precipitating problem, the likely outcomes, and potential consequences of these outcomes.</p>\n<p>Provide written educational material. Drawings may be helpful.</p>\n<h3>Arrange anÂ interpreter, if necessary.</h3>\n<p>Address the issue at different appointments, if time allows.</p>\n<p>When dealing with chronic problems, consider visiting the patient in their home if this would reduce stress.</p>\n<ul>\n<li>Check whether the patient can retain the information long enough to make the decision.</li>\n<li>CheckÂ ability to weigh and use information:</li>\n<li>ConsiderÂ personality factors that may affect decision-making.</li>\n<li>Personality factors that may affect decision-making</li>\n<li>The patient's values and goals, and the preferred outcomes that are important to them</li>\n<li>Outcomes that are acceptable and unacceptable for the patient</li>\n</ul>\n<p>Cultural needs, values, and beliefs â€“ invite support people to participate in the assessment, if helpful</p>\n<ul>\n<li>Ask specific questions relating to the decision being made. Capacity is domain-specific:</li>\n<li>Medical treatment consent</li>\n<li>Medical treatment consent</li>\n<li>Ask the patient if they understand:</li>\n<li>the general nature of the interventionÂ and other options.</li>\n<li>theÂ likely and foreseeableÂ risks and benefits.</li>\n<li>that they may refuse treatment, and the consequences of refusal.</li>\n<li>Legal matters</li>\n</ul>\n<strong>Lasting power of attorney (LPA) or advance decision to refuse treatment (ADRT)Â â€“ ask the patient if they:</strong>\n<ul>\n<li>understand the purpose of the legal document.</li>\n<li>areÂ making decisions freely and voluntarily.</li>\n<li>chose their attorney(s).</li>\n<li>Wills (testamentary capacity)</li>\n<li>Wills (Testamentary Capacity)</li>\n<li>Ask the patient if:</li>\n<li>they understand the purpose of a will.</li>\n<li>they know the extent of their assets and liabilities.</li>\n<li>theyÂ areÂ aware of the people who could make a claim on the estate.</li>\n<li>what moral obligations they feel they have to those people.</li>\n</ul>\n<p>Consider askingÂ theÂ patient to demonstrate the reasoning behind any decisions they make, even if the decisions seem unusual or irrational.</p>\n<strong>Check communication â€“ consider whether the patient needs help toÂ communicate a meaningful decisionÂ about the choice.</strong>\n<h3>CommunicateÂ a meaningful decision</h3>\n<p>A patient with a speech disorder, e.g. dysphasia or dysarthria, may not be able to communicate their wishes easily. If a patient is having difficulty communicating their decisions, the onus is on the healthcare provider to help communication.</p>\n<p>Arrange for anÂ interpreter, or phone interpreting service, to be present during a consultation for patients who do not speak English.</p>\n<p>ConsiderÂ requestingÂ speech and language therapy assessment if the patient has communication issues.</p>\n<p>Consider whether the patient has an impairment of their mind or brain.</p>\n<p>A known psychiatric or neurological disorder may be an indicator of impairment but does not always mean a patient must be impaired.</p>\n<ul>\n<li>Consider anyÂ evidence ofÂ impaired executive functionÂ orÂ impaired decision-making.</li>\n<li>Impaired decision-making</li>\n<li>Confused or delusional thinking</li>\n<li>Difficulty making a definite choice about treatment</li>\n<li>Extreme anxiety, or suicidal ideation</li>\n<li>Reduced consciousness, or impairment by alcohol or drugs</li>\n<li>Intellectual disability, impairment of executive function, or cognitive impairment</li>\n<li>Being unduly under the influence of another person</li>\n<li>Decisions that are inconsistent with their values, goals, and beliefs</li>\n<li>Impaired executive function</li>\n</ul>\n<p>Patients with impaired executive function may seem to understand the situation but struggle to execute the intention at the appropriate time.</p>\n<ul>\n<li>Patients with executive impairment may show the following signs:</li>\n<li>Unable to translate intention into action</li>\n<li>\"Full of promises\" and seems plausible</li>\n<li>Apathetic</li>\n<li>Inability to initiate, plan, and sequence activities</li>\n<li>Less able to adapt to change or new situations (better with familiar situations)</li>\n<li>Aimless, impulsive, or fragmented behaviour</li>\n<li>Unable to monitor and evaluate their own actions</li>\n<li>Unable to think flexibly or abstractly</li>\n<li>Black and white thinking style</li>\n<li>Lack of a filter in social situations</li>\n</ul>\n<p>If there are concerns about executive dysfunction, it is important to get collateral history from other professionals, family, and friends to be able to evidence this.</p>\n<p>For further information, see Lancashire Safeguarding Adults Board â€“Â MCA Guidance Executive Functioning.</p>\n<ul>\n<li>Record the cause ofÂ anyÂ impairment andÂ how it impacts on decision-making.</li>\n<li>Check if there is anyÂ impaired capacity as a result of a treatable condition.</li>\n<li>Impaired capacity as a result of a treatable condition</li>\n<li>Capacity, or the lack of it, is time-specific and not necessarily permanent.</li>\n<li>Addressing the condition may resolve the capacity issue.</li>\n</ul>\n<p>Consider whether the decisions being madeÂ can be delayed to a time when capacity may be recovered without any adverse impacts to the patient.</p>\n<p>When the patient is stable, review the need for aÂ repeatÂ capacity assessment.</p>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<p>Practice point</p>\n<h3>Request safeguarding advice for self-neglect</h3>\n<p>If a patient isÂ putting themselves or others at risk as a result of self-neglect,Â and refuses care or support,Â seekÂ adult safeguarding advice, even if the patient is assessed as having capacity.</p>\n<p>Communicate the outcome of the assessment to the patient, and its implications for them.</p>\n<p>Specify the domains and decisions where capacity is intact and where it is impaired.</p>\n<p>Encourage decision-making in matters where capacity is intact, even if many decisions will require a substitute decision-maker.</p>\n<strong>If there is inadequate evidence that capacity is impaired, be aware no further action is required exceptÂ if:</strong>\n<p>aÂ Gillick-competentÂ adolescent youngerÂ thanÂ 16Â years refuses treatment for a serious condition which may lead to disability or a life-threatening condition, this may be overruled by someone withÂ parental responsibility.</p>\n<p>the patient agedÂ 16Â orÂ 17Â years refuses life-sustaining treatment thatÂ theÂ parents wishÂ forÂ them to have,Â theÂ court of protectionÂ or high court must be involved.</p>\n<p>if there are concerns about self-neglectÂ with associated high levels of risk to the patient or others, andÂ anÂ adult refuses care or support,Â seekÂ adult safeguarding advice. Be aware thatÂ there are circumstances in whichÂ the local authority must undertake a needs assessment even if theÂ patientÂ refuses.</p>\n<ul>\n<li>If uncertainty remains, seekÂ mental capacity advice.</li>\n<li>Mental capacity advice</li>\n<li>In the first instance, contact the:</li>\n<li>specialist practitioner for Mental Capacity Act (MCA) onÂ ext.Â 42242.</li>\n<li>STSFT safeguarding team onÂ (0191)Â 541Â 0555.</li>\n</ul>\n<strong>If the patient is assessed as lacking capacity, check if there areÂ legal representatives who can make the decisionÂ or anÂ ADRT.</strong>\n<ul>\n<li>Advance Decision to Refuse Treatment (ADRT)</li>\n<li>Usually written but can be given verbally.</li>\n<li>Must be written and comply with legal requirements when refusing life-sustaining treatment.</li>\n</ul>\n<p>Documents an adult patientâ€™s decision to refuse a specific treatment and applies in all settings for peopleÂ agedÂ 18Â yearsÂ orÂ older.</p>\n<p>The patient must be deemed to have mental capacity to refuse treatmentÂ when makingÂ anÂ ADRT. Use theÂ Checking Advance Decisions checklistÂ to ensure the validity and applicability of an ADRT.</p>\n<p>If refusing treatment of a mental illness,Â thisÂ can be over-ruled by detention under the Mental Health Act.</p>\n<ul>\n<li>Printable ADRT form.</li>\n<li>Legal representatives who can make the decision</li>\n<li>For example:</li>\n<li>Parental responsibilityÂ for patients youngerÂ thanÂ 16Â years</li>\n<li>Lasting power of attorney</li>\n<li>Court appointed deputy</li>\n<li>Guardianship order</li>\n<li>If unsure, check GOV.UK â€“Â Find Out if Someone Has an Attorney, Deputy or Guardian Acting for Them.</li>\n<li>If there are no legal representatives or ADRT:</li>\n<li>andÂ considering an application to theÂ court of protection, seekÂ mental capacity advice.</li>\n<li>Mental capacity advice</li>\n<li>In the first instance, contact the:</li>\n<li>specialist practitioner for Mental Capacity Act (MCA) onÂ ext.Â 42242.</li>\n<li>STSFT safeguarding team onÂ (0191)Â 541Â 0555.</li>\n</ul>\n<p>andÂ impairment in capacity may be related to mental illness, manage according to theÂ relevant pathway.</p>\n<p>consider making decisions in the patient's best interests.</p>\n<p>If making decisions in the patient's best interests, follow theÂ MCA section 4 best interest checklistÂ and consider whether you need to liaise with others or arrange aÂ Best Interest meeting.</p>\n<h3>Best Interest meeting</h3>\n<p>Use the mental capacity assessment data entry template inÂ MeditechÂ to guide you and record the decisions and outcome.</p>\n<p>Decide who will be theÂ decision makerÂ and who will chair the meeting â€“ this should not normally be the same person.</p>\n<ul>\n<li>Decision maker</li>\n<li>If the decision is about:</li>\n<li>medical treatment, this will normally be the lead health professional.</li>\n<li>care or finances, this will normally be the case manager or social worker.</li>\n<li>Invite other involved professionals and key people, e.g. family, friends, carers.</li>\n<li>Determine if the patient needs anÂ Independent Mental Capacity Advocate (IMCA).</li>\n<li>Independent Mental Capacity Advocate criteria</li>\n<li>Request anÂ Independent Mental Capacity Advocate (IMCA)Â if:</li>\n<li>Independent Mental Capacity Advocate (IMCA) referral</li>\n</ul>\n<p>South Tyneside (and Gateshead/Newcastle) residents:Â Your Voice Counts Advocacy Services â€“Â Make a Referral</p>\n<ul>\n<li>Sunderland residents: VoiceAbilityÂ â€“Â Make a Referral</li>\n<li>Durham residents: Cloverleaf AdvocacyÂ â€“Â Referrals</li>\n<li>there are adult safeguarding issues, especially involving family or friends, or</li>\n<li>there are no family or friends to represent the patient's view, and:</li>\n<li>a serious medical treatment is started or withdrawn.</li>\n<li>a hospital stay of longer than 28Â days is proposed.</li>\n<li>a change of accommodation for over 8Â weeks is proposed.</li>\n</ul>\n<p>ConsiderÂ howÂ it is appropriate to involve the patient's views at the meetingÂ even if they lack capacity.</p>\n<ul>\n<li>During the meeting:</li>\n<li>Consider:</li>\n<li>past and present views the patient has expressed, either written or verbal.</li>\n<li>beliefs and values of the patient.</li>\n</ul>\n<p>factors the patient would be likely to consider if they could do so, e.g. effect of the decision on dependants or wider society.</p>\n<p>using a balance sheet to weigh up potential benefits and disadvantages for the patient's emotional, medical, and social welfare.</p>\n<p>Before the decision is made, consider whether a less restrictive option is available.</p>\n<p>ConsiderÂ theÂ patient's wishes and feelings when making a Best Interest Decision, especially any writtenÂ advanceÂ statements that may have been made.</p>\n<p>Individual health or social care professionals can make simple decisions in the patient's best interests, e.g. vaccination, urethral catheterisation.</p>\n<p>ForÂ a more complex decision, consult with involved professionals, family, and friends to determine the best outcome for the patient.</p>\n<p>In an emergency, use the available information, and when possible, consult with the relevant people to make a decision.</p>\n<p>If it is not an emergency, consider holding a formalÂ Best Interest meeting.</p>\n<h3>Best Interest meeting</h3>\n<p>Use the mental capacity assessment data entry template inÂ MeditechÂ to guide you and record the decisions and outcome.</p>\n<p>Decide who will be theÂ decision makerÂ and who will chair the meeting â€“ this should not normally be the same person.</p>\n<ul>\n<li>Invite other involved professionals and key people, e.g. family, friends, carers.</li>\n<li>Determine if the patient needs anÂ Independent Mental Capacity Advocate (IMCA).</li>\n<li>Independent Mental Capacity Advocate criteria</li>\n<li>Request anÂ Independent Mental Capacity Advocate (IMCA)Â if:</li>\n<li>Independent Mental Capacity Advocate (IMCA) referral</li>\n</ul>\n<p>South Tyneside (and Gateshead/Newcastle) residents:Â Your Voice Counts Advocacy Services â€“Â Make a Referral</p>\n<ul>\n<li>Sunderland residents: VoiceAbilityÂ â€“Â Make a Referral</li>\n<li>Durham residents: Cloverleaf AdvocacyÂ â€“Â Referrals</li>\n<li>there are adult safeguarding issues, especially involving family or friends, or</li>\n<li>there are no family or friends to represent the patient's view, and:</li>\n<li>a serious medical treatment is started or withdrawn.</li>\n<li>a hospital stay of longer than 28Â days is proposed.</li>\n<li>a change of accommodation for over 8Â weeks is proposed.</li>\n</ul>\n<p>ConsiderÂ howÂ it is appropriate to involve the patient's views at the meetingÂ even if they lack capacity.</p>\n<ul>\n<li>During the meeting:</li>\n<li>Consider:</li>\n<li>past and present views the patient has expressed, either written or verbal.</li>\n<li>beliefs and values of the patient.</li>\n</ul>\n<p>factors the patient would be likely to consider if they could do so, e.g. effect of the decision on dependants or wider society.</p>\n<p>using a balance sheet to weigh up potential benefits and disadvantages for the patient's emotional, medical, and social welfare.</p>\n<p>Before the decision is made, consider whether a less restrictive option is available.</p>\n<strong>If the patient's lack of capacity is likely to be enduring, consider signposting family members or close friends to the Court of Protection toÂ apply to be a deputy.</strong>\n<strong>Document contact details for anyÂ appointed attorneys or legal guardiansÂ in the patient's medical record.</strong>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Advice and Referrals","content":"<strong>Request anÂ Independent Mental Capacity Advocate (IMCA)Â if:</strong>\n<h3>Independent Mental Capacity Advocate (IMCA) referral</h3>\n<p>South Tyneside (and Gateshead/Newcastle) residents:Â Your Voice Counts Advocacy Services â€“Â Make a Referral</p>\n<ul>\n<li>Sunderland residents: VoiceAbilityÂ â€“Â Make a Referral</li>\n<li>Durham residents: Cloverleaf AdvocacyÂ â€“Â Referrals</li>\n<li>there are adult safeguarding issues, especially involving family or friends, or</li>\n<li>there are no family or friends to represent the patient's view, and:</li>\n<li>a serious medical treatment is started or withdrawn.</li>\n<li>a hospital stay of longer than 28Â days is proposed.</li>\n<li>a change of accommodation for over 8Â weeks is proposed.</li>\n</ul>\n<p>If concerns about self-neglect with attendant high levels of risk to the patient or others, and an adult refuses care or support, seekÂ adult safeguarding advice.</p>\n<ul>\n<li>SeekÂ mental capacity adviceÂ if:</li>\n<li>Mental capacity advice</li>\n<li>In the first instance, contact the:</li>\n<li>specialist practitioner for Mental Capacity Act (MCA) onÂ ext.Â 42242.</li>\n<li>STSFT safeguarding team onÂ (0191)Â 541Â 0555.</li>\n<li>considering an application to the court of protection.</li>\n<li>uncertainty remains.</li>\n</ul>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>For health professionals</h4>\n<ul>\n<li>Further information</li>\n<li>Department for Constitutional Affairs â€“Â Mental Capacity Act Code of Practice</li>\n<li>Health and Social Care Workers â€“Â Mental Capacity Act decisions</li>\n<li>General Medical Council â€“Â Decision Making and Consent</li>\n<li>STSFT:</li>\n<li>MCA team</li>\n<li>MCA and DOLS Policy</li>\n<li>MCA and DOLS Guidance Document</li>\n</ul>\n<h4>For patients</h4>\n<p>Mind â€“Â Mental Capacity Act 2005</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nMental Capacity","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Perioperative management of diabetes","filename":"Perioperative management of diabetes Draft V.1.docx","category":"Metabolic & Endocrine","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Background","content":"<h3>About perioperative management of diabetes</h3>\n<ul>\n<li>The key aims of management are to:</li>\n<li>avoid hypoglycaemia and significant hyperglycaemia.</li>\n<li>reduce the risk of type 1 diabetics developing diabetic ketoacidosis (DKA).</li>\n<li>reduce the risk of post-operative wound infections.</li>\n</ul>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<p>Determine whether the patient has type 1 or type 2 diabetes. If the patient has a rare type of diabetes or the type is unclear, seek acuteÂ diabetes advice.</p>\n<ul>\n<li>Check:</li>\n<li>glycaemic control usingÂ HbA1c, and previous and current blood glucose tests.</li>\n<li>HbA1c</li>\n<li>A diagnosis of diabetes mellitus can be made:</li>\n</ul>\n<p>ifÂ the patient has anÂ HbA1c ofÂ 48Â mmol/mol or higher.Â Confirm with a repeat sample if the patient is asymptomaticÂ orÂ the result is unexpected.</p>\n<p>on 2 fasting glucose results ofÂ 7Â mmol/L or higher, or 2 random glucose results ofÂ 11.1Â mmol/L or higher.</p>\n<p>An HbA1cÂ ofÂ 42Â toÂ 47.9Â mmol/mol indicates pre-diabetes which requires further testing or monitoring.</p>\n<p>HbA1c reflects the amount of glucose adhered to haemoglobin and indicates average blood glucose levels over the last 3Â months.</p>\n<p>It may be unreliable if patients have conditions that affect haemoglobin, e.g. anaemia, rapid red cell turnover (bleeding, transfusions, recent pregnancy), haemoglobinopathies (thalassaemia).</p>\n<ul>\n<li>SeeÂ HbA1c as Indicator of Diabetes Control.</li>\n<li>sodium, potassium, creatinine, glucose.</li>\n<li>ECG for evidence of myocardial ischaemia or infarction.</li>\n<li>Review patient's diabetic medications and check theÂ type of insulinÂ they are using.</li>\n<li>Types of insulin</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<p>Practice point</p>\n<h3>Ensure continuous insulin for type 1</h3>\n<p>Patients with type 1 diabetes are at high risk of diabetic ketoacidosis in the absence of exogenous insulin. If adjusting insulin regimens, ensure that the patient has continuous exposure to insulin. For example, if changing from continuous insulin infusion to subcutaneous insulin, give the first subcutaneous dose before the end of the infusion.</p>\n<p>The following are guidelines only. The anaesthetist will usually supervise perioperative management of patients with diabetes.</p>\n<strong>Manage according to the type of surgery:</strong>\n<h3>Emergency surgery</h3>\n<strong>Start to manageÂ the patient'sÂ diabetes medication for surgery as soon as the need for possible surgery is identified.</strong>\n<p>Plan whichÂ oral diabetes medicines should be omittedÂ as soon as the patient isÂ nil by mouth â€“ See table 1 ofÂ South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII)</p>\n<p>ContinueÂ injectableÂ glucagon-like peptide 1 receptor agonists, e.g.Â Ozempic, Mounjaro.</p>\n<strong>In patients on sodium-glucose co-transporter 2 (SGLT2) inhibitors:</strong>\n<p>Be awareÂ thatÂ these drugsÂ are usually omitted the day before elective surgery. Omit as soon as the need for possible emergency surgery is identified.</p>\n<p>CheckÂ blood ketones daily until normal diet resumes or if patient is acutely unwell. There is an increased risk of euglycaemic ketoacidosis with SGLT2 inhibitors (e.g.Â empagliflozin,Â dapagliflozin) with acute illness. IfÂ blood ketone levelÂ is more than 1.5 mmol/L or there is significant acidosis startÂ variable rate insulinÂ infusion.</p>\n<h3>Variable rate insulin infusion</h3>\n<p>InitiateÂ by prescription on Meditech V6 via Order Sets > VRIII â€“ Peri-operative. Instructions are readily available within the prescription area.</p>\n<p>Follow South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII)Â (see pages 7 to 9).</p>\n<ul>\n<li>consider seeking acuteÂ diabetes advice.</li>\n<li>StartÂ variable rate insulinÂ infusionÂ if the patient:</li>\n<li>Variable rate insulin infusion</li>\n</ul>\n<p>InitiateÂ by prescription on Meditech V6 via Order Sets > VRIII â€“ Peri-operative. Instructions are readily available within the prescription area.</p>\n<p>Follow South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII)Â (see pages 7 to 9).</p>\n<ul>\n<li>isÂ anticipated to miss 2Â or moreÂ meals</li>\n<li>hasÂ poorly controlled diabetes (HbA1CÂ of more thanÂ 69Â mmol/mol)</li>\n<li>has perioperative capillary blood glucoseÂ valuesÂ ofÂ 12Â mmol/LÂ or more.</li>\n</ul>\n<p>Otherwise, if the patient is on insulin, has well-controlled diabetes, and is anticipated to miss one meal or less, adjust theirÂ dose according toÂ table 2 ofÂ South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII).</p>\n<p>On the day of surgery, monitor blood glucose every 1 to 2Â hours. If the patient has type 1 diabetes, check for DKA if current blood glucose exceeds 15Â mmol/L for more than 6Â hours. For further management, seeÂ Diabetic Ketoacidosis (DKA) in Adults.</p>\n<p>Manage the diabetes post-operativelyÂ byÂ following South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII)Â (see page 9).</p>\n<h3>Elective surgery</h3>\n<p>To manage elective surgery patients perioperatively,Â follow South Tyneside and Sunderland NHS Foundation Trust â€“Â Clinical Guideline: Perioperative Management of Diabetes Mellitus and Perioperative Variable Rate Insulin Infusion (VRIII).</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Advice and Referrals","content":"<strong>Seek acuteÂ diabetes adviceÂ if:</strong>\n<p>the patient has a rare type of diabetes or the type is unclear.</p>\n<p>a patient on sodium-glucose co-transporter 2 (SGLT2) inhibitors hasÂ blood ketone levelÂ of more than 1.5 mmol/L, or significant acidosis.</p>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"CLINICAL GUIDELINE TITLE \nPerioperative management of diabetes","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]},{"title":"Sepsis in Adults","filename":"Sepsis in Adults Draft V.1.docx","category":"Acute Medicine","directorate":"","author":"","date_ratification":"","date_review":"","sections":[{"header":"Red Flags","content":"<ul>\n<li>Hypotension</li>\n<li>Non-blanching rash</li>\n<li>Patient not improving with standard resuscitative measures and treatment</li>\n<li>Sepsis mimics</li>\n</ul>","colors":{"emoji":"ğŸš¨","bg":"#fde8e8","text":"#991b1b","accent":"#dc3545"}},{"header":"Background","content":"<h3>About Sepsis In Adults</h3>\n<p>Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection.</p>\n<p>Patients may present with vague or non-specific symptoms.</p>\n<p>It can progress rapidly to shock and multi organ failure with a high mortality rate.</p>\n<p>Survival depends on early recognition of sepsis and prompt treatment. Patients at high risk of sepsis need immediate assessment and treatment.</p>\n<p>Septic shock is a subset of sepsis in which underlying circulatory and cellular or metabolic abnormalities are profound enough to substantially increase mortality. This is typically identified by persistent hypotension or high blood lactate following fluid resuscitation.</p>","colors":{"emoji":"ğŸ“‹","bg":"#dbeafe","text":"#1e3a5f","accent":"#0066cc"}},{"header":"Assessment","content":"<h3>Think, could this be sepsis?</h3>\n<p>Consider sepsis as a diagnosis in any patient presenting with symptoms or signs of infection.</p>\n<h3>Immediate assessment.</h3>\n<ul>\n<li>Use the ABCDE approach to rapidly assess your patient. If they are seriously unwell:</li>\n<li>contact a senior clinician or activate aÂ clinical emergencyÂ as appropriate.</li>\n<li>do not delay immediate management steps (below), commence in parallel with assessment.</li>\n</ul>\n<p>Consider the possibility of central nervous infection such as encephalitis or meningitis, particularly in a previously healthy patient who is atypically unwell.</p>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Secondary Assessment","content":"<p>1.Calculate and review NEWS2. If NEWS2 is 5 or more or the patient is immunocompromised, screen for sepsis using the sepsis screening tool on Meditech. If sepsis is suspected, perform sepsis grading within 60 minutes.</p>\n<ul>\n<li>2.Take a history to assess if the patient:</li>\n<li>general risk factors for sepsis:</li>\n<li>Aged 65 years or older</li>\n<li>Previous sepsis</li>\n<li>Deterioration despite treatment</li>\n<li>Recent surgery or wound</li>\n<li>Central line or other invasive or implanted device</li>\n<li>Co morbidities, e.g. chronic illness, congenital heart disease, metabolic disease</li>\n<li>Is Immunocompromised:</li>\n<li>Steroid therapy</li>\n<li>Splenectomy</li>\n<li>Malignancy</li>\n<li>Immunosuppressive therapy</li>\n<li>Biological agents</li>\n<li>Beware of sepsis mimics.</li>\n</ul>\n<strong>Be aware that acute severe illness is very often sepsis related but other acute clinical situations can mimic sepsis presentation â€“ do not overlook:</strong>\n<p>Acute drug toxicity â€“ pyrexia can enhance drug absorption from transdermal patches leading to acute toxicity. For example, fentanyl or buprenorphine patch leading to opioid overdose.</p>\n<ul>\n<li>Acute shock can have other causes:</li>\n<li>Anaphylaxis can also present with a blanching rash.</li>\n<li>Cardiac â€“ ensure shock is not a primary cardiac issue.</li>\n</ul>\n<p>Internal bleeding â€“ hypotension from hypovolaemia due to hidden bleeding, e.g. ruptured aortic aneurysm, gastrointestinal bleed.</p>\n<strong>Sepsis leads to metabolic and electrolyte disturbances, but these can also be primary issues that lead to acute severe illness:</strong>\n<p>Addisonian crisis â€“ hypotension with hyponatraemia and hyperkalaemia.</p>\n<p>Diabetes related crises, e.g. diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or profound hypoglycaemia.</p>\n<ul>\n<li>Severe:</li>\n<li>hypokalaemia or hyperkalaemia.</li>\n<li>hypocalcaemia or hypercalcaemia.</li>\n<li>hyponatraemia or hypernatraemia.</li>\n<li>Post seizure activity and lactic acidosis.</li>\n</ul>\n<h3>Examine the patient for signs of infection in specific sites:</h3>\n<ul>\n<li>Urinary tract</li>\n<li>Respiratory tract</li>\n<li>Central nervous system, e.g. brain</li>\n<li>Abdomen</li>\n<li>Surgical sites</li>\n</ul>\n<p>Skin, joint, or wound â€“ fully expose and look for possible necrotising fasciitis in skin creases and perineal regions</p>\n<ul>\n<li>Indwelling devices, e.g. PICC lines or ports</li>\n<li>Investigation â€“ arrange:</li>\n<li>Two sets of blood cultures, even if apyrexial. Call the blood culture team for urgent attention.</li>\n<li>relevant blood tests.</li>\n<li>Blood tests</li>\n<li>Meditech Order Set Sepsis (Adults)</li>\n<li>Full blood count</li>\n</ul>\n<p>CRP</p>\n<ul>\n<li>Calcium, magnesium, and phosphate</li>\n<li>Lactate</li>\n<li>Venous or arterial blood gas if the patient has signs of respiratory failure</li>\n<li>Glucose</li>\n<li>Urea and electrolytes</li>\n<li>When requesting urea and electrolytes, the laboratory will automatically test and provide:</li>\n<li>Sodium</li>\n<li>Potassium</li>\n<li>Urea</li>\n<li>Creatinine</li>\n<li>eGFR, a calculation based on the patient's age and creatinine.</li>\n<li>Coagulation screen if the patient is on anticoagulants</li>\n</ul>\n<p>Coagulation screen Includes prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen.</p>\n<ul>\n<li>Reference ranges:</li>\n<li>PT â€“ 9.9 to 11.8 seconds</li>\n<li>APTT â€“ 23.0 to 35.5 seconds</li>\n<li>Fibrinogen â€“ 1.7 to 4.2 g/L</li>\n</ul>\n<p>Disseminated intravascular coagulation (DIC) screen if the patient has signs of shock or abnormal bleeding</p>\n<ul>\n<li>Tests according to the source of infection:</li>\n<li>Viral swabs, e.g. COVID-19 and flu.</li>\n<li>Urinary tract â€“ midstream urine or catheter specimen.</li>\n<li>Respiratory tract â€“ nasopharyngeal swab, sputum sample.</li>\n<li>Sputum sample</li>\n<li>Rinse mouth out with water before collection.</li>\n<li>Prior antibiotic usage must be recorded.</li>\n</ul>\n<p>Sputum may be refrigerated (4ÂºC) for up to 24 hours but must reach the lab within 4 hours of warming to room temperature.</p>\n<ul>\n<li>Central nervous system, e.g. brain â€“ lumbar puncture.</li>\n<li>Abdomen.</li>\n<li>Surgical sites â€“ swab for culture and sensitivity.</li>\n<li>Skin, throat, or wound â€“ swab for culture and sensitivity.</li>\n</ul>\n<p>Indwelling devices â€“ remove and replace, if necessary, swab for culture and sensitivity. If uncertain, seek microbiology advice.</p>\n<ul>\n<li>Faeces culture and Clostridioides difficile screen, if looser or increased stoma output.</li>\n<li>Joints â€“ if suspected septic arthritis, consider joint aspiration.</li>\n<li>Assess the risk of sepsis:</li>\n<li>High Risk:</li>\n<li>Neutropenic or immunocompromised â€“ see Sepsis in Immunocompromised Patients</li>\n<li>Objective evidence of altered behaviour or mental state</li>\n<li>Responds only to voice or pain, or is unresponsive</li>\n<li>Respiratory:</li>\n<li>Rate 25 breaths per minute or more</li>\n</ul>\n<p>Distress â€“ tripod position, supraclavicular recession, grunting, exhaustion, impending respiratory distress</p>\n<ul>\n<li>Oxygen:</li>\n<li>Scale 1 â€“ saturations 91% or less</li>\n<li>Scale 2 â€“ saturations 87% or less</li>\n<li>Increasing oxygen requirement</li>\n<li>Heart rate 131 beats per minute or more</li>\n<li>Systolic blood pressure 90 mmHg or less, or a drop more than 40 mmHg below normal</li>\n<li>Not passed urine in previous 18 hours, or urine output less than 0.5 mL/kg per hour if catheterised</li>\n<li>Temperature:</li>\n<li>35Â°C or less</li>\n<li>39.1Â°C or more</li>\n<li>Mottled or ashen appearance:</li>\n<li>Cyanosis of skin, lips, or tongue</li>\n<li>Non blanching rash â€“ may indicate meningitis, seek acute microbiology advice</li>\n<li>Prolonged capillary refill time</li>\n<li>Moderate risk:</li>\n<li>Family report abnormal behaviour, mental state, or reduced functional ability</li>\n<li>Respiratory:</li>\n<li>Rate 21 to 24 breaths per minute</li>\n<li>Distress â€“ tracheal tug, intercostal recession, inspiratory or expiratory noises</li>\n<li>Oxygen:</li>\n<li>saturation 92 to 93%</li>\n<li>Heart rate 91 to 129 beats per minute</li>\n<li>Systolic blood pressure 91 to 100 mmHg</li>\n</ul>\n<p>Not passed urine in 12 to 18 hours, or urine output 0.5 mL/kg per hour to 1 mL/kg per hour if catheterised</p>\n<ul>\n<li>Temperature:</li>\n<li>35.1 to 36Â°C</li>\n<li>38.1 to 39Â°C</li>\n<li>Low risk:</li>\n<li>Normal behaviour</li>\n<li>No high or moderate risks</li>\n<li>No non blanching rash</li>\n</ul>","colors":{"emoji":"ğŸ”","bg":"#d1fae5","text":"#065f46","accent":"#17a2b8"}},{"header":"Management","content":"<h3>Initial Management</h3>\n<ul>\n<li>Treat according toÂ NEWS2:</li>\n<li>NEWS2 â€“ 7 or more</li>\n<li>Suspect sepsis and start investigations and treatment immediately:</li>\n</ul>\n<h3>Arrange urgent assessment by ST4 or above.</h3>\n<p>Give intravenous antibiotics within 1 hour of calculating the NEWS2 score.</p>\n<p>NEWS2 â€“ 5 or 6 (with 3 in 1 category)</p>\n<h3>Arrange urgent assessment by ST4 or above.</h3>\n<ul>\n<li>Give intravenous antibiotics within 1 hour of calculating the NEWS2 score.</li>\n<li>If the patient deteriorates, reassess for immediate management.</li>\n<li>NEWS2 â€“ 5 or 6 (with no 3 in 1 category)</li>\n<li>Consider discussion with senior decision-maker if unsure whether to give antibiotics.</li>\n<li>Consider another diagnosis.</li>\n<li>Give antibiotics within 3Â hours of calculating the NEWS2 score if suspicion of sepsis.</li>\n<li>If the patient deteriorates, reassess for sepsis.</li>\n<li>NEWS2 score of 1 to 4</li>\n<li>The risk of sepsis is low.</li>\n<li>Consider another diagnosis.</li>\n<li>If the patient deteriorates, reassess for sepsis.</li>\n<li>NEWS score of 0 or more in an immunocompromised patient</li>\n<li>Suspect sepsis and start investigations and treatment immediately.</li>\n</ul>\n<h3>Arrange urgent assessment by ST4 or above.</h3>\n<p>Give intravenous antibiotics within 1Â hour of suspicion of sepsis or within 1Â hour of attending the emergency department.</p>\n<ul>\n<li>RequestÂ acute oncology assessmentÂ orÂ acute haematology assessmentÂ as indicated.</li>\n<li>If indicated Start oxygen</li>\n<li>If the patient is shocked or otherwise critically ill:</li>\n<li>start oxygen therapy using a reservoir mask at a rate of 15Â L/minute.</li>\n</ul>\n<p>once the patient is stable, reduce the oxygen flow and aim for target saturations of 95% or greater.</p>\n<h3>Be aware that:</h3>\n<p>giving high-flow oxygen may help prevent metabolic acidosis and maintain aerobic metabolism.</p>\n<p>patients with COPD and other risk factors for hypercapnia who develop critical illness should have the same initial target saturations as other critically-ill patients, pending the results of blood gas measurements. If they are at risk of hypercapnic respiratory failure, aim for target saturations of 88 to 92% and put on Scale 2 on NEWS2.</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Ongoing Management","content":"<strong>If the patient is immunocompromised, follow theÂ Sepsis in Immunocompromised PatientsÂ pathway.</strong>\n<p>If unsure of the source of infection, seekÂ microbiology advice.</p>\n<strong>Aim toÂ startÂ antibiotics within 1Â hour of suspicion of sepsis.Â Check for any patient allergyÂ and prescribe according to the likely source of infection:</strong>\n<h3>Community-acquired pneumonia</h3>\n<p>GiveÂ amoxicillin 1Â toÂ 2Â gÂ intravenously three times a dayÂ plus doxycycline 100Â mgÂ orally once or twice a day.Â IfÂ the oral routeÂ is unavailable, use clarithromycinÂ intravenouslyÂ instead of doxycyclineÂ orally. Treat for 5Â toÂ 7 days.</p>\n<h3>IfÂ the patient has:</h3>\n<p>aÂ rash allergy to penicillins, use cefuroxime 750 toÂ 1500Â mgÂ intravenously three times a dayÂ plus doxycycline or clarithromycin.</p>\n<p>anÂ anaphylaxisÂ reactionÂ to penicillins, use co-trimoxazoleÂ intravenouslyÂ 960Â mg twice a day by itself.</p>\n<h3>Hospital-acquired lower respiratory tract infection</h3>\n<p>GiveÂ co-amoxiclav 1.2Â gÂ intravenously three times a dayÂ for 5 days.Â Review every dayÂ in caseÂ switching to oral routeÂ is possible.</p>\n<h3>If the patient has:</h3>\n<p>an allergicÂ reactionÂ to penicillin,Â giveÂ cefuroximeÂ 1.5Â gÂ intravenously three times a dayÂ for 5Â days. Avoid cefuroxime if the patient hasÂ an anaphylacticÂ reactionÂ to penicillins orÂ there is aÂ high risk ofÂ Clostridioides difficileÂ infection.</p>\n<p>an anaphylacticÂ reactionÂ to penicillins,Â giveÂ moxifloxacinÂ 400Â mgÂ intravenously once a dayÂ for 5Â days.</p>\n<p>Urinary tract infection associated with sepsis</p>\n<h4>First-line â€“ give co-amoxiclavÂ 1.2Â gÂ intravenously three times a day.</h4>\n<h3>If the patient has:</h3>\n<p>a mild penicillin allergy, e.g. rash,Â giveÂ cefuroximeÂ 1.5Â gÂ intravenously three times a day.</p>\n<p>a severe penicillin allergy, e.g. anaphylaxis,Â giveÂ co-trimoxazole 960Â mgÂ intravenously twice a day.</p>\n<h3>Sepsis in chronic liver disease</h3>\n<strong>If treating spontaneous bacterial peritonitisÂ and prophylaxis for variceal bleeding:</strong>\n<p>First-line â€“Â giveÂ piperacillinÂ +Â tazobactamÂ 4.5Â gÂ intravenously three times a day.</p>\n<strong>If the patient is allergicÂ to beta-lactams,Â giveÂ aztreonamÂ 2Â gÂ intravenously three times a dayÂ plus vancomycinÂ 1Â gÂ intravenously twice a day, or teicoplanin 400Â mgÂ every 12Â hours for 3Â doses, then 400Â mg onceÂ a day.Â Be aware thatÂ there is an order set to assist with prescribing teicoplanin â€“ \"Teicoplanin Loading\".</strong>\n<p>Only use broad spectrum antibiotics if not confident of the source of the infection, or if considering neutropenic sepsis.</p>\n<strong>Ensure correct preparation and rate of administration of drugs.</strong>\n<h3>Seek microbiology advice if:</h3>\n<p>A drug-resistant organism is suspected, e.g. meticillin-resistantÂ Staphylococcus aureusÂ (MRSA), extended spectrum beta-lactamase (ESBL).</p>\n<ul>\n<li>there has been prior and recent complex antibiotic therapy during inpatient stay.</li>\n<li>other antimicrobial advice is required, e.g. severe penicillin allergy.</li>\n<li>StartÂ Fluid resuscitation</li>\n</ul>\n<strong>Start fluid resuscitation with sodium chloride 0.9% or Hartmannâ€™s if lactate is 2Â mmol/L or more, or hypotensive (systolic blood pressureÂ 90Â mmHg or less):</strong>\n<ul>\n<li>Give 500Â mL as an intravenous bolus, reassess and give further fluids. Maximum 30 mL/kg.</li>\n<li>If the patient has heart failure, be cautious:</li>\n<li>Consider giving smaller fluid volumes, e.g. 250Â mL.</li>\n<li>Reassess more frequently.</li>\n</ul>\n<p>If more than 30 mL/kg of intravenous fluid is required to stabilise the patient, arrangeÂ intensive care assessmentÂ as inotropic or vasopressor support may be required.</p>\n<ul>\n<li>Give intravenousÂ fluids for at least 24Â hours andÂ take observationsÂ at least every 4Â hours.</li>\n<li>CommenceÂ Procedures to manage the source of infection</li>\n<li>Some sources of infection will need additional procedures in addition to antibiotics.</li>\n<li>Drain obstructed ureter or biliary system.</li>\n<li>Drain abscesses.</li>\n</ul>\n<strong>Do not removeÂ central venous access devices empirically during the initial management of neutropenicÂ sepsis. Seek microbiology adviceÂ before removing potentially infected medical devices.</strong>\n<strong>If suspected intra-abdominal sepsis or pleural effusion, requestÂ acute general surgery assessment.</strong>\n<p>For drainage of abscess, joint effusion, or infection involving a prosthetic joint, requestÂ acute orthopaedic assessment.</p>\n<ul>\n<li>Consult relevant specialists early.</li>\n<li>Monitor the patient's:</li>\n<li>serial lactate levels. Repeat within 2Â hours of initial treatment.</li>\n<li>fluid balance â€“ input and output. If the patient is in acute kidney injury:</li>\n<li>stageÂ 3 or is haemodynamically unstable, insert a urinary catheter.</li>\n<li>stageÂ 2 and is not improving, consider inserting a urinary catheter.</li>\n<li>stageÂ 1, catheter is not required.</li>\n<li>observations according toÂ NEWS2.</li>\n<li>Reassess the patient within 2Â hours of starting treatment:</li>\n<li>Check for improvement or stabilisation of initial features of concern for sepsis.</li>\n</ul>\n<h3>Arrange arterial blood gas if the patient has signs of metabolic acidosis.</h3>\n<p>Review lactate â€“ if this remains aboveÂ 2Â mmol/L after twoÂ hours, further treatment is required.</p>\n<strong>Check the results of initial investigations and adjust treatment accordingly.</strong>\n<strong>If the patient is in the emergency department, requestÂ acute general medicine assessmentÂ to arrange admission.</strong>\n<h3>ArrangeÂ intensive care assessmentÂ if:</h3>\n<h3>the patient's:</h3>\n<ul>\n<li>blood pressure remains low after initial fluid resuscitation (up to a maximum of 30Â mL/kg).</li>\n<li>lactate is greater than 4Â mmol/L.</li>\n<li>the patient is in:</li>\n<li>respiratory failure.</li>\n<li>metabolic acidosis and is not responding to treatment.</li>\n</ul>\n<p>ReviewÂ blood culturesÂ within 24Â toÂ 48Â hours to determine antibiotic management. Seek microbiology advice if required.</p>\n<ul>\n<li>Blood cultures</li>\n<li>Review to determine if:</li>\n<li>intravenous antibiotics need to be changed.</li>\n<li>intravenous to oral switch is required, due to the patient improving.</li>\n</ul>\n<p>antibiotics can be discontinued because the patient has improved, or another cause has been found.</p>\n<h3>Note:</h3>\n<p>If the bottle flags positive, the Gram stain is performed, and this result goes on ICE as soon as it is available. This initial report can take anywhere between a few hours to 5 days. This is likely to be faster if adequate volumes are collected and the bottles are loaded onto the analyser as quickly as possible.</p>\n<p>If blood culture bottles do not flag positive, they remain on the automated incubator for up to 5 days before being discarded as negative, at which point a result goes on ICE. If negative at 48Â hours, an interim negative report is transmitted to ICE.</p>\n<p>Continue to monitorÂ NEWS2Â and blood tests until the patient has stabilised.</p>","colors":{"emoji":"ğŸ’Š","bg":"#dcfce7","text":"#166534","accent":"#28a745"}},{"header":"Discharge and Follow up","content":"<strong>Complete the patient's discharge summary with clear information to the general practitioner about the patient's:</strong>\n<ul>\n<li>diagnosis.</li>\n<li>treatment given and alterations to medications.</li>\n<li>follow-up arrangements.</li>\n</ul>","colors":{"emoji":"ğŸ“¤","bg":"#ede9fe","text":"#5b21b6","accent":"#6f42c1"}},{"header":"Advice and Referrals","content":"<strong>If the patient is immunocompromised, requestÂ acute oncology assessmentÂ orÂ acute haematology assessmentÂ as indicated.</strong>\n<h3>ArrangeÂ intensive care assessmentÂ if:</h3>\n<h3>the patient's:</h3>\n<ul>\n<li>blood pressure remains low after initial resuscitation (up to a maximum of 30Â mL/kg).</li>\n<li>lactate is greater than 4Â mmol/L.</li>\n<li>the patient is in:</li>\n<li>respiratory failure.</li>\n<li>metabolic acidosis not responding to treatment.</li>\n<li>more than 30Â mL/kg of intravenous fluid is required to stabilise the patient.</li>\n</ul>\n<p>RequestÂ acute orthopaedic assessmentÂ for drainage of abscess, if joint effusion, or infection involving a prosthetic joint.</p>\n<ul>\n<li>RequestÂ acute general surgery assessmentÂ if:</li>\n<li>suspected intra-abdominal sepsis or pleural effusion.</li>\n<li>patient in the emergency department, to arrange admission.</li>\n<li>If non-blanching rash which may indicate meningitis, seek acuteÂ microbiology advice.</li>\n<li>Seek microbiology advice if:</li>\n</ul>\n<p>drug-resistant organism suspected, e.g. meticillin-resistantÂ Staphylococcus aureusÂ (MRSA), extended spectrum beta-lactamase (ESBL).</p>\n<ul>\n<li>prior and recent complex antibiotic therapy during inpatient stay.</li>\n<li>other antimicrobial advice required, e.g. severe penicillin allergy.</li>\n<li>uncertain how to manage indwelling devices.</li>\n<li>required on review of blood cultures at 24 and 48Â hours.</li>\n</ul>","colors":{"emoji":"ğŸ“","bg":"#ffedd5","text":"#9a3412","accent":"#ff8c42"}},{"header":"Information and References","content":"<h4>References</h4>\n<p>Singer M, Deutschman CS, Seymour CW, et al.Â The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).Â JAMA.Â 2016 Feb 23;315(8):801-10.</p>","colors":{"emoji":"ğŸ“š","bg":"#f3f4f6","text":"#374151","accent":"#6b7280"}},{"header":"CLINICAL GUIDELINE TITLE \nSepsis in Adults","content":"<p>Directorate</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Guideline Statement","content":"<p>Applies to</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}},{"header":"Version","content":"<p>1.1</p>","colors":{"emoji":"ğŸ“","bg":"#e2e8f0","text":"#1e293b","accent":"#475569"}}]}];
        const categories = {"categories":{"Acute Medicine":{"emoji":"ğŸ¥","guidelines":["Acute Hypertension","Acute Kidney Injury","Sepsis in Adults"]},"General Surgery":{"emoji":"ğŸ”ª","guidelines":["Abdominal Pain in Adults"]},"Gastroenterology":{"emoji":"ğŸ”¬","guidelines":["Inflammatory Bowel Disease (IBD)"]},"Metabolic & Endocrine":{"emoji":"âš—ï¸","guidelines":["Hyponatraemia","Perioperative management of diabetes"]},"Mental Health & Cognition":{"emoji":"ğŸ§ ","guidelines":["Delirium","Mental Capacity"]},"End of Life Care":{"emoji":"ğŸ•Šï¸","guidelines":["Death of an adult","Last days of life"]}},"category_order":["Acute Medicine","General Surgery","Gastroenterology","Metabolic & Endocrine","Mental Health & Cognition","End of Life Care"],"directorate_mapping":{"Medicine":"Acute Medicine","Surgery":"General Surgery","Gastroenterology":"Gastroenterology","Metabolic":"Metabolic & Endocrine","Endocrine":"Metabolic & Endocrine","Psychiatry":"Mental Health & Cognition","Mental Health":"Mental Health & Cognition","Palliative":"End of Life Care","End of Life":"End of Life Care"}};
        const guidelineIndex = {
            "Abdominal Pain in Adults": 0,
            "Acute Hypertension": 1,
            "Acute Kidney Injury": 2,
            "Death of an adult": 3,
            "Delirium": 4,
            "Hyponatraemia": 5,
            "Inflammatory Bowel Disease (IBD)": 6,
            "Last days of life": 7,
            "Mental Capacity": 8,
            "Perioperative management of diabetes": 9,
            "Sepsis in Adults": 10,
        };
        const app = {
            currentScreen: 'home',
            currentCategory: null,
            currentGuidelineIdx: null,

            init() {
                this.renderHome();
                this.setupEventListeners();
                window.addEventListener('popstate', (e) => {
                    if (e.state && e.state.screen) {
                        this.currentScreen = e.state.screen;
                        this.currentCategory = e.state.category;
                        this.currentGuidelineIdx = e.state.guidelineIdx;
                        this.renderScreen();
                    }
                });
            },

            setupEventListeners() {
                ['Home', 'Category', 'Guideline'].forEach(type => {
                    const input = document.getElementById(`searchInput${type}`);
                    const results = document.getElementById(`searchResults${type}`);
                    input.addEventListener('input', (e) => this.handleSearch(e.target.value, results));
                    input.addEventListener('focus', () => {
                        if (results.children.length > 0) results.classList.add('active');
                    });
                });

                document.addEventListener('click', (e) => {
                    if (!e.target.closest('.search-container')) {
                        document.querySelectorAll('.search-results').forEach(r => r.classList.remove('active'));
                    }
                });
            },

            handleSearch(query, resultsEl) {
                resultsEl.innerHTML = '';
                if (query.length < 2) {
                    resultsEl.classList.remove('active');
                    return;
                }

                const searchResults = [];
                const lowerQuery = query.toLowerCase();

                guidelinesData.forEach((guideline, idx) => {
                    if (guideline.title.toLowerCase().includes(lowerQuery)) {
                        searchResults.push({ type: 'guideline', guidelineIdx: idx, section: null, title: guideline.title });
                    }
                    guideline.sections.forEach(section => {
                        if (section.content.toLowerCase().includes(lowerQuery)) {
                            if (!searchResults.some(r => r.guidelineIdx === idx && r.section === section.header)) {
                                searchResults.push({ type: 'section', guidelineIdx: idx, section: section.header, title: guideline.title });
                            }
                        }
                    });
                });

                if (searchResults.length > 0) {
                    searchResults.slice(0, 10).forEach(result => {
                        const div = document.createElement('div');
                        div.className = 'search-result-item';
                        div.innerHTML = `<div class="search-result-guideline">${result.title}</div>${result.section ? `<div class="search-result-section">${result.section}</div>` : ''}`;
                        div.addEventListener('click', () => {
                            this.openGuideline(result.guidelineIdx);
                            resultsEl.classList.remove('active');
                        });
                        resultsEl.appendChild(div);
                    });
                    resultsEl.classList.add('active');
                }
            },

            renderHome() {
                const content = document.getElementById('homeContent');
                content.innerHTML = '';
                const catData = categories.categories || categories;
                const catOrder = categories.category_order || Object.keys(catData);
                catOrder.forEach(categoryName => {
                    const data = catData[categoryName];
                    if (!data) return;
                    const card = document.createElement('div');
                    card.className = 'category-card';
                    card.innerHTML = `<div class="category-emoji">${data.emoji}</div><div class="category-name">${categoryName}</div><div class="category-count">${data.guidelines.length} guidelines</div>`;
                    card.addEventListener('click', () => this.openCategory(categoryName));
                    content.appendChild(card);
                });
            },

            openCategory(categoryName) {
                this.currentScreen = 'category';
                this.currentCategory = categoryName;
                history.pushState({ screen: 'category', category: categoryName }, '');
                this.renderScreen();
            },

            renderCategory() {
                const catData = categories.categories || categories;
                const categoryData = catData[this.currentCategory];
                document.getElementById('categoryTitle').textContent = this.currentCategory;
                const list = document.getElementById('guidelineList');
                list.innerHTML = '';
                categoryData.guidelines.forEach(guidelineName => {
                    const idx = guidelineIndex[guidelineName];
                    const card = document.createElement('div');
                    card.className = 'guideline-card';
                    card.innerHTML = `<span>${guidelineName}</span><span class="guideline-card-arrow">â†’</span>`;
                    card.addEventListener('click', () => this.openGuideline(idx));
                    list.appendChild(card);
                });
            },

            openGuideline(guidelineIdx) {
                this.currentScreen = 'guideline';
                this.currentGuidelineIdx = guidelineIdx;
                history.pushState({ screen: 'guideline', guidelineIdx: guidelineIdx }, '');
                this.renderScreen();
            },

            renderGuideline() {
                const guideline = guidelinesData[this.currentGuidelineIdx];
                document.getElementById('guidelineTitle').textContent = guideline.title;
                const content = document.getElementById('guidelineContent');
                content.innerHTML = '';

                guideline.sections.forEach((section) => {
                    const div = document.createElement('div');
                    div.className = 'accordion-section' + (section.header === 'Red Flags' ? ' expanded' : '');

                    const colors = section.colors || { emoji: 'ğŸ“‹', bg: '#dbeafe', text: '#1e3a5f' };

                    const header = document.createElement('div');
                    header.className = 'accordion-header';
                    header.style.backgroundColor = colors.bg;
                    header.style.color = colors.text;
                    header.innerHTML = `<span class="accordion-header-text"><span>${colors.emoji}</span><span>${section.header}</span></span><span class="accordion-toggle">â–¼</span>`;
                    header.addEventListener('click', () => div.classList.toggle('expanded'));

                    const body = document.createElement('div');
                    body.className = 'accordion-body';
                    body.innerHTML = `<div class="accordion-body-content">${this.formatContent(section.content, guideline.title)}</div>`;

                    div.appendChild(header);
                    div.appendChild(body);
                    content.appendChild(div);
                });
            },

            formatContent(text, currentGuidelineTitle) {
                if (!text) return '';

                // Content from build.py already contains HTML - just apply cross-links
                let html = text;

                const guidelineLinks = [
                    { title: "Sepsis in Adults", patterns: [/\bsepsis\b/gi] },
                    { title: "Acute Hypertension", patterns: [/\bacute hypertension\b/gi] },
                    { title: "Acute Kidney Injury", patterns: [/\bacute kidney injury\b/gi, /\bAKI\b/g] },
                    { title: "Abdominal Pain in Adults", patterns: [/\babdominal pain\b/gi] },
                    { title: "Inflammatory Bowel Disease (IBD)", patterns: [/\bIBD\b/g, /\binflammatory bowel disease\b/gi] },
                    { title: "Hyponatraemia", patterns: [/\bhyponatraemia\b/gi] },
                    { title: "Delirium", patterns: [/\bdelirium\b/gi] },
                    { title: "Mental Capacity", patterns: [/\bmental capacity\b/gi] },
                    { title: "Last days of life", patterns: [/\blast days of life\b/gi] }
                ];

                guidelineLinks.forEach(link => {
                    if (link.title.toLowerCase() !== currentGuidelineTitle.toLowerCase()) {
                        link.patterns.forEach(regex => {
                            html = html.replace(regex, (match) => {
                                return `<a class="cross-link" onclick="app.openGuidelineByTitle('${link.title}')">${match}</a>`;
                            });
                        });
                    }
                });

                return html;
            },

            openGuidelineByTitle(title) {
                const idx = guidelineIndex[title];
                if (idx !== undefined) this.openGuideline(idx);
            },

            renderScreen() {
                document.getElementById('homeScreen').classList.remove('active');
                document.getElementById('categoryScreen').classList.remove('active');
                document.getElementById('guidelineScreen').classList.remove('active');

                if (this.currentScreen === 'home') {
                    document.getElementById('homeScreen').classList.add('active');
                    document.getElementById('searchInputHome').value = '';
                } else if (this.currentScreen === 'category') {
                    document.getElementById('categoryScreen').classList.add('active');
                    this.renderCategory();
                    document.getElementById('searchInputCategory').value = '';
                } else if (this.currentScreen === 'guideline') {
                    document.getElementById('guidelineScreen').classList.add('active');
                    this.renderGuideline();
                    document.getElementById('searchInputGuideline').value = '';
                }

                document.querySelectorAll('.search-results').forEach(r => r.classList.remove('active'));
            },

            goHome() {
                this.currentScreen = 'home';
                this.currentCategory = null;
                this.currentGuidelineIdx = null;
                history.pushState({ screen: 'home' }, '');
                this.renderScreen();
            },

            goBack() {
                if (this.currentScreen === 'guideline') {
                    this.currentScreen = 'category';
                    history.pushState({ screen: 'category', category: this.currentCategory }, '');
                } else if (this.currentScreen === 'category') {
                    this.goHome();
                    return;
                }
                this.renderScreen();
            },

            showMetadata() {
                const guideline = guidelinesData[this.currentGuidelineIdx];
                const metadata = document.getElementById('metadataContent');
                metadata.innerHTML = `
                    <div class="metadata-item">
                        <div class="metadata-label">Guideline Title</div>
                        <div class="metadata-value">${guideline.title}</div>
                    </div>
                    <div class="metadata-item">
                        <div class="metadata-label">Source File</div>
                        <div class="metadata-value">${guideline.filename}</div>
                    </div>
                    <div class="metadata-item">
                        <div class="metadata-label">Number of Sections</div>
                        <div class="metadata-value">${guideline.sections.length}</div>
                    </div>
                    <div class="metadata-item">
                        <div class="metadata-label">Sections</div>
                        <div class="metadata-value">${guideline.sections.map(s => s.header).join(', ')}</div>
                    </div>
                `;
                document.getElementById('metadataModal').classList.add('active');
            },

            hideMetadata() {
                document.getElementById('metadataModal').classList.remove('active');
            }
        };

        document.addEventListener('DOMContentLoaded', () => app.init());
        document.getElementById('metadataModal').addEventListener('click', (e) => {
            if (e.target.id === 'metadataModal') app.hideMetadata();
        });
    </script>

    <script>
        if ('serviceWorker' in navigator) {
            window.addEventListener('load', () => {
                navigator.serviceWorker.register('./sw.js')
                    .then(reg => console.log('Service worker registered'))
                    .catch(err => console.log('Service worker registration failed:', err));
            });
        }
    </script>
</body>
</html>
